Hemopexin-Lke Structure As Polypeptide-Scaffold

The invention concerns a method for the preparation of a polypeptide with specific binding properties to a predetermined target molecule which are not naturally inherent to that polypeptide. At the same time a process for the optimization of the binding specifity and a process of production are described. The invention further concerns a method for the identification and modification of alterable amino acid positions within a polypeptide scaffold.

Technological Background

In recent years the number of applications and publications related to affinity reagents steadily increased. The majority thereof is related to antibodies, i.e. monoclonal or polyclonal immunoglobulines. Only a minor part deals with possible alternatives. One of these is the use of protein scaffolds. This concept requires a stable protein architecture tolerating multiple substitutions or insertions at the primary structural level (Nygren, P-A., Skerra, A., J. Immun. Meth. 290 (2004) 3-28).

Modified protein scaffolds can overcome existing problems and extent the application area of affinity reagents. Only one problem among many others is the intracellular application of antibodies. The bottleneck of this protein knockout technology is that not all antibodies expressed within cells perform well. This is called the "disulphide bond problem". To overcome this problem time-consuming experiments have to be performed to optimize a complex list of parameters (Visintin, M., et al., J. Immun. Meth. 290 (2004) 135-153).

In this regard proteins possess several advantages. Among these are low molecular weight, ease of production by microorganisms, simplicity to modify and broad applicability. Different protein scaffolds have been described in this context, e.g. Zinc-finger proteins for DNA recognition (Segal, D.J., et al., Biochem. 42 (2003) 2137-2148); Thioredoxin based peptide aptamers modified by introduction of variable polypeptide sequences in the active-site loop (Klevenz, B., et al., Cell. Mol. Life Sci. 59 (2002) 1993-1998); Protein A as "Affibody" scaffold (Sandström, K., et al., Prot. Eng. 16 (2003) 691-697; Andersson, M., et al., J. Immun. Meth. 283 (2003) 225-234); mRNA-protein molecules of the tenth fibronectin type III domain

(Xu, L., et al., Chem. Biol. 9 (2002) 933-942) or alpha-Amylase inhibitor based binding molecules (McConnell, S.J., and Hoess, R.H., J. Mol. Biol. 250 (1995) 460-470).

Two criteria substantially characterize an applicable protein-scaffold: First, the protein should belong to a family which reveals a well defined hydrophobic core. A close relationship between the individual family members is beneficial (Skerra, A., J. Mol. Recognit. 13 (2000) 167-187). Second, the protein should possess a spatially separated and functionally independent accessible active site or binding pocket. This should not contribute to the intrinsic core-stability (Predki, P.F., et al., Nature Struct. Biol. 3 (1996) 54-58). Ideally, this protein-family is inherently involved in the recognition of multiple, non-related targets.

As described in Nygren, P-A., and Skerra, A., J. Immun. Meth. 290 (2004) 3-28 several polypeptide scaffolds have been employed for the development of novel affinity proteins. These scaffolds can be divided into three groups: (i) single peptide loops, (ii) engineered interfaces and (iii) non-contiguous hyper variable loops.

With the scaffolds of the first group either single amino acids in an exposed loop are diversified or small polypeptide sequences are inserted into this exposed loop (see e.g. Roberts, B.L., et al., PNAS 89 (1992) 2429-2433 and Gene 121 (1992) 9-16; Röttgen, P., and Collins, J., Gene 164 (1995) 243; Lu, Z., et al., Bio/Technology 13 (1995) 366-372). One drawback of this approach is, that affinity, if any, to a completely novel target is difficult to achieve (Klevenz, B., et al., Cell. Mol. Life Sci. 59 (2002) 1993-1998). The intrinsic binding affinity to the natural or closely related targets can be modified, but the target or the target class can hardly be changed. Another drawback is that in the case of insertion of small randomized polypeptides, the target has to be known and these sequences have to be generated beforehand based on already established knowledge.

To the scaffolds of the second group belong e.g. the immunoglobulin binding domain of Staphylococcal protein A (e.g. Sandström, K., et al., Prot. Eng. 16 (2003) 691-697), the C-terminal cellulose-binding domain of cellobiohydrolase I of the fungus T. reesei (Smith, G.P., et al., J. Mol. Biol. 277 (1998) 317-322) and the gamma-crystallines (Fiedler, U., and Rudolph, R., WO 01/04144).

The third class is represented by the immunoglobulin itself and the distantly related fibronectin type III domain as well as some classes of neurotoxins.

Beside the suitability as scaffold for the generation of specific binding characteristics to predetermined target molecules, the application conditions have to be considered. Among other things especially the stability, selectivity, solubility and functional production of the affinity polypeptide have to be taken into account. As an example, already mentioned above, the bottleneck of the protein knockout technology is that not all antibodies expressed as affinity molecules within cells are functionally produced ("disulphide bond problem", Visintin, M., et al., J. Immun. Meth. 290 (2004) 135-153).

Therefore it is the objective of the current invention to overcome these drawbacks by providing an alternative polypeptide scaffold with specific binding properties to a predetermined target molecule which are not naturally inherent to that polypeptide. This comprises the randomization of amino acids, the optimization of the binding characteristics and a method of production of the optimized polypeptide with specific binding properties.

Summary of the invention

The present invention provides a polypeptide, that specifically binds a predetermined target molecule, characterized in that the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:02 to SEQ ID NO:61, wherein in said amino acid sequence at least one amino acid according to table V is altered.

The invention further comprises a process for the production of a polypeptide specifically binding a predetermined target molecule in a prokaryotic or eukaryotic microorganism, characterized in that said microorganism contains a gene which encodes said polypeptide and said polypeptide is expressed.

The invention further comprises a vector for the expression of the polypeptide that specifically binds a predetermined target molecule in a prokaryotic or eukaryotic microorganism.

The polypeptide can be isolated and purified by methods known to a person skilled in the art.

In another embodiment of the invention the predetermined target molecule is a member of one of the groups consisting of hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons.

The invention further provides a method for identifying a nucleic acid encoding a polypeptide which specifically binds a target molecule from a DNA-library, wherein the method comprises the steps of

a) selecting a sequence from the group consisting of SEQ ID NO:02 to SEQ ID NO:61;

b) preparing a DNA-library of the selected sequence in which at least one amino acid position according to table V is altered;

c) screening the prepared DNA-library for encoded polypeptides specifically binding a predetermined target molecule;

d) choosing the nucleic acid encoding one specific binder identified in step c);

e) repeating the steps b) to d) for two to five times; and

f) isolating said nucleic acid encoding a polypeptide specifically binding a predetermined target molecule.

In another embodiment the method for identifying a nucleic acid encoding a polypeptide which specifically binds a target molecule from a DNA-library, comprises linear expression elements.

In another embodiment the library of the polypeptide is expressed by display on ribosomes.

In another embodiment the library of the polypeptide is expressed by display on bacteriophages.

The invention further comprises a method for the determination of alterable amino acid positions in a polypeptide comprising the steps of

a) assembling of a plurality of sequences of polypeptides which are homologous in structure and/or function from the same and/or different organisms; and

b) aligning the sequences according to a common structural and/or consensus sequence and/or functional motif; and

c) determining the variability of all amino acids positions in the alignment by counting the number of different amino acids found for each position of the sequence; and

d) identifying alterable amino acid positions as amino acid positions with a total number of different amino acids of eight or more.

Detailed description of the invention

The present invention provides a polypeptide, that specifically binds a predetermined target molecule, characterized in that the amino acid sequence of the polypeptide is selected from the group consisting of SEQ ID NO:02 to SEQ ID NO:61, wherein in said amino acid sequence at least one amino acid according to table V is altered. The invention further provides a method for identifying a nucleic acid encoding a polypeptide which specifically binds a predetermined target molecule from a DNA-library and a method for the determination of alterable amino acid positions in a polypeptide.

The polypeptide can be defined by its amino acid sequence and by the DNA sequence derived there from.

The polypeptide according to the invention can be produced by recombinant means, or synthetically.

The use of recombinant DNA technology enables the production of numerous derivatives of the polypeptide. Such derivatives can, for example, be modified in individual or several amino acid positions by substitution, alteration or exchange. The derivatisation can, for example, be carried out by means of site directed mutagenesis. Such variations can easily be carried out by a person skilled in the art (Sambrook, J., et al., Molecular Cloning: A laboratory manual (1999) Cold Spring Harbor Laboratory Press, New York, USA; Hames, B.D., and Higgins, S.G., Nucleic acid hybridization – a practical approach (1985) IRL Press, Oxford, England).

The invention further comprises a process for the production of a polypeptide specifically binding a predetermined target molecule in a prokaryotic or eukaryotic microorganism, characterized in that said microorganism contains a nucleic acid sequence which encodes said polypeptide and said polypeptide is expressed.

The invention therefore in addition concerns a polypeptide which is a product of prokaryotic or eukaryotic expression of an exogenous nucleic acid molecule according to the invention. With the aid of such nucleic acids, the polypeptide according to the invention can be obtained in a reproducible manner in large amounts. For expression in eukaryotic or prokaryotic host cells, the nucleic acid, encoding the amino acid sequence of the polypeptide, is integrated into suitable expression vectors, according to methods familiar to a person skilled in the art. Such an expression vector preferably contains a regulable or inducible promoter. These recombinant vectors are then introduced for expression into suitable host cells such as, e.g., E.coli as a prokaryotic host cell or Saccharomyces cerevisiae, insect cells or CHO cells as eukaryotic host cells and the transformed or transduced host cells are cultured under conditions which allow expression of the heterologous gene.

The polypeptide can be isolated and purified after recombinant production by methods known to a person skilled in the art, e.g. by affinity chromatography using known protein purification techniques, including immunoprecipitation, gel filtration, ion exchange chromatography, chromatofocussing, isoelectric focusing, selective precipitation, electrophoresis, or the like (see e.g. Ausubel, I., and Frederick, M., Curr. Prot. Mol. Biol. (1992) John Wiley and Sons, New York; Sambrook, J., et al., Molecular Cloning: A laboratory manual (1999) Cold Spring

Harbor Laboratory Press, New York, USA; Hames, B.D., and Higgins, S.G., Nucleic acid hybridization – a practical approach (1985) IRL Press, Oxford, England).

The following abbreviations and definitions are used within this invention.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 20 amino acid residues may be referred to as "peptides"; polypeptides of more than about 100 amino acid residues may be referred to as "proteins".

The term "hemopexin-like domain" (PEX) stands for a polypeptide which displays sequence and structure homology to the blood protein hemopexin. This domain has a mean sequence of about 200 amino acids and consists of four repeating subdomains.

The abbreviation "PEX2" stands for the C-terminal domain of human matrix-metalloproteinase 2, comprising the amino acid positions 466 to 660 of the full length protein.

The term "consensus sequence" stands for a deduced sequence, either nucleotide or amino acid sequence. This sequence represents a plurality of similar sequences. Each position in the consensus sequence corresponds to the most frequently occurring base or amino acid at that position which is determined by aligning three or more sequences.

The term "alter" stands for a process in which a defined position in a sequence, either nucleic acid sequence or amino acid sequence, is modified. This comprises the replacement of an amino acid or a nucleic acid (nucleotide) with a different amino acid or nucleic acid (nucleotide) as well as the deletion or insertion.

The expression "a polypeptide binding a molecule" stands for a polypeptide that has the ability to bind a target molecule. The term "specifically binds" stands for a binding activity with an affinity constant of more than 10 E 7 (10^7) liters/mole.

The expression "predetermined target molecule" denotes a molecule which is a member of the groups of proteins comprising hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons, immunoglobulins, enzymes, inhibitors, activators, and cell surface proteins.

The term "expression vector" or "vector" stands for a natural or artificial DNA sequence comprising at least a nucleic acid sequence encoding the amino acid sequence of a polypeptide, a promoter sequence, a terminator sequence, a selection marker and an origin of replication.

The term "nucleic acid molecule" or "nucleic acid" stands for a polynucleotide molecule which can be, e.g., DNA, RNA or derivatives thereof. Due to the degeneracy of the genetic code, different nucleic acid sequences encode the same polypeptide. These variations are also included.

The term "amino acid" stands for alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).

The term "amino acid diversity number" stands for the number of different amino acids present at a specific position of an amino acid sequence. This number is determined by aligning the sequences of an assembly of a plurality of sequences of polypeptides which are homologous in structure and/or function from the same and/or different organisms to a reference or consensus sequence and identifying the total number of different amino acids present in all aligned sequences at the specific position.

The term "aligning" stands for the process of lining up two or more sequences to achieve maximal levels of identity and conservation. It comprises the determination of positional homology for molecular sequences, involving the juxtaposition of amino acids or nucleotides in homologous molecules. As a result the compared sequences are presented in a form that the regions of greatest statistical similarity

are shown. During this process it may be found that some sequences do not contain all positions of other aligned sequences, i.e. it may be possible that sequences contain one or more deletions. To achieve maximal levels of identity and conservation gaps can be introduced in these sequences. The gaps are denoted by hyphens in the illustration of the alignment.

The terms "Overlapping Extension Ligation PCR" (OEL-PCR) and "Linear Expression Element" (LEE) stand for a method to ligate DNA fragments and describe linear DNA fragments used in and obtained by this method (see e.g. Ho, S.N., et al., Gene 77 (1989) 51-59; Kain, K.C., et al., Biotechniques 10 (1991) 366-374; Shuldiner, A.R., et al., Anal. Biochem. 194 (1991) 9-15). A gene-transcript is segmented into the modules "promotor-module", "gene-module" and "terminator-module". The promotor-module encodes the T7 phage transcription promotor sequence, a translation control sequence (RBS = ribosomal binding site) and the T7 phage enhancer sequence (g10epsilon) (Lee, S.S., and Kang, C., Kor. Biochem. J. 24 (1991) 673-679). These regulatory sequences enable a coupled transcription and translation in a rapid translation system, e.g. RTS 100 E.coli HY System from Roche Applied Sciences, Mannheim, Germany. The terminator-module encodes a translation stop-codon and a palindromic T7 phage termination-motif (T7T). Optionally, these modules comprised DNA sequences encoding polypeptides, which can be used in subsequent affinity purification or labeling procedures. Linear Expression Elements (Sykes, K.F., and Johnston, S.A., Nature Biotechnol. 17 (1999) 355-359) were assembled by these modules by a two-step PCR. In a first standard PCR using the Pyrococcus woesii DNA-polymerase (PWO-PCR) an intron-less open reading frame, i.e. the gene-module, is amplified by sequence-specific flanking primer oligonucleotides, which introduce overlapping complementary sequences to the promotor- and terminator-modules. The PCR-mediated ligation of these DNA fragments requires a free hybridization energy of the complementary sequences, which has to be lower than a delta G of —25 kcal/mol. This is achieved by sequence extensions, which are in average 25 bp in length. The primer oligonucleotides are designed to hybridize with the gene template at a temperature between 48 °C to 55 °C. This enforces the use of primer oligonucleotides with an average length of 45 bp to 55 bp. After 30 PCR cycles the PCR mixture containing approximately 50 ng of the elongated gene-module DNA is transferred into a second PCR mixture. This PCR is supplied with 50 ng to 100 ng of the respective promotor- and terminator-DNA-modules and sequence specific

terminal primers. In the presence of a DNA-polymerase the 3´-ends of the hybridized complementary DNA-fragments are enzymatic elongated (Barik, S., Meth. Mol. Biol. 192 (2002) 185-196) to a full length DNA transcript comprising all three modules.

The term "microorganism" denotes prokaryotic microorganisms and eukaryotic microorganisms. The "microorganism" is preferably selected from the group consisting of E.coli strains, Bacillus subtilis strains, Klebsiella strains, Salmonella strains, Pseudomonas strains or Streptomyces strains and yeast strains. For example, E.coli strains comprises E.coli-K12, UT5600, HB101, XL1, X1776, W3110; yeast strains, e.g., comprises Saccharomyces, Pichia, Hansenula, Kluyveromyces and Schizosaccharomyces.

Two criteria substantially characterize an applicable protein-scaffold: First, the protein should belong to a family which reveals a well defined hydrophobic core. A close relationship between the individual family members is beneficial (Skerra, A., J. Mol. Recognit. 13 (2000) 167-187). Second, the protein should posses a spatially separated and functionally independent accessible active site or binding pocket. This should not contribute to the intrinsic core-stability (Predki, P.F., et al., Nature Struct. Biol. 3 (1996) 54-58). Ideally, this protein-family is inherently involved in the recognition of multiple, non-related targets.

The hemopexin-like (PEX) protein scaffold fulfills these criteria. This structural motive is present in a plurality of different proteins and protein families, e.g. hemopexin (Altruda, F. et al., Nucleic Acids Res. 13 (1985) 3841-3859), vitronectin (Jenne, D., and Stanley, K.K., Biochemistry 26 (1987) 6735-6742) or pea seed albumin 2 (Jenne, D., Biochem. Biophys. Res. Commun. 176 (1991) 1000-1006).

The crystal structure analyses of proteins containing hemopexin-like domains show that this domain adopts a four bladed beta-propeller topology (Li, J., et al., Structure 3 (1995) 541-549; Faber, H.R., et al., Structure 3 (1995) 551-559). The blades are each composed of four beta-sheets in an anti-parallel orientation. Together they form a cavity in the center of the molecule. The four blades are linked together via loops from the fourth outermost beta-strand of the preceding

blade to the first innermost beta-strand of the next blade. A disulphide bond connects the terminal ends of the structure, i.e. blade 4 and blade 1.

The PEX scaffold is involved in different, but quite specific protein-protein- and protein-ligand-interactions. Therefore the hemopexin-like structure forms a versatile framework for molecular recognition (Bode, W., Structure 3 (1995) 527-530). For example, binding sites for ions like calcium, sodium and chloride (Libson, A.M., et al., Nat. Struct. Biol. 2 (1995) 938-942; Gohlke, U., et al., FEBS Lett. 378 (1996) 126-130) as well as for interaction with fibronectin, TIMP-1/2 (tissue inactivator of human matrix metalloproteinase 1/2), integrins and heparin are known (Wallon, U.M., and Overall, C.M., J. Biol. Chem. 272 (1997) 7473-7481; Willenbrock, F., et al., Biochemistry 32 (1993) 4330-4337; Brooks, P.C., et al., Cell 92 (1998) 391-400; Bode, W., Structure 3 (1995) 527-530).

The hemopexin-like protein domain offers a high structural homology among its protein family members. High structural equivalence of the hemopexin-domains of e.g. human Matrix-metalloproteinases 1, 2 and 13 has been reported (Gomis-Ruth, F.X., et al., J. Mol. Biol. 264 (1996) 556-566). The predominantly hydrophobic interactions between the adjacent and perpendicularly oriented beta-sheets provide most of the required structural stability (Gomis-Ruth, F.X., et al., J. Mol. Biol. 264 (1996) 556-566; Fulop, V., and Jones, D.T., Curr. Opin. Struct. Biol. 9 (1999) 715-721).

Protein-databases like SMART (Schultz, J., et al., PNAS 95 (1998) 5857-5864; Letunic, I., et al., Nuc. Acids Res. 30 (2002) 242-244) were recently used to compare homologous sequences and protein-folds in order to identify non-conserved, and thus theoretically alterable, i.e. randomizable, amino acid positions in suitable protein frameworks (Binz, H.K., et al., J. Mol. Biol. 332 (2003) 489-503; Forrer, P., et al., ChemBioChem 5 (2004) 183-189).

To identify potentially alterable, i.e. randomizable, amino acid positions in the PEX fold, a similar approach was performed using the SMART database. Amino acid positions were identified in the PEX domain, which are randomizable without affecting the proteins structure, functional conformation and stability.

From the SMART database 60 PEX-domains, that are listed in the following table I, from different species were aligned with the Pretty bioinformatics tool (GCG) using the scoring matrix blosum 62.

Table I: Listing of the 60 proteins containing the PEX-domain.

Protein family	PEX-fold in PDB data bank code	swissprot data bank number	sequence id of the hemopexin domain as used in this invention (SEQ ID NO:)
peroxisome assembly factor	PEX2_mouse PEX2_rat	P55098 P24392	03 04
matrix metalloproteinase 1	MM01_Bovin MM01_HORSE MM01_human MM01_PIG	P28053 Q9XSZ5 P03956 P21692	06 07 08 09
matrix metalloproteinase 2	MM02_chick (chicken) MM02_human MM02_rabbit	Q90611 P08253 P50757	02 10 05
matrix metalloproteinase 3	MM03_human MM03_MOUSE MM03_RABIT MM03_RAT	P08254 P28862 P28863 P03957	11 12 13 14
matrix metalloproteinase 8	MM08_human MM08_MOUSE MM08_RAT	P22894 O70138 O88766	15 16 17
matrix metalloproteinase 9	MM09_BOVIN MM09_CANFA (canis familiaris, dog) MM09_human MM09_MOUSE	P52176 O18733 P14780 P41245	18 19 20 21
matrix metalloproteinase 10	MM10_human MM10_MOUSE	P09238 O55123	22 23
matrix metalloproteinase 11	MM11_human MM11_MOUSE	P24347 Q02853	24 25
matrix metalloproteinase 12	MM12_human MM12_MOUSE MM12_RABIT MM12_RAT	P39900 P34960 P79227 Q63341	26 27 28 29
matrix metalloproteinase 13	MM13_BOVIN MM13_HORSE MM13_human MM13_RABIT	O77656 O18927 P45452 O62806	30 31 32 33
matrix metalloproteinase 14	MM14_human MM14_mouse MM14_PIG MM14_RABIT MM14_RAT	P50281 P53690 Q9XT90 Q95220 Q10739	34 35 36 37 38
matrix metalloproteinase 15	MM15_human MM15_MOUSE	P51511 O54732	39 40
matrix metalloproteinase 16	MM16_human MM16_MOUSE MM16_RAT	P51512 Q9WTR0 O35548	41 42 43

Protein family	PEX-fold in PDB data bank code	swissprot data bank number	sequence id of the hemopexin domain as used in this invention (SEQ ID NO:)
matrix metalloproteinase 17	MM17_human MM17_MOUSE	Q9ULZ9 Q9R0S3	44 45
matrix metalloproteinase 18	MM18_XENLA (Xenopus laevis, African clawed frog)	O13065	46
matrix metalloproteinase 19	MM19_human MM19_MOUSE	Q99542 Q9JHI0	47 48
matrix metalloproteinase 20	MM20_BOVIN MM20_human MM20_MOUSE MM20_PIG	O18767 O60882 P57748 P79287	49 50 51 52
matrix metalloproteinase 24	MM24_human MM24_MOUSE MM24_RAT	Q9Y5R2 Q9R0S2 Q99PW6	53 54 55
matrix metalloproteinase 25	MM25_human	Q9NPA2	56
matrix metalloproteinase 28	MM28_human	Q9H239	57
vitronectin	VTNC_human VTNC_MOUSE VTNC_PIG VTNC_RABIT	P04004 P29788 P48819 P22458	58 59 60 61

(Table I end).

The hemopexin-like domain just accounts for a small part of the full length protein. The following table lists the location of the aligned hemopexin-like domain in the full length proteins.

Table II: Location of the hemopexin-like domains in the proteins of table I.

protein	sequence amino acids total	hemopexin-like domain start	end
SEQ ID NO:02	663	469-	663-
SEQ ID NO:03	305	97	280
SEQ ID NO:04	305	97-	280
SEQ ID NO:05	662	468	662

protein	sequence amino acids total	hemopexin-like domain	
		start	end
SEQ ID NO:06	469	275	469
SEQ ID NO:07	469	275	469
SEQ ID NO:08	469	275	469-
SEQ ID NO:09	469	275	469
SEQ ID NO:10	660	466	660
SEQ ID NO:11	477	287	477-
SEQ ID NO:12	477	287-	477-
SEQ ID NO:13	478	288-	478-
SEQ ID NO:14	475	285-	475-
SEQ ID NO:15	467	276-	467-
SEQ ID NO:16	465	276-	465-
SEQ ID NO:17	466	277-	466-
SEQ ID NO:18	712	518-	712-
SEQ ID NO:19	704	510-	704-
SEQ ID NO:20	707	513-	707-
SEQ ID NO:21	730	531-	730-
SEQ ID NO:22	476	286-	476-
SEQ ID NO:23	476	286-	476-
SEQ ID NO:24	488	291-	483-
SEQ ID NO:25	492	295-	487-
SEQ ID NO:26	470	279-	470-
SEQ ID NO:27	462	272	462-
SEQ ID NO:28	464	274-	464-
SEQ ID NO:29	465	275-	465-
SEQ ID NO:30	471	281-	471-
SEQ ID NO:31	472	282-	472-
SEQ ID NO:32	471	281-	471-
SEQ ID NO:33	471	281-	471-
SEQ ID NO:34	582	316-	511-
SEQ ID NO:35	582	316-	511
SEQ ID NO:36	580	314	-509

protein	sequence amino acids total	hemopexin-like domain	
		start	end
SEQ ID NO:37	582	316	-511
SEQ ID NO:38	582	316	-511
SEQ ID NO:39	669	367	-562
SEQ ID NO:40	657	365	-558
SEQ ID NO:41	607	340	-535
SEQ ID NO:42	607	340	-535
SEQ ID NO:43	607	340	-535
SEQ ID NO:44	606	332	529
SEQ ID NO:45	578	333	-530
SEQ ID NO:46	467	277	-467
SEQ ID NO:47	508	286	-475
SEQ ID NO:48	527	286	-474
SEQ ID NO:49	481	291	481
SEQ ID NO:50	483	293	483
SEQ ID NO:51	482	292	-482
SEQ ID NO:52	483	293	483
SEQ ID NO:53	645	377	572
SEQ ID NO:54	618	350	545
SEQ ID NO:55	618	350	545
SEQ ID NO:56	562	314	511
SEQ ID NO:57	520	328	520
SEQ ID NO:58	478	288	478
SEQ ID NO:59	478	287	478
SEQ ID NO:60	459	265	459
SEQ ID NO:61	475	288	475

(Table II end).

A consensus sequence of 210 positions has been determined by the alignment of the above listed hemopexin-like domains (SEQ ID NO:01, SEQ ID NO:88).

The number of different amino acids per position has been determined in order to compile an amino acid diversity number ("determination of variability"; see table III). Gaps in the sequence are marked by a hyphen (-) (see table IV for the alignment of all sequences). For every position of the consensus sequence the number of different amino acids (amino acid diversity number) is given. The maximum possible number is 21 (20 different amino acids + 1 gap). A low diversity number indicates a highly conserved position. A high diversity number indicates flexibility at this position.

Table III: Amino acid diversity number for each position of the 210 positions of the consensus sequence; for the consensus sequence without gaps see SEQ ID NO:01, for the consensus sequence with gaps see SEQ ID NO:88.

amino acid position in consensus sequence	amino acid diversity number	amino acid position in consensus sequence	amino acid diversity number	amino acid position in consensus sequence	amino acid diversity number	amino acid position in consensus sequence	amino acid diversity number	amino acid position in consensus sequence	amino acid diversity number
1	56	44	11	87	11	130	10	173	6
2	11	45	7	88	8	131	6	174	5
3	12	46	7	89	9	132	3	175	5
4	2	47	9	90	11	133	5	176	8
5	5	48	12	81	8	134	5	177	3
6	7	49	11	92	8	135	6	178	13
7	10	50	3	93	5	136	7	179	13
8	10	51	7	94	89	137	14	180	65
9	11	52	8	95	12	138	11	181	6
10	3	53	3	96	11	139	9	182	7
11	4	54	2	97	6	140	13	183	6
12	6	55	2	98	9	141	8	184	8
13	7	56	2	99	8	142	6	185	10
14	4	57	2	100	89	143	8	186	12
15	10	58	9	101	4	144	10	187	10
16	7	59	11	102	9	145	7	188	12
17	4	60	4	103	8	146	4	189	5
18	7	61	5	104	13	147	8	190	4
19	7	62	3	105	11	148	12	191	1
20	2	63	2	106	10	149	8	192	3
21	8	64	4	107	11	150	8	193	1
22	7	65	4	108	10	151	14	194	1
23	7	66	10	109	8	152	10	195	2
24	2	67	13	110	7	153	9	196	10
25	4	68	11	111	5	154	6	197	8

amino acid position in consensus sequence	amino acid diversity number
26	5
27	9
28	7
29	6
30	2
31	7
32	7
33	8
34	5
35	11
36	10
37	12
38	15
39	11
40	11
41	12
42	9
43	6

amino acid position in consensus sequence	amino acid diversity number
69	9
70	9
71	12
72	7
73	7
74	4
75	4
76	5
77	3
78	10
79	7
80	8
81	4
82	8
83	9
84	12
85	8
86	13

amino acid position in consensus sequence	amino acid diversity number
112	7
113	7
114	9
115	11
116	10
117	13
118	11
119	2
120	1
121	8
122	3
123	9
124	5
125	4
126	4
127	8
128	9
129	12

amino acid position in consensus sequence	amino acid diversity number
155	4
156	4
157	12
158	14
159	11
160	10
161	6
162	4
163	7
164	5
165	3
166	10
167	13
168	12
169	10
170	8
171	8
172	8

amino acid position in consensus sequence	amino acid diversity number
198	7
199	12
200	9
201	10
202	10
203	8
204	8
205	11
206	5
207	4
208	4
209	9
210	1

(Table III end).

Table IV: Alignment table for the sequences SEQ ID NO:02 to sequence SEQ ID NO:61.

SEQ ID NO:02	P	E	L	C	K	H	D	I	V	F	D	G	V	A	Q	I	R	G	E	-
SEQ ID NO:03	Q	P	P	S	K	N	Q	K	L	L	Y	A	V	C	T	-	I	G	G	R
SEQ ID NO:04	Q	P	P	S	K	N	Q	K	L	L	Y	A	V	C	T	-	I	G	G	R
SEQ ID NO:05	P	E	I	C	T	Q	D	I	V	F	D	G	I	A	Q	I	R	G	E	-
SEQ ID NO:06	P	E	V	C	D	S	K	L	T	F	D	A	I	T	T	I	R	G	E	-
SEQ ID NO:07	P	E	V	C	D	S	K	L	T	F	D	A	I	T	T	I	R	G	E	-
SEQ ID NO:08	P	K	A	C	D	S	K	L	T	F	D	A	I	T	T	I	R	G	E	-
SEQ ID NO:09	P	Q	V	C	D	S	K	L	T	F	D	A	I	T	T	L	R	G	E	-
SEQ ID NO:10	P	E	I	C	K	Q	D	I	V	F	D	G	I	A	Q	I	R	G	E	-
SEQ ID NO:11	P	A	N	C	D	P	A	L	S	F	D	A	V	S	T	L	R	G	E	-
SEQ ID NO:12	S	P	M	C	S	S	T	L	F	F	D	A	V	S	T	L	R	G	E	-
SEQ ID NO:13	P	V	M	C	D	P	D	L	S	F	D	A	I	S	T	L	R	G	E	-
SEQ ID NO:14	L	P	M	C	S	S	A	L	S	F	D	A	V	S	T	L	R	G	E	-
SEQ ID NO:15	P	K	P	C	D	P	S	L	T	F	D	A	I	T	T	L	R	G	E	-
SEQ ID NO:16	P	K	A	C	D	P	H	L	R	F	D	A	T	T	T	L	R	G	E	-
SEQ ID NO:17	P	T	A	C	D	P	H	L	R	F	D	A	A	T	T	L	R	G	E	-
SEQ ID NO:18	E	D	V	C	N	V	D	-	I	F	D	A	I	A	E	I	R	N	R	-
SEQ ID NO:19	E	D	I	C	K	V	N	-	I	F	D	A	I	A	E	I	R	N	Y	-
SEQ ID NO:20	D	D	A	C	N	V	N	-	I	F	D	A	I	A	E	I	G	N	Q	-
SEQ ID NO:21	D	N	P	C	N	V	D	-	V	F	D	A	I	A	E	I	Q	G	A	-
SEQ ID NO:22	P	A	K	C	D	P	A	L	S	F	D	A	I	S	T	L	R	G	E	-
SEQ ID NO:23	P	D	K	C	D	P	A	L	S	F	D	S	V	S	T	L	R	G	E	-
SEQ ID NO:24	P	D	A	C	E	A	-	-	S	F	D	A	V	S	T	I	R	G	E	-
SEQ ID NO:25	P	D	V	C	E	T	-	-	S	F	D	A	V	S	T	I	R	G	E	-
SEQ ID NO:26	P	A	L	C	D	P	N	L	S	F	D	A	V	T	T	V	G	N	K	-
SEQ ID NO:27	S	T	F	C	H	Q	S	L	S	F	D	A	V	T	T	V	G	E	K	-
SEQ ID NO:28	P	T	A	C	D	H	N	L	K	F	D	A	V	T	T	V	G	N	K	-
SEQ ID NO:29	S	T	V	C	H	Q	S	L	S	F	D	A	V	T	T	V	G	D	K	-
SEQ ID NO:30	P	D	K	C	D	P	S	L	S	L	D	A	I	T	S	L	R	G	E	-
SEQ ID NO:31	P	D	K	C	D	P	S	L	S	L	D	A	I	T	S	L	R	G	E	-
SEQ ID NO:32	P	D	K	C	D	P	S	L	S	L	D	A	I	T	S	L	R	G	E	-
SEQ ID NO:33	P	D	K	C	D	P	S	L	S	L	D	A	I	T	S	L	R	G	E	-
SEQ ID NO:34	P	N	I	C	D	G	N	-	-	F	D	T	V	A	M	L	R	G	E	-
SEQ ID NO:35	P	N	I	C	D	G	N	-	-	F	D	T	V	A	M	L	R	G	E	-
SEQ ID NO:36	P	N	I	C	D	G	N	-	-	F	D	T	V	A	M	L	R	G	E	-
SEQ ID NO:37	P	K	I	C	D	G	N	-	-	F	D	T	V	A	V	F	R	G	E	-
SEQ ID NO:38	P	N	I	C	D	G	N	-	-	F	D	T	V	A	M	L	R	G	E	-
SEQ ID NO:39	P	N	I	C	D	G	D	-	-	F	D	T	V	A	M	L	R	G	E	-
SEQ ID NO:40	-	-	I	C	D	G	N	-	-	F	D	T	V	A	V	L	R	G	E	-
SEQ ID NO:41	P	N	I	C	D	G	N	-	-	F	N	T	L	A	I	L	R	R	E	-
SEQ ID NO:42	P	N	I	C	D	G	N	-	-	F	N	T	L	A	I	L	R	R	E	-
SEQ ID NO:43	P	N	I	C	D	G	N	-	-	F	N	T	L	A	I	L	R	R	E	-
SEQ ID NO:44	P	H	R	C	S	T	H	-	-	F	D	A	V	A	Q	I	R	G	E	-
SEQ ID NO:45	P	H	R	C	T	A	H	-	-	F	D	A	V	A	Q	I	R	G	E	-
SEQ ID NO:46	P	S	R	C	D	P	N	V	V	F	N	A	V	T	T	M	R	G	E	-
SEQ ID NO:47	P	D	P	C	S	S	E	L	D	A	M	M	L	G	-	P	R	G	K	-
SEQ ID NO:48	P	N	P	C	S	G	E	V	D	A	M	V	L	G	-	P	R	G	K	-
SEQ ID NO:49	P	D	L	C	D	S	N	L	S	F	D	A	V	T	M	L	G	K	E	-
SEQ ID NO:50	P	D	L	C	D	S	S	S	S	F	D	A	V	T	M	L	G	K	E	-
SEQ ID NO:51	P	D	L	C	D	S	S	S	S	F	D	A	V	T	M	L	G	K	E	-
SEQ ID NO:52	P	D	I	C	D	S	S	S	S	F	D	A	V	T	M	L	G	K	E	-
SEQ ID NO:53	P	N	I	C	D	G	N	-	-	F	N	T	V	A	L	F	R	G	E	-
SEQ ID NO:54	P	N	I	C	D	G	N	-	-	F	N	T	V	A	L	F	R	G	E	-
SEQ ID NO:55	P	N	I	C	D	G	N	-	-	F	N	T	V	A	L	F	R	G	E	-
SEQ ID NO:56	P	D	R	C	E	G	N	-	-	F	D	A	I	A	N	I	R	G	E	-
SEQ ID NO:57	-	-	-	-	-	-	-	-	-	F	D	A	I	T	V	D	R	Q	Q	Q
SEQ ID NO:58	Q	E	E	C	E	G	S	S	V	F	E	H	F	A	M	M	Q	R	D	-
SEQ ID NO:59	Q	E	E	C	E	G	S	S	V	F	E	H	F	A	L	L	Q	R	D	-
SEQ ID NO:60	R	E	E	C	E	G	S	S	V	F	A	H	F	A	L	M	Q	R	D	-
SEQ ID NO:61	Q	E	E	C	E	G	S	S	V	F	E	H	F	A	M	L	H	R	D	-

(Table IV continued)

21										31									
I	F	F	F	K	D	R	F	M	W	R	T	-	V	N	P	R	G	K	P
-	-	W	L	E	E	R	C	Y	D	L	F	R	N	R	-	-	-	-	-
-	-	W	L	E	E	R	C	Y	D	L	F	R	N	R	-	-	-	-	-
I	F	F	F	K	D	R	F	I	W	R	T	-	V	T	P	G	D	K	P
V	M	F	F	K	D	R	F	Y	M	R	T	-	N	P	L	Y	P	E	-
V	M	F	F	K	D	R	F	Y	M	R	I	-	N	P	Y	Y	P	E	-
V	M	F	F	K	D	R	F	Y	M	R	T	-	N	P	F	Y	P	E	-
L	M	F	F	K	D	R	F	Y	M	R	T	-	N	S	F	Y	P	E	-
I	F	F	F	K	D	R	F	I	W	R	T	-	V	T	P	R	D	K	P
I	L	I	F	K	D	R	H	F	W	R	K	-	S	L	R	K	L	E	-
V	L	F	F	K	D	R	H	F	W	R	K	-	S	L	R	T	P	E	-
I	L	F	F	K	D	R	Y	F	W	R	K	-	S	L	R	I	L	E	-
V	L	F	F	K	D	R	H	F	W	R	K	-	S	L	R	T	P	E	-
I	L	F	F	K	D	R	Y	F	W	R	R	-	H	P	Q	L	Q	R	-
I	Y	F	F	K	E	K	Y	F	W	R	R	-	H	P	Q	L	R	T	-
I	Y	F	F	K	D	K	Y	F	W	R	R	-	H	P	Q	L	R	T	-
L	H	F	F	K	A	G	K	Y	W	R	L	S	E	G	G	G	R	R	V
L	H	F	F	K	E	G	K	Y	W	R	F	S	K	G	K	G	R	R	V
L	Y	L	F	K	D	G	K	Y	W	R	F	S	E	G	R	G	S	R	P
L	H	F	F	K	D	G	W	Y	W	K	F	L	N	H	R	G	S	P	L
Y	L	F	F	K	D	R	Y	F	W	R	R	-	S	H	W	N	P	E	-
V	L	F	F	K	D	R	Y	F	W	R	R	-	S	H	W	N	P	E	-
L	F	F	F	K	A	G	F	V	W	R	L	R	G	G	Q	-	L	Q	P
L	F	F	F	K	A	G	F	V	W	R	L	R	S	G	R	-	L	Q	P
I	F	F	F	K	D	R	F	F	W	L	K	-	V	S	E	R	P	K	-
I	L	F	F	K	D	W	F	F	W	W	K	-	L	P	G	S	P	A	-
I	F	F	F	K	D	S	F	F	W	W	K	-	I	P	K	S	S	T	-
I	F	F	F	K	D	W	F	F	W	W	R	-	L	P	G	S	P	A	-
T	L	I	F	K	D	R	F	F	W	R	L	-	H	P	Q	Q	V	E	-
T	M	V	F	K	D	R	F	F	W	R	L	-	H	P	Q	L	V	D	-
T	M	I	F	K	D	R	F	F	W	R	L	-	H	P	Q	Q	V	D	-
T	M	I	F	K	D	R	F	F	W	R	L	-	H	P	Q	Q	V	D	-
M	F	V	F	K	K	R	W	F	W	R	V	R	N	N	Q	-	V	M	D
M	F	V	F	K	E	R	W	F	W	R	V	R	N	N	Q	-	V	M	D
M	F	V	F	K	E	R	W	F	W	R	V	R	K	N	Q	-	V	M	D
M	F	V	F	K	E	R	W	F	W	R	V	R	N	N	Q	-	V	M	D
M	F	V	F	K	E	R	W	F	W	R	V	R	N	N	Q	-	V	M	D
M	F	V	F	K	G	R	W	F	W	R	V	R	H	N	R	-	V	L	D
M	F	V	F	K	G	R	W	F	W	R	V	R	H	N	R	-	V	L	D
M	F	V	F	K	D	Q	W	F	W	R	V	R	N	N	R	-	V	M	D
M	F	V	F	K	D	Q	W	F	W	R	V	R	N	N	R	-	V	M	D
A	F	F	F	K	G	K	Y	F	W	R	L	T	R	D	R	H	L	V	S
A	F	F	F	K	G	K	Y	F	W	R	L	T	R	D	R	H	L	V	S
L	I	F	F	V	K	R	F	L	W	R	K	-	H	P	Q	A	S	E	-
T	Y	A	F	K	G	D	Y	V	W	T	V	S	D	S	G	P	G	P	-
T	Y	A	F	K	G	D	Y	V	W	T	V	T	D	S	G	P	G	P	-
L	L	L	F	R	D	R	I	F	W	R	R	-	Q	V	H	L	M	S	G
L	L	L	F	K	D	R	I	F	W	R	R	-	Q	V	H	L	R	T	G
L	L	F	F	K	D	R	I	F	W	R	R	-	Q	V	H	L	P	T	G
L	L	F	F	R	D	R	I	F	W	R	R	-	Q	V	H	L	M	S	G
M	F	V	F	K	D	R	W	F	W	R	L	R	N	N	R	-	V	Q	E
M	F	V	F	K	D	R	W	F	W	R	L	R	N	N	R	-	V	Q	E
M	F	V	F	K	D	R	W	F	W	R	L	R	N	N	R	-	V	Q	E
T	F	F	F	K	G	P	W	F	W	R	L	Q	P	S	G	Q	L	V	S
L	Y	I	F	K	G	S	H	F	W	E	V	A	A	D	G	N	V	S	-
S	W	E	D	I	F	E	L	L	F	W	G	R	T	S	A	G	T	R	-
S	W	E	N	I	F	E	L	L	F	W	G	R	S	S	D	G	A	R	-
S	W	E	D	I	F	R	L	L	F	W	S	H	S	F	G	G	A	I	-
S	W	E	D	I	F	K	L	L	F	W	G	R	P	S	G	G	A	R	-

(Table IV continued)

T	G	P	L	L	V	A	T	F	W
-	H	L	A	S	F	G	K	A	K
-	H	L	A	S	F	G	K	A	K
M	G	P	L	L	V	A	T	F	W
V	E	L	N	F	I	S	V	F	W
A	E	L	N	F	I	S	I	F	W
V	E	L	N	F	I	S	V	F	W
V	E	L	N	F	I	S	V	F	W
M	G	P	L	L	V	A	T	F	W
P	E	L	H	L	I	S	S	F	W
P	E	F	Y	L	I	S	S	F	W
P	E	F	H	L	I	S	S	F	W
P	G	F	Y	L	I	S	S	F	W
V	E	M	N	F	I	S	L	F	W
V	D	L	N	F	I	S	L	F	W
V	D	L	N	F	I	S	L	F	W
Q	G	P	F	L	V	K	S	K	W
Q	G	P	F	L	S	P	S	T	W
Q	G	P	F	L	I	A	D	K	W
Q	G	P	F	L	T	A	R	T	W
P	E	F	H	L	I	S	A	F	W
P	E	F	H	L	I	S	A	F	W
G	Y	P	A	L	A	S	R	H	W
G	Y	P	A	L	A	S	R	H	W
T	S	V	N	L	I	S	S	L	W
T	N	I	T	S	I	S	S	I	W
T	S	V	R	L	I	S	S	L	W
T	N	I	T	S	I	S	S	M	W
A	E	L	F	L	T	K	S	F	G
A	E	L	F	L	T	K	S	F	W
A	E	L	F	L	T	K	S	F	W
A	E	L	F	L	T	K	S	F	W
G	Y	P	M	P	I	G	Q	F	W
G	Y	P	M	P	I	G	Q	F	W
G	Y	P	M	P	I	G	Q	F	W
G	Y	P	M	P	I	G	Q	L	W
G	Y	P	M	P	I	G	Q	F	W
N	Y	P	M	P	I	G	H	F	W
N	Y	P	M	P	I	G	H	F	W
G	Y	P	M	Q	I	T	Y	F	W
G	Y	P	M	Q	I	T	Y	F	W
G	Y	P	M	Q	I	T	Y	F	W
L	Q	P	A	Q	M	H	R	F	W
L	Q	P	A	Q	M	H	R	F	W
A	E	L	M	F	V	Q	A	F	W
-	-	L	F	R	V	S	A	L	W
-	-	L	F	Q	I	S	A	L	W
I	R	P	S	T	I	T	S	S	F
I	R	P	S	T	I	T	S	S	F
I	R	P	S	T	I	T	S	S	F
I	R	P	S	T	I	T	S	S	F
G	Y	P	M	Q	I	E	Q	F	W
G	Y	P	M	Q	I	E	Q	F	W
G	Y	P	M	Q	I	E	Q	F	W
P	R	P	A	R	L	H	R	F	W
-	E	P	R	P	L	Q	E	R	W
-	Q	P	Q	F	I	S	R	D	W
-	E	P	Q	F	I	S	R	N	W
-	E	P	R	V	I	S	Q	D	W
-	Q	P	Q	F	I	S	R	D	W

P	D	L	P	E	-	-	-	K	I
Q	C	M	N	F	V	V	G	-	-
Q	C	M	N	F	V	V	G	-	-
P	E	L	P	E	-	-	-	K	I
P	Q	L	P	N	-	-	-	G	L
P	Q	L	P	N	-	-	-	G	L
P	Q	L	P	N	-	-	-	G	L
P	Q	V	P	N	-	-	-	G	L
P	E	L	P	E	-	-	-	K	I
P	S	L	P	S	-	-	-	G	V
P	S	L	P	S	-	-	-	N	M
P	S	L	P	S	-	-	-	A	V
P	S	L	P	S	-	-	-	N	M
P	S	L	P	T	-	-	-	G	I
P	G	L	P	N	-	-	-	G	L
P	F	L	P	N	-	-	-	G	L
P	A	L	P	R	-	-	-	K	L
P	A	L	P	R	-	-	-	K	L
P	A	L	P	R	-	-	-	K	L
P	A	L	P	A	-	-	-	T	L
P	S	L	P	S	-	-	-	Y	L
P	T	L	P	S	-	-	-	D	L
Q	G	L	P	S	-	-	-	P	V
Q	G	L	P	S	-	-	-	P	V
P	T	L	P	S	-	-	-	G	I
P	S	I	P	S	-	-	-	A	I
P	T	L	P	S	-	-	-	G	I
P	T	I	P	S	-	-	-	G	I
P	E	L	P	N	-	-	-	R	I
P	E	L	P	N	-	-	-	R	I
P	E	L	P	N	-	-	-	R	I
P	E	L	P	N	-	-	-	R	I
R	G	L	P	A	-	-	-	S	I
R	G	L	P	A	-	-	-	S	I
R	G	L	P	A	-	-	-	S	I
R	G	L	P	A	-	-	-	S	I
R	G	L	P	A	-	-	-	S	I
R	G	L	P	G	-	-	-	D	I
R	G	L	P	G	-	-	-	N	I
R	G	L	P	P	-	-	-	S	I
R	G	L	P	P	-	-	-	S	I
R	G	L	P	P	-	-	-	S	I
R	G	L	P	L	H	L	D	S	V
R	G	L	P	L	H	L	D	S	V
P	S	L	P	T	-	-	-	N	I
E	G	L	P	G	-	-	-	N	L
E	G	L	P	G	-	-	-	N	L
P	Q	L	M	S	-	-	-	N	V
P	Q	L	M	S	-	-	-	N	V
P	Q	L	M	S	-	-	-	N	V
P	Q	L	M	S	-	-	-	N	V
K	G	L	P	A	-	-	-	R	I
K	G	L	P	A	-	-	-	R	I
K	G	L	P	A	-	-	-	R	I
E	G	L	P	A	Q	V	R	V	V
V	G	L	P	P	-	-	-	N	I
H	G	V	P	G	-	-	-	-	-
H	G	V	P	G	-	-	-	-	-
L	G	L	P	E	-	-	-	-	-
H	G	V	P	G	-	-	-	-	-

(Table IV continued)

69										71									
D	A	V	Y	E	S	P	Q	D	E	K	A	V	F	F	A	G	N	E	Y
.	.	.	.	.	.	.	.	.	.	L	L	K	L	G	E	L	M	N	F
.	.	.	.	.	.	.	.	.	.	L	L	K	L	G	E	L	M	N	F
D	A	V	Y	E	A	P	Q	E	E	K	A	V	F	F	A	G	N	E	Y
Q	A	A	Y	E	V	A	D	R	D	E	V	R	F	F	K	G	N	K	Y
Q	A	A	Y	E	V	S	H	R	D	E	V	R	F	F	K	G	N	K	Y
E	A	A	Y	E	F	A	D	R	D	E	V	R	F	F	K	G	N	K	Y
Q	A	A	Y	E	I	A	D	R	D	E	V	R	F	F	K	G	N	K	Y
D	A	V	Y	E	A	P	Q	E	E	K	A	V	F	F	A	G	N	E	Y
D	A	A	Y	E	V	T	S	K	D	L	V	F	I	F	K	G	N	Q	F
D	A	A	Y	E	V	T	N	R	D	T	V	F	I	F	K	G	N	Q	F
D	A	A	Y	E	V	I	S	R	D	T	V	F	I	F	K	G	T	Q	F
D	A	A	Y	E	V	T	N	R	D	T	V	F	I	L	K	G	N	Q	I
Q	A	A	Y	E	D	F	D	R	D	L	I	F	L	F	K	G	N	Q	Y
Q	A	A	Y	E	D	F	D	R	D	L	V	F	L	F	K	G	R	Q	Y
Q	A	A	Y	E	D	F	D	R	D	L	V	F	L	F	K	G	R	Q	Y
D	S	A	F	E	D	P	L	T	K	K	I	F	F	F	S	G	R	Q	V
D	S	A	F	E	D	G	L	T	K	K	T	F	F	F	S	G	R	Q	V
D	S	V	F	E	E	P	L	S	K	K	L	F	F	F	S	G	R	Q	V
D	S	A	F	E	D	P	Q	T	K	R	V	F	F	F	S	G	R	Q	M
D	A	A	Y	E	V	N	S	R	D	T	V	F	I	F	K	G	N	E	F
D	A	A	Y	E	A	H	N	T	D	S	V	L	I	F	K	G	S	Q	F
D	A	A	F	E	D	A	Q	G	-	H	I	W	F	F	Q	G	A	Q	Y
D	A	A	F	E	D	A	Q	G	-	Q	I	W	F	F	Q	G	A	Q	Y
E	A	A	Y	E	I	E	A	R	N	Q	V	F	L	F	K	D	D	K	Y
Q	A	A	Y	E	I	E	S	R	N	Q	L	F	L	F	K	D	E	K	Y
E	A	A	Y	E	I	G	D	R	H	Q	V	F	L	F	K	G	D	K	F
Q	A	A	Y	E	I	G	G	R	N	Q	L	F	L	F	K	D	E	K	Y
D	A	A	Y	E	H	P	S	H	D	L	I	F	I	F	R	G	R	K	F
D	A	A	Y	E	H	P	S	K	D	L	I	F	I	F	R	G	R	K	F
D	A	A	Y	E	H	P	S	H	D	L	I	F	I	F	R	G	R	K	F
D	A	A	Y	E	H	P	A	R	D	L	I	F	I	F	R	G	K	K	F
N	T	A	Y	E	R	K	-	D	G	K	F	V	F	F	K	G	D	K	H
N	T	A	Y	E	R	K	-	D	G	K	F	V	F	F	K	G	D	K	H
N	T	A	Y	E	R	K	-	D	G	K	F	V	F	F	K	G	D	K	H
N	T	A	Y	E	R	K	-	D	G	K	F	V	F	F	K	G	D	K	H
N	T	A	Y	E	R	K	-	D	G	K	F	V	F	F	K	G	D	K	H
S	A	A	Y	E	R	Q	-	D	G	R	F	V	F	F	K	G	D	R	Y
S	A	A	Y	E	R	Q	-	D	G	H	F	V	F	F	K	G	N	R	Y
D	A	V	Y	E	N	S	-	D	G	N	F	V	F	F	K	G	N	K	Y
D	A	V	Y	E	N	S	-	D	G	N	F	V	F	F	K	G	N	K	Y
D	A	V	Y	E	N	S	-	D	G	N	F	V	F	F	K	G	N	K	Y
D	A	V	Y	E	R	T	S	D	H	K	I	V	F	F	K	G	D	R	Y
D	A	V	Y	E	R	T	S	D	H	K	I	V	F	F	K	G	D	R	Y
D	A	A	Y	E	N	P	I	T	E	Q	I	L	V	F	K	G	S	K	Y
D	A	A	V	Y	S	P	R	T	Q	W	I	H	F	F	K	G	D	K	V
D	A	A	V	Y	S	P	R	T	R	R	T	H	F	F	K	G	N	K	V
D	A	A	Y	E	V	A	E	R	G	T	A	Y	F	F	K	G	P	H	Y
D	A	A	Y	E	V	A	E	R	G	T	A	Y	F	F	K	G	P	H	Y
D	A	A	Y	E	V	A	E	R	G	I	A	F	F	F	K	G	P	H	Y
D	A	A	Y	E	V	A	D	R	G	M	A	Y	F	F	K	G	P	H	Y
D	A	A	Y	E	R	A	-	D	G	R	F	V	F	F	K	G	D	K	Y
D	A	A	Y	E	R	A	-	D	G	R	F	V	F	F	K	G	D	K	Y
D	A	A	Y	E	R	A	-	D	G	R	F	V	F	F	K	G	D	K	Y
Q	A	A	Y	A	R	H	R	D	G	R	I	L	L	F	S	G	P	Q	F
E	A	A	A	V	S	L	N	D	G	D	F	Y	F	F	K	G	G	R	C
-	-	Q	V	D	A	A	M	A	G	R	I	Y	I	S	G	M	A	P	R
-	-	K	V	D	A	A	M	A	G	R	I	Y	V	T	G	S	L	S	H
-	-	Q	V	D	A	A	M	A	G	Q	I	Y	I	S	G	S	A	L	K
-	-	K	V	D	A	A	M	A	G	R	I	Y	I	S	G	L	T	P	S

(Table IV continued)

88										10									
W	V	Y	T	A	S	N	L	D	R	G	Y	P	K	K	L	T	-	S	L
L	I	F	L	Q	K	G	K	F	A	T	L	T	E	R	L	L	G	I	H
L	I	F	L	Q	K	G	K	F	A	T	L	T	E	R	L	L	G	I	H
W	V	Y	S	A	S	T	L	E	R	G	Y	P	K	P	L	T	-	S	L
W	A	V	K	G	Q	D	V	L	R	G	Y	P	R	D	I	Y	R	S	F
W	A	V	K	G	Q	D	V	L	Y	G	Y	P	K	D	I	H	R	S	F
W	A	V	Q	G	Q	N	V	L	H	G	Y	P	K	D	I	Y	S	S	F
W	A	V	R	G	Q	D	V	L	Y	G	Y	P	K	D	I	H	R	S	F
W	I	Y	S	A	S	T	L	E	R	G	Y	P	K	P	L	T	-	S	L
W	A	I	R	G	N	E	V	R	A	G	Y	P	R	G	I	H	-	T	L
W	A	I	R	G	H	E	E	L	A	G	Y	P	K	S	I	H	-	T	L
W	A	I	R	G	N	E	V	Q	A	G	Y	P	R	S	I	H	-	T	L
W	A	I	R	G	H	E	E	L	A	G	Y	P	K	S	I	H	-	T	L
W	A	L	S	G	Y	D	I	L	Q	G	Y	P	K	D	I	S	-	N	Y
W	A	L	S	G	Y	D	L	Q	Q	G	Y	P	R	D	I	S	-	N	Y
W	A	L	S	A	Y	D	L	Q	Q	G	Y	P	R	D	I	S	-	N	Y
W	V	Y	T	G	-	A	S	L	L	G	-	P	R	R	L	D	-	K	L
W	V	Y	T	G	-	T	S	V	V	G	-	P	R	R	L	D	-	K	L
W	V	Y	T	G	-	A	S	V	L	G	-	P	R	R	L	D	-	K	L
W	V	Y	T	G	-	K	T	V	L	G	-	P	R	S	L	D	-	K	L
W	A	I	R	G	N	E	V	Q	A	G	Y	P	R	G	I	H	-	T	L
W	A	V	R	G	N	E	V	Q	A	G	Y	P	K	G	I	H	-	T	L
W	V	Y	D	G	E	K	P	V	L	G	-	P	A	P	L	T	-	E	L
W	V	Y	D	G	E	K	P	V	L	G	-	P	A	P	L	S	-	K	L
W	L	I	S	N	L	R	P	E	P	N	Y	P	K	S	I	H	-	S	F
W	L	I	N	N	L	V	P	E	P	H	Y	P	R	S	I	Y	-	S	L
W	L	I	S	H	L	R	L	Q	P	N	Y	P	K	S	I	H	-	S	L
W	L	I	N	N	L	V	P	E	P	H	Y	P	R	S	I	H	-	S	L
W	A	L	S	G	Y	D	I	L	E	D	Y	P	K	K	I	S	-	E	L
W	A	L	N	G	Y	D	I	L	E	G	Y	P	Q	K	I	S	-	E	L
W	A	L	N	G	Y	D	I	L	E	G	Y	P	K	K	I	S	-	E	L
W	A	P	N	G	Y	D	I	L	E	G	Y	P	Q	K	L	S	-	E	L
W	V	F	D	E	A	S	L	E	P	G	Y	P	K	H	I	K	E	L	G
W	V	F	D	E	A	S	L	E	P	G	Y	P	K	H	I	K	E	L	G
W	V	F	D	E	A	S	L	E	P	G	Y	P	K	H	I	K	E	L	G
W	V	F	D	E	A	S	L	E	P	G	Y	P	K	H	I	K	E	L	G
W	V	F	D	E	A	S	L	E	P	G	Y	P	K	H	I	K	E	L	G
W	L	F	R	E	A	N	L	E	P	G	Y	P	Q	P	L	T	S	Y	G
W	L	F	R	E	A	N	L	E	P	G	Y	P	Q	P	L	S	S	Y	G
W	V	F	K	D	T	T	L	Q	P	G	Y	P	H	D	L	I	T	L	G
W	V	F	K	D	T	T	L	Q	P	G	Y	P	H	D	L	I	T	L	G
W	V	F	K	D	T	T	L	Q	P	G	Y	P	H	D	L	I	T	L	G
W	V	F	K	D	N	N	V	E	E	G	Y	P	R	P	V	S	D	F	S
W	V	F	K	D	N	N	V	E	E	G	Y	P	R	P	V	S	D	F	S
T	A	L	D	G	F	D	V	V	Q	G	Y	P	R	N	I	Y	-	S	L
W	R	Y	I	N	F	K	M	S	P	G	F	P	K	K	L	N	-	-	-
W	R	Y	V	D	F	K	M	S	P	G	F	P	M	K	F	N	-	-	-
W	I	T	R	G	F	Q	M	Q	-	G	P	P	R	T	I	Y	-	D	F
W	I	T	R	G	F	Q	M	Q	-	G	P	P	R	T	I	Y	-	D	F
W	V	T	R	G	F	H	M	Q	-	G	P	P	R	T	I	Y	-	D	F
W	I	T	R	G	F	Q	M	Q	-	G	P	P	R	T	I	Y	-	D	F
W	V	F	K	E	V	T	V	E	P	G	Y	P	H	S	L	G	E	L	G
W	V	F	K	E	V	T	V	E	P	G	Y	P	H	S	L	G	E	L	G
W	V	F	K	E	V	T	V	E	P	G	Y	P	H	S	L	G	E	L	G
W	V	F	Q	D	R	Q	L	E	G	G	-	A	R	P	L	T	E	L	G
W	R	F	R	G	P	K	P	V	W	G	L	P	Q	L	C	R	-	-	-
P	S	L	A	K	K	Q	R	F	R	H	R	N	R	K	G	Y	R	S	Q
S	A	Q	A	K	K	Q	K	S	K	R	R	S	R	K	R	Y	R	S	R
P	S	Q	P	K	M	T	K	S	A	R	R	S	G	K	R	Y	R	S	R
P	S	-	A	K	K	Q	K	S	R	R	R	S	R	K	R	Y	R	S	R

(Table IV continued)

101										111							
G	L	P	P	D	V	Q	R	I	D	A	A	F	N	W	G	R	N
S	V	F	C	K	P	Q	N	M	R	E	V	G	F	E	Y	M	N
S	V	F	C	K	P	Q	S	M	R	E	V	G	F	E	Y	M	N
G	L	P	P	D	V	Q	R	V	D	A	A	F	N	W	S	K	N
G	F	P	R	T	V	K	S	I	D	A	A	V	S	E	E	D	T
G	F	P	S	T	V	K	N	I	D	A	A	V	S	E	E	D	T
G	F	P	R	T	V	K	H	I	D	A	A	L	S	E	E	N	T
G	F	P	S	T	V	K	N	I	D	A	A	V	F	E	E	D	T
G	L	P	P	D	V	Q	R	V	D	A	A	F	N	W	S	K	N
G	F	P	P	T	V	R	K	I	D	A	A	I	S	D	K	E	K
G	L	P	A	T	V	K	K	I	D	A	A	I	S	N	K	E	K
G	F	P	S	T	I	R	K	I	D	A	A	I	S	D	K	E	R
G	L	P	E	T	V	Q	K	I	D	A	A	I	S	L	K	D	Q
G	F	P	S	S	V	Q	A	I	D	A	A	V	F	Y	R	-	-
G	F	P	R	S	V	Q	A	I	D	A	A	V	S	Y	N	-	-
G	F	P	R	S	V	Q	A	I	D	A	A	V	S	Y	N	-	-
G	L	G	P	E	V	A	Q	V	T	G	A	L	P	R	P	E	-
G	L	G	P	E	V	T	Q	V	T	G	A	L	P	Q	G	G	-
G	L	G	A	D	V	A	Q	V	T	G	A	L	R	S	G	R	-
G	L	G	P	E	V	T	H	V	S	G	L	L	P	R	R	P	-
G	F	P	P	T	I	R	K	I	D	A	A	V	S	D	K	E	K
G	F	P	P	T	V	K	K	I	D	A	A	V	F	E	K	E	K
G	L	V	R	F	P	V	H	A	A	L	V	W	G	P	E	K	-
G	L	Q	G	S	P	V	H	A	A	L	V	W	G	P	E	K	-
G	F	P	N	F	V	K	K	I	D	A	A	V	F	N	P	R	F
G	F	S	A	S	V	K	K	V	D	A	A	V	F	D	P	L	R
G	F	P	D	F	V	K	K	I	D	A	A	V	F	N	P	S	L
G	F	P	A	S	V	K	K	I	D	A	A	V	F	D	P	L	R
G	F	P	K	H	V	K	K	I	S	A	A	L	H	F	E	D	S
G	F	P	K	D	V	K	K	I	S	A	A	V	H	F	E	D	T
G	L	P	K	E	V	K	K	I	S	A	A	V	H	F	E	D	T
G	F	P	R	E	V	K	K	I	S	A	A	V	H	F	E	D	T
R	G	L	P	T	D	K	-	I	D	A	A	L	F	W	M	P	N
R	G	L	P	T	D	K	-	I	D	A	A	L	F	W	M	P	N
R	R	L	P	T	D	K	-	I	D	A	A	L	F	W	M	P	N
R	G	L	P	T	D	K	-	I	D	A	A	L	F	W	M	P	N
R	G	L	P	T	D	K	-	I	D	A	A	L	F	W	M	P	N
L	G	I	P	Y	D	R	-	I	D	T	A	I	W	W	E	P	T
T	D	I	P	Y	D	R	-	I	D	T	A	I	W	W	E	P	T
S	G	I	P	P	H	G	-	I	D	S	A	I	W	W	E	D	V
N	G	I	P	P	H	G	-	I	D	S	A	I	W	W	E	D	V
N	G	I	P	P	H	G	-	I	D	S	A	I	W	W	E	D	V
-	-	L	P	P	G	G	-	I	D	A	A	F	S	W	A	H	N
-	-	L	P	P	G	G	-	I	D	A	V	F	S	W	A	H	N
G	F	P	K	T	V	K	R	I	D	A	A	V	H	I	E	Q	L
-	-	-	R	V	E	P	N	L	D	A	A	L	Y	W	P	L	N
-	-	-	R	V	E	P	N	L	D	A	A	L	Y	W	P	V	N
G	F	P	R	Y	V	Q	R	I	D	A	A	V	Y	L	K	D	A
G	F	P	R	H	V	Q	Q	I	D	A	A	V	Y	L	R	E	P
G	F	P	R	H	V	Q	R	I	D	A	A	V	Y	L	K	E	P
G	F	P	R	Y	V	Q	R	I	D	A	A	V	H	L	K	D	T
S	C	L	P	R	E	G	-	I	D	T	A	L	R	W	E	P	V
S	C	L	P	R	E	G	-	I	D	T	A	L	R	W	E	P	V
S	C	L	P	R	E	G	-	I	D	T	A	L	R	W	E	P	V
-	-	L	P	P	G	E	E	V	D	A	V	F	S	W	P	Q	N
-	A	G	G	L	P	R	H	P	D	A	A	L	F	F	P	P	L
R	G	H	S	R	G	R	N	Q	-	-	-	-	N	S	R	R	P
R	G	R	G	H	R	R	S	Q	S	-	-	S	N	S	R	R	S
R	G	R	G	R	G	R	G	H	S	R	S	Q	K	S	H	R	Q
Y	G	-	-	R	G	R	S	Q	-	-	-	-	N	S	R	R	L

(Table IV continued)

121									
K	K	T	Y	I	F	S	G	D	R
R	E	L	L	W	H	G	F	A	E
R	E	L	L	W	H	G	F	A	E
K	K	T	Y	I	F	A	G	D	K
G	K	T	Y	F	F	V	A	N	K
G	K	T	Y	F	F	V	A	D	K
G	K	T	Y	F	F	V	A	N	K
G	K	T	Y	F	F	V	A	H	E
K	K	T	Y	I	F	A	G	D	K
N	K	T	Y	F	F	V	E	D	K
R	K	T	Y	F	F	V	E	D	K
K	K	T	Y	F	F	V	E	D	K
K	K	T	Y	F	F	V	E	D	K
S	K	T	Y	F	F	V	N	D	Q
G	K	T	Y	F	F	I	N	N	Q
G	K	T	Y	F	F	V	N	N	Q
G	K	V	L	L	F	S	G	Q	S
G	K	V	L	L	F	S	R	Q	R
G	K	M	L	L	F	S	G	R	R
G	K	A	L	L	F	S	K	G	R
K	K	T	Y	F	F	A	A	D	K
K	K	T	Y	F	F	V	G	D	K
N	K	I	Y	F	F	R	G	R	D
N	K	I	Y	F	F	R	G	G	D
Y	R	T	Y	F	F	V	D	N	Q
Q	K	V	Y	F	F	V	D	K	H
R	K	T	Y	F	F	V	D	N	L
Q	K	V	Y	F	F	V	D	K	Q
G	K	T	L	F	F	S	E	N	Q
G	K	T	L	F	F	S	G	N	Q
G	K	T	L	L	F	S	G	N	Q
G	K	T	L	F	F	S	G	N	Q
G	K	T	Y	F	F	R	G	N	K
G	K	T	Y	F	F	R	G	N	K
G	K	D	Y	F	F	R	G	N	K
G	K	T	Y	F	F	R	G	N	K
G	K	T	Y	F	F	R	G	N	K
G	H	T	F	F	F	Q	E	D	R
G	H	T	F	F	F	Q	A	D	R
G	K	T	Y	F	F	K	G	D	R
G	K	T	Y	F	F	K	G	D	R
G	K	T	Y	F	F	K	G	D	R
D	R	T	Y	F	F	K	D	Q	L
D	R	T	Y	F	F	K	D	Q	L
G	K	T	Y	F	F	A	A	K	K
Q	K	V	F	L	F	K	G	S	G
Q	K	V	F	L	F	K	G	S	G
Q	K	T	L	F	F	V	G	D	E
Q	K	T	L	F	F	V	G	D	E
Q	K	T	L	F	F	V	G	E	E
Q	K	T	L	F	F	V	G	D	E
G	K	T	Y	F	F	K	G	E	R
G	K	T	Y	F	F	K	G	E	R
G	K	T	Y	F	F	K	G	E	R
G	K	T	Y	L	V	R	G	R	Q
R	R	L	I	L	F	K	G	A	R
S	R	A	T	W	L	S	-	-	-
S	R	S	I	W	F	S	-	-	-
S	R	S	T	W	L	P	-	-	-
S	R	S	I	S	R	L	-	-	-

131									
Y	W	K	Y	N	E	E	K	K	K
F	L	I	F	L	L	P	L	I	N
F	L	V	F	L	L	P	L	I	N
F	W	R	Y	N	E	V	K	K	K
C	W	R	Y	D	E	Y	K	Q	S
Y	W	R	Y	D	E	Y	K	R	S
Y	W	R	Y	D	E	Y	K	R	S
C	W	R	Y	D	E	Y	K	Q	S
F	W	R	Y	N	E	V	K	K	K
Y	W	R	F	D	E	K	R	N	S
Y	W	R	F	D	E	K	K	Q	S
Y	W	R	F	D	E	K	R	Q	S
F	W	R	F	D	E	K	K	Q	S
F	W	R	Y	D	N	Q	R	Q	F
C	W	R	Y	D	N	E	R	R	S
C	W	R	Y	D	N	Q	R	R	S
F	W	R	F	D	V	K	T	Q	K
F	W	S	F	D	V	K	T	Q	T
L	W	R	F	D	V	K	A	Q	M
V	W	R	F	D	L	K	S	Q	K
Y	W	R	F	D	E	N	S	Q	S
Y	W	R	F	D	E	T	R	H	V
Y	W	R	F	H	P	S	T	R	R
Y	W	R	F	H	P	R	T	Q	R
Y	W	R	Y	D	E	R	R	Q	M
Y	W	R	Y	D	V	R	Q	E	L
Y	W	R	Y	D	E	R	R	E	V
Y	W	R	Y	D	V	R	Q	E	L
V	W	S	Y	D	D	T	N	H	V
V	W	R	Y	D	D	T	N	R	M
V	W	R	Y	D	D	T	N	H	I
V	W	S	Y	D	D	T	N	H	T
Y	Y	R	F	N	E	E	L	R	A
Y	Y	R	F	N	E	E	F	R	A
Y	Y	R	F	N	E	E	L	R	A
Y	Y	R	F	N	E	E	L	R	A
Y	Y	R	F	N	E	E	F	R	A
Y	W	R	F	N	E	E	T	Q	R
Y	W	R	F	N	E	E	T	Q	H
Y	W	R	Y	S	E	E	M	K	T
Y	W	R	Y	S	E	E	M	K	T
Y	W	R	Y	S	E	E	M	K	T
Y	W	R	Y	D	D	H	T	R	H
Y	W	R	Y	D	D	H	T	R	R
Y	W	S	Y	D	E	D	K	K	Q
Y	W	Q	W	D	E	L	A	R	T
Y	W	Q	W	D	E	L	A	R	T
Y	Y	S	Y	D	E	R	K	R	K
Y	Y	S	Y	D	E	R	K	R	K
Y	Y	S	Y	D	E	R	K	K	K
Y	Y	S	Y	D	E	R	K	R	K
Y	W	R	Y	S	E	E	R	R	A
Y	W	R	Y	S	E	E	R	R	A
Y	W	R	Y	S	E	E	R	R	A
Y	W	R	Y	D	E	A	A	A	R
Y	Y	V	L	A	R	G	G	L	Q
L	F	S	S	E	E	S	N	L	G
L	F	S	S	E	E	S	G	L	G
W	F	S	S	E	E	T	G	P	G
W	F	S	S	E	E	V	S	L	G

(Table IV continued)

141										151									
M	E	L	A	T	P	K	F	I	A	D	S	W	N	G	V	P	D	N	L
I	Q	K	L	R	A	K	L	S	S	W	C	T	L	C	T	G	A	A	G
I	Q	K	L	K	A	K	L	S	S	W	C	I	P	L	T	S	T	A	G
M	D	P	G	F	P	R	L	I	A	D	A	W	N	A	I	P	D	H	L
M	D	A	G	Y	P	K	M	I	A	E	D	F	P	G	I	G	N	K	V
M	D	A	G	Y	P	K	M	I	A	D	D	F	P	G	I	G	D	K	V
M	D	P	G	Y	P	K	M	I	A	H	D	F	P	G	I	G	H	K	V
M	D	T	G	Y	P	K	M	I	A	E	E	F	P	G	I	G	N	K	V
M	D	P	G	F	P	K	L	I	A	D	A	W	N	A	I	P	D	N	L
M	E	P	G	F	P	K	Q	I	A	E	D	F	P	G	I	D	S	K	I
M	E	P	G	F	P	R	K	I	A	E	D	F	P	G	V	D	S	R	V
L	E	P	G	F	P	R	H	I	A	E	D	F	P	G	I	N	P	K	I
M	D	P	E	F	P	R	K	I	A	E	N	F	P	G	I	G	T	K	V
M	E	P	G	Y	P	K	S	I	S	G	A	F	P	G	I	E	S	K	V
M	D	P	G	Y	P	K	S	I	P	S	M	F	P	G	V	N	C	R	V
M	D	P	G	Y	P	T	S	I	A	S	V	F	P	G	I	N	C	R	I
V	D	P	Q	S	V	T	P	V	D	Q	M	F	P	G	V	P	I	S	T
V	D	P	R	S	A	G	S	V	E	Q	M	Y	P	G	V	P	L	N	T
V	D	P	R	S	A	S	E	V	D	R	M	F	P	G	V	P	L	D	T
V	D	P	Q	S	V	I	R	V	D	K	E	F	S	G	V	P	W	N	S
M	E	Q	G	F	P	R	L	I	A	D	D	F	P	G	V	E	P	K	V
M	D	K	G	F	P	R	Q	I	T	D	D	F	P	G	I	E	P	Q	V
V	D	S	-	P	V	P	R	R	A	T	D	W	R	G	V	P	S	E	I
V	D	N	-	P	V	P	R	R	S	T	D	W	R	G	V	P	S	E	I
M	D	P	G	Y	P	K	L	I	T	K	N	F	Q	G	I	G	P	K	I
M	D	P	A	Y	P	K	L	I	S	T	H	F	P	G	I	K	P	K	I
M	D	A	G	Y	P	K	L	I	T	K	H	F	P	G	I	G	P	K	I
M	D	A	A	Y	P	K	L	I	S	T	H	F	P	G	I	R	P	K	I
M	D	K	D	Y	P	R	L	I	E	E	V	F	P	G	I	G	D	K	V
M	D	K	D	Y	P	R	L	I	E	E	D	F	P	G	I	G	D	K	V
M	D	K	D	Y	P	R	L	I	E	E	D	F	P	G	I	G	D	K	V
M	D	Q	D	Y	P	R	L	I	E	E	E	F	P	G	I	G	G	K	V
V	D	S	E	Y	P	K	N	I	K	-	V	W	E	G	I	P	E	S	P
V	D	S	E	Y	P	K	N	I	K	-	V	W	E	G	I	P	E	S	P
V	D	S	E	Y	P	K	N	I	K	-	V	W	E	G	I	P	E	S	P
V	D	S	E	Y	P	K	N	I	K	-	V	W	E	G	I	P	E	S	P
V	D	S	E	Y	P	K	N	I	K	-	V	W	E	G	I	P	E	S	P
G	D	P	G	Y	P	K	P	I	S	-	V	W	Q	G	I	P	A	S	P
G	D	P	G	Y	P	K	P	I	S	-	V	W	Q	G	I	P	T	S	P
M	D	P	G	Y	P	K	P	I	T	-	V	W	K	G	I	P	E	S	P
M	D	P	G	Y	P	K	P	I	T	-	I	W	K	G	I	P	E	S	P
M	D	P	G	Y	P	K	P	I	T	-	I	W	K	G	I	P	E	S	P
M	D	P	G	Y	P	A	Q	S	P	-	L	W	R	G	V	P	S	T	L
M	D	P	G	Y	P	A	Q	G	P	-	L	W	R	G	V	P	S	M	L
M	D	K	G	F	P	K	Q	I	S	N	D	F	P	G	I	P	D	K	I
D	F	S	S	Y	P	K	P	I	K	G	L	F	T	G	V	P	N	Q	P
D	L	S	R	Y	P	K	P	I	K	E	L	F	T	G	V	P	D	R	P
M	E	K	D	Y	P	K	S	T	E	E	E	F	S	G	V	N	G	Q	I
M	E	K	D	Y	P	K	N	T	E	E	E	F	S	G	V	N	G	Q	I
M	E	K	D	Y	P	K	N	T	E	E	E	F	S	G	V	S	G	H	I
M	D	K	D	Y	P	K	N	T	E	E	E	F	S	G	V	N	G	Q	I
T	D	P	G	Y	P	K	P	I	T	-	V	W	K	G	I	P	Q	A	P
T	D	P	G	Y	P	K	P	I	T	-	V	W	K	G	I	P	Q	A	P
T	D	P	G	Y	P	K	P	I	T	-	V	W	K	G	I	P	Q	A	P
P	D	P	G	Y	P	R	D	L	S	-	L	W	E	G	A	P	P	S	P
V	E	P	Y	Y	P	R	S	L	Q	-	D	W	G	G	I	P	E	E	V
A	N	N	Y	D	D	Y	R	M	D	W	L	V	P	A	T	C	E	P	I
T	Y	N	N	Y	D	Y	D	M	D	W	L	V	P	A	T	C	E	P	I
G	Y	N	Y	D	D	Y	K	M	D	W	L	V	P	A	T	C	E	P	I
P	Y	N	Y	E	D	Y	E	T	S	W	L	K	P	A	T	S	E	P	I

(Table IV continued)

161										171									
D	A	V	L	G	L	T	D	S	G	Y	T	Y	F	F	K	D	Q	Y	Y
H	D	S	T	L	G	S	S	G	K	E	C	A	L	C	G	E	W	P	T
S	D	S	T	L	G	S	S	G	K	E	C	A	L	C	G	E	W	P	T
D	A	V	V	D	L	Q	G	S	G	H	S	Y	F	F	K	G	T	Y	Y
D	A	V	F	Q	K	G	-	-	G	F	F	Y	F	F	H	G	R	R	Q
D	A	V	F	Q	K	D	-	-	G	F	F	Y	F	F	H	G	T	R	Q
D	A	V	F	M	K	D	-	-	G	F	F	Y	F	F	H	G	T	R	Q
D	A	V	F	Q	K	D	-	-	G	F	L	Y	F	F	H	G	T	R	Q
D	A	V	V	D	L	Q	G	G	G	H	S	Y	F	F	K	G	A	Y	Y
D	A	V	F	E	E	F	-	-	G	F	F	Y	F	F	T	G	S	S	Q
D	A	V	F	E	A	F	-	-	G	F	L	Y	F	F	S	G	S	S	Q
D	A	V	F	E	A	F	-	-	G	F	F	Y	F	F	S	G	S	S	Q
D	A	V	F	E	A	F	-	-	G	F	L	Y	F	F	S	G	S	S	Q
D	A	V	F	Q	Q	E	-	-	H	F	F	H	V	F	S	G	P	R	Y
D	A	V	F	L	Q	D	-	-	S	F	F	L	F	F	S	G	P	Q	Y
D	A	V	F	Q	Q	D	-	-	S	F	F	L	F	F	S	G	P	Q	Y
H	D	I	F	Q	Y	Q	E	-	-	K	A	Y	F	C	Q	D	H	F	Y
H	D	I	F	Q	Y	Q	E	-	-	K	A	Y	F	C	Q	D	R	F	Y
H	D	V	F	Q	Y	R	E	-	-	K	A	Y	F	C	Q	D	R	F	Y
H	D	I	F	Q	Y	Q	D	-	-	K	A	Y	F	C	H	G	K	F	F
D	A	V	L	Q	A	F	-	-	G	F	F	Y	F	F	S	G	S	S	Q
D	A	V	L	H	E	F	-	-	G	F	F	Y	F	F	R	G	S	S	Q
D	A	A	F	Q	D	A	D	G	-	Y	A	Y	F	L	R	G	R	L	Y
D	A	A	F	Q	D	A	E	G	-	Y	A	Y	F	L	R	G	H	L	Y
D	A	V	F	Y	S	K	N	-	K	Y	Y	Y	F	F	Q	G	S	N	Q
D	A	V	L	Y	F	K	-	-	R	H	Y	Y	I	F	Q	G	A	Y	Q
D	A	V	F	Y	F	Q	-	-	R	Y	Y	Y	F	F	Q	G	P	N	Q
D	A	V	L	Y	F	K	-	-	R	H	Y	Y	I	F	Q	G	A	Y	Q
D	A	V	Y	Q	K	N	-	-	G	Y	I	Y	F	F	N	G	P	I	Q
D	A	V	Y	E	K	N	-	-	G	Y	I	Y	F	F	N	G	P	I	Q
D	A	V	Y	E	K	N	-	-	G	Y	I	Y	F	F	N	G	P	I	Q
D	A	V	Y	E	K	N	-	-	G	Y	I	Y	F	F	N	G	P	I	Q
R	G	S	F	M	G	S	D	E	V	F	T	Y	F	Y	K	G	N	K	Y
R	G	S	F	M	G	S	D	E	V	F	T	Y	F	Y	K	G	N	K	Y
R	G	S	F	M	G	S	D	E	V	F	T	Y	F	Y	K	G	N	K	Y
R	G	S	F	M	G	S	D	E	V	F	T	Y	F	Y	K	G	N	K	Y
R	G	S	F	M	G	S	D	E	V	F	T	Y	F	Y	K	G	N	K	Y
K	G	A	F	L	S	N	D	A	A	Y	T	Y	F	Y	K	G	T	K	Y
K	G	A	F	L	S	N	D	A	A	Y	T	Y	F	Y	K	G	T	K	Y
Q	G	A	F	V	H	K	E	N	G	F	T	Y	F	Y	K	G	K	E	Y
Q	G	A	F	V	H	K	E	N	G	F	T	Y	F	Y	K	G	K	E	Y
Q	G	A	F	V	H	K	E	N	G	F	T	Y	F	Y	K	G	K	E	Y
D	D	A	M	R	W	S	D	G	-	A	S	Y	F	F	R	G	Q	E	Y
D	D	A	M	R	W	S	D	G	-	A	S	Y	F	F	R	G	Q	E	Y
D	A	A	F	Y	Y	R	-	-	G	R	L	Y	F	F	I	G	R	S	Q
S	A	A	M	S	W	Q	D	-	G	R	V	Y	F	F	K	G	K	V	Y
S	A	A	M	S	W	Q	D	-	G	Q	V	Y	F	F	K	G	K	E	Y
D	A	A	V	E	L	N	-	-	G	Y	I	Y	F	F	S	G	P	K	A
D	A	A	V	E	L	N	-	-	G	Y	I	Y	F	F	S	G	P	K	T
D	A	A	V	E	L	N	-	-	G	Y	I	Y	F	F	S	G	R	K	T
D	A	A	V	E	L	N	-	-	G	Y	I	Y	F	F	S	G	P	K	A
Q	G	A	F	I	S	K	E	G	Y	Y	T	Y	F	Y	K	G	R	D	Y
Q	G	A	F	I	S	K	E	G	Y	Y	T	Y	F	Y	K	G	R	D	Y
Q	G	A	F	I	S	K	E	G	Y	Y	T	Y	F	Y	K	G	R	D	Y
D	D	V	T	V	S	N	A	G	-	D	T	Y	F	F	K	G	A	H	Y
S	G	A	L	P	R	P	D	-	G	S	I	I	F	F	R	D	D	R	Y
Q	S	-	-	-	-	-	-	-	-	-	V	F	F	F	S	G	D	K	Y
Q	S	-	-	-	-	-	-	-	-	-	V	Y	F	F	S	G	D	K	Y
Q	S	-	-	-	-	-	-	-	-	-	V	Y	F	F	S	G	E	E	Y
Q	S	-	-	-	-	-	-	-	-	-	V	Y	F	F	S	G	D	K	Y

(Table IV continued)

181										191									
L	Q	M	E	D	K	S	L	K	I	-	-	-	-	-	-	-	V	K	I
M	P	H	T	I	G	C	E	H	V	F	C	Y	-	-	-	-	Y	C	V
M	P	H	T	I	G	C	E	H	V	F	C	Y	-	-	-	-	Y	C	V
L	K	L	E	N	Q	S	L	K	S	-	-	-	-	-	-	-	V	K	V
Y	K	F	D	P	Q	T	K	R	I	-	-	-	-	-	-	-	L	T	L
Y	K	F	D	P	K	T	K	R	I	-	-	-	-	-	-	-	L	T	L
Y	K	F	D	P	K	T	K	R	I	-	-	-	-	-	-	-	L	T	L
Y	Q	F	D	F	K	T	K	R	I	-	-	-	-	-	-	-	L	T	L
L	K	L	E	N	Q	S	L	K	S	-	-	-	-	-	-	-	V	K	F
L	E	F	D	P	N	A	K	K	V	-	-	-	-	-	-	-	T	H	T
L	E	F	D	P	N	A	K	K	V	-	-	-	-	-	-	-	T	H	I
S	E	F	D	P	N	A	K	K	V	-	-	-	-	-	-	-	T	H	V
L	E	F	D	P	N	A	G	K	V	-	-	-	-	-	-	-	T	H	I
Y	A	F	D	L	I	A	Q	R	V	-	-	-	-	-	-	-	T	R	V
F	A	F	N	F	V	S	H	R	V	-	-	-	-	-	-	-	T	R	V
F	A	F	N	L	V	S	R	R	V	-	-	-	-	-	-	-	T	R	V
W	R	V	S	S	Q	N	E	V	N	-	-	-	-	-	-	-	Q	V	D
W	R	V	N	S	R	N	E	V	N	-	-	-	-	-	-	-	Q	V	D
W	R	V	S	S	R	S	E	L	N	-	-	-	-	-	-	-	Q	V	D
W	R	V	S	F	Q	N	E	V	N	K	V	D	P	E	V	N	Q	V	D
F	E	F	D	P	N	A	R	M	V	-	-	-	-	-	-	-	T	H	I
F	E	F	D	P	N	A	R	T	V	-	-	-	-	-	-	-	T	H	I
W	K	F	D	P	V	K	V	K	A	-	-	-	-	-	-	-	L	E	G
W	K	F	D	P	V	K	V	K	V	-	-	-	-	-	-	-	L	E	G
F	E	Y	D	F	L	L	Q	R	I	-	-	-	-	-	-	-	T	K	T
L	E	Y	D	P	L	F	R	R	V	-	-	-	-	-	-	-	T	K	T
L	E	Y	D	T	F	S	S	R	V	-	-	-	-	-	-	-	T	K	K
L	E	Y	D	P	L	L	D	R	V	-	-	-	-	-	-	-	T	K	T
F	E	Y	S	I	W	S	N	R	I	-	-	-	-	-	-	-	V	R	V
F	E	Y	S	I	W	S	N	R	I	-	-	-	-	-	-	-	V	R	V
F	E	Y	S	I	W	S	N	R	I	-	-	-	-	-	-	-	V	R	V
F	E	Y	S	I	W	S	K	R	I	-	-	-	-	-	-	-	V	R	V
W	K	F	N	N	Q	K	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	K	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	K	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	K	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	K	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	D	N	E	R	L	R	M	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	E	R	L	R	M	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	I	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	I	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	F	N	N	Q	I	L	K	V	-	-	-	-	-	-	-	E	P	G
W	K	V	L	D	G	E	L	E	V	-	-	-	-	-	-	-	A	P	G
W	K	V	L	D	G	E	L	E	A	-	-	-	-	-	-	-	A	P	G
F	E	Y	N	I	N	S	K	R	I	-	-	-	-	-	-	-	V	Q	V

W	R	L	N	Q	Q	L	R	V	E	-	-	-	-	-	-	-	-	K	G
W	R	L	N	Q	Q	L	R	V	A	-	-	-	-	-	-	-	-	K	G
Y	K	S	D	T	E	K	E	D	V	-	-	-	-	-	-	-	V	S	E
Y	K	Y	D	T	E	K	E	D	V	-	-	-	-	-	-	-	V	S	V
F	K	Y	D	T	E	K	E	D	V	-	-	-	-	-	-	-	V	S	V
Y	K	Y	D	T	E	K	E	D	V	-	-	-	-	-	-	-	V	S	V
W	K	F	D	N	Q	K	L	S	V	-	-	-	-	-	-	-	E	P	G
W	K	F	D	N	Q	K	L	S	V	-	-	-	-	-	-	-	E	P	G
W	K	F	D	N	Q	K	L	S	V	-	-	-	-	-	-	-	E	P	G
W	R	F	P	K	N	S	I	K	T	-	-	-	-	-	-	-	E	P	D
W	R	L	D	Q	A	K	L	Q	A	-	-	-	-	-	-	-	T	T	S
Y	R	V	N	L	R	T	R	R	V	D	T	-	-	-	-	V	D	P	P
Y	R	V	N	L	R	T	R	R	V	D	S	-	-	-	-	V	N	P	P
Y	R	V	N	L	R	T	Q	R	V	D	T	-	-	-	-	V	T	P	P
Y	R	V	N	L	R	T	Q	R	V	D	T	-	-	-	-	V	N	P	P

(Table IV continued)

201									210
G	K	I	S	S	D	W	L	G	C
K	S	S	F	L	F	Y	F	T	C
K	S	S	F	L	F	Y	F	T	C
G	S	I	K	T	D	W	L	G	C
L	K	A	N	S	-	W	F	N	C
Q	K	A	N	S	-	W	F	N	C
Q	K	A	N	S	-	W	F	N	C
Q	K	A	N	S	-	W	F	N	C
G	S	I	K	S	D	W	L	G	C
L	K	S	N	S	-	W	L	N	C
L	K	S	N	S	-	W	F	N	C
L	K	S	N	S	-	W	F	Q	C
L	K	S	N	S	-	W	F	N	C
A	R	G	N	K	-	W	L	N	C
A	R	S	N	L	-	W	L	N	C
A	R	S	N	L	-	W	L	N	C
Y	V	G	Y	V	T	L	L	K	C
E	V	G	Y	V	T	I	L	Q	C
Q	V	G	Y	V	T	I	L	Q	C
D	V	G	Y	V	T	L	L	Q	C
L	K	S	N	S	-	W	L	H	C
L	K	S	N	S	-	W	L	L	C
F	P	R	L	V	G	F	F	G	C
F	P	R	P	V	G	F	F	D	C
L	K	S	N	S	-	W	F	G	C
L	K	S	T	S	-	W	F	G	C
L	K	S	N	S	-	W	F	D	C
L	S	S	T	S	-	W	F	G	C
M	T	T	N	S	-	L	L	W	C
M	P	T	N	S	-	L	L	W	C
M	P	A	N	S	-	I	L	W	C
M	P	T	N	S	-	L	L	W	C
Y	P	K	S	A	L	W	M	G	C
Y	P	K	S	A	L	W	M	G	C
Y	P	K	S	A	L	W	M	G	C
Y	P	K	S	A	L	W	M	G	C
Y	P	K	S	A	L	W	M	G	C
Y	P	K	S	I	L	F	M	G	C
H	P	K	S	I	L	F	M	G	C
Y	P	R	S	I	L	F	M	G	C
Y	P	R	S	I	L	F	M	G	C
Y	P	R	S	I	L	F	M	G	C
Y	P	Q	S	T	A	W	L	V	C
Y	P	Q	S	T	A	W	L	V	C
L	R	S	N	S	-	W	L	G	C
Y	P	R	N	I	S	W	M	H	C
Y	P	R	N	T	T	W	M	H	C
L	K	S	S	S	-	W	I	G	C
V	K	S	S	S	-	W	I	G	C
V	K	S	S	S	-	W	I	G	C
L	K	S	N	S	-	W	I	G	C
Y	P	R	N	I	L	W	M	G	C
Y	P	R	N	I	L	W	M	G	C
Y	P	R	N	I	L	W	M	G	C
A	P	Q	P	M	G	W	L	D	C
G	R	W	A	T	E	W	M	G	C
Y	P	R	S	I	A	W	L	G	C
Y	P	R	S	I	A	W	L	G	C
Y	P	R	S	I	A	W	L	G	C
Y	P	R	S	I	A	W	L	G	C

(Table IV end).

This method for the determination of the amino acid diversity number is an all-purpose method and generally applicable and not limited to a specific amino acid sequence, polypeptide, domain or protein. Thus, the proceeding can be applied

similarly and accordingly with other sequences to determine and identify amino acid positions with a high variability and which are accessible for alteration without having a strong influence on the stability and functionality of the structure.

With the amino acid diversity calculation amino acid positions with a low diversity number, i.e. smaller than 6, have been identified. This low diversity number resembles a high conservation like e.g. for the cysteine residue in position Nr. 4 (see table III), which was found to be conserved in 57 of the 60 sequences analyzed (see table IV). The cysteine residue in position Nr. 210 was found to be conserved in all analyzed hemopexin-like sequences. This demonstrates the excellent applicability of this approach, as these two cysteine residues are of high importance in the scaffold. These two residues form the disulphide bond that is essential for the formation of the hemopexin-like structure by linking the fourth blade with the first blade of the polypeptide.

From the amino acid diversity number as compiled and listed table III amino acid positions in the consensus sequence with a high diversity/variability can be identified. Because from the identified high diversity amino acid numbers of the consensus sequence the corresponding amino acid numbers of the full length polypeptide cannot be obtained directly, table V lists the amino acid numbers of the identified high diversity amino acids, i.e. alterable amino acids, of the full length polypeptides of SEQ ID NO:02 to SEQ ID NO:61.

Table V: Listing of the alterable amino acid positions in each of the sequences SEQ ID NO:02 to sequence SEQ ID NO:61. The numbering of the positions in each sequence is in consistency with the amino acid numbering of the corresponding full length protein.

SEQ ID NO:02:

470	471	475	476	477	484	501	502	503	504
505	506	507	510	514	515	522	529	530	531
534	541	547	549	550	553	558	559	566	567
568	569	570	577	578	579	580	589	590	597
598	600	604	608	611	612	617	618	619	620
626	627	628	629	638	639	645	646	647	648
650	652	654	655	658	663				

SEQ ID NO:03:

98	99	103	104	105	111	128	131	135	136
145	146	153	159	161	162	165	170	171	179
180	181	182	183	190	191	192	193	202	203
210	211	213	217	221	224	225	230	231	232
233	239	240	241	242	251	252	258	259	260
261	266	268	270	271	274	279			

SEQ ID NO:04:

98	99	103	104	105	111	128	131	135	136
145	146	153	159	161	162	165	170	171	179
180	181	182	183	190	191	192	193	202	203
210	211	213	217	221	224	225	230	231	232
233	239	240	241	242	251	252	258	259	260
261	266	268	270	271	274	279			

(Table V continued)

SEQ ID NO:05:

469	470	474	475	476	483	500	501	502	503
504	505	506	509	513	514	521	528	529	530
533	540	546	548	549	552	557	558	565	566
567	568	569	576	577	578	579	588	589	596
597	599	603	607	610	611	616	617	618	619
625	626	627	628	637	638	644	645	646	647
649	651	653	654	657	662				

SEQ ID NO:06:

276	277	281	282	283	290	307	308	309	310
311	312	315	319	320	327	334	335	336	339
346	352	354	355	358	363	364	372	373	374
375	376	383	384	385	386	395	396	403	404
406	410	414	417	418	423	424	425	426	432
433	442	443	449	450	451	452	456	458	460
461	464	468							

SEQ ID NO:07:

276	277	281	282	283	290	307	308	309	310
311	312	315	319	320	327	334	335	336	339
346	352	354	355	358	363	364	372	373	374
375	376	383	384	385	386	395	396	403	404
406	410	414	417	418	423	424	425	426	432
433	442	443	449	450	451	452	456	458	460
461	464	468							

(Table V continued)

SEQ ID NO:08:

276	277	281	282	283	290	307	308	309	310
311	312	315	319	320	327	334	335	336	339
346	352	354	355	358	363	364	372	373	374
375	376	383	384	385	386	395	396	403	404
406	410	414	417	418	423	424	425	426	432
433	442	443	449	450	451	452	456	458	460
461	464	468							

SEQ ID NO:09:

276	277	281	282	283	290	307	308	309	310
311	312	315	319	320	327	334	335	336	339
346	352	354	355	358	363	364	372	373	374
375	376	383	384	385	386	395	396	403	404
406	410	414	417	418	423	424	425	426	432
433	442	443	449	450	451	452	456	458	460
461	464	468							

SEQ ID NO:10:

467	468	472	473	474	481	498	499	500	501
502	503	504	507	511	512	519	526	527	528
529	531	538	544	546	547	550	555	556	563
564	565	566	567	574	575	576	577	578	586
587	594	595	596	597	601	605	608	609	614
615	616	617	623	624	625	626	635	636	642
643	644	645	647	649	651	652	655	660	

(Table V continued)

SEQ ID NO:11:

288	289	293	294	295	302	319	320	321	322
323	324	327	331	332	339	346	347	348	351
358	364	366	367	370	375	376	383	384	385
386	387	394	395	396	397	406	407	414	415
417	421	425	428	429	434	435	436	437	443
444	454	455	461	462	463	464	467	469	471
472	475	479							

SEQ ID NO:12:

288	289	293	294	295	302	319	320	321	322
323	324	327	331	332	339	346	347	348	351
358	364	366	367	370	375	376	383	384	385
386	387	394	395	396	397	406	407	414	415
417	421	425	428	429	434	435	436	437	443
444	454	455	461	462	463	464	467	469	471
472	475	479							

SEQ ID NO:13:

289	290	294	295	296	303	320	321	322	323
324	325	328	332	333	340	347	348	349	352
359	365	367	368	371	376	377	384	385	386
387	388	395	396	397	398	407	408	415	416
418	422	426	429	430	435	436	437	438	444
445	455	456	462	463	464	465	468	470	472
473	476	480							

(Table V continued)

SEQ ID NO:14:

286	287	291	292	293	300	317	318	319	320
321	322	325	329	330	337	344	345	346	349
356	362	364	365	368	373	374	381	382	383
384	385	392	393	394	395	404	405	412	413
415	419	423	426	427	432	433	434	435	441
442	452	453	459	460	461	462	465	467	469
470	473	477							

SEQ ID NO:15:

277	278	282	283	284	291	308	309	310	311
312	313	316	320	321	328	335	336	337	340
347	353	355	356	359	364	365	372	373	374
375	376	383	384	394	395	402	403	405	409
413	416	417	422	423	424	425	431	432	441
442	448	449	450	451	453	455	457	458	461
465									

SEQ ID NO:16:

277	278	282	283	284	291	308	309	310	311
312	313	316	320	321	328	335	336	337	340
347	353	355	356	359	364	365	372	373	374
375	376	383	384	394	395	402	403	405	409
413	416	417	422	423	424	425	431	432	441
442	448	449	450	451	453	455	457	458	461
465									

(Table V continued)

SEQ ID NO:17:

278 279 283 284 285 292 309 310 311 312
313 314 317 321 322 329 336 337 338 341
348 354 356 357 360 365 366 373 374 375
376 377 384 385 395 396 403 404 406 410
414 417 418 423 424 425 426 432 433 442
443 449 450 451 452 454 456 458 459 462
466

SEQ ID NO:18:

519 520 524 525 532 550 551 552 553 554
555 556 559 563 564 571 578 579 580 583
590 596 597 598 601 605 606 613 614 615
616 617 624 625 626 635 636 643 644 646
650 654 657 658 663 664 665 666 672 673
674 682 683 689 690 691 692 694 696 698
699 702 707

SEQ ID NO:19:

511 512 516 517 524 542 543 544 545 546
547 548 551 555 556 563 570 571 572 575
582 588 589 590 593 597 598 605 606 607
608 609 616 617 618 627 628 635 636 638
642 646 649 650 655 656 657 658 664 665
666 674 675 681 682 683 684 686 688 690
691 694 699

(Table V continued)

SEQ ID NO:20:

514	515	519	520	527	545	546	547	548	549
550	551	554	558	559	566	573	574	575	578
585	591	592	593	596	600	601	608	609	610
611	612	619	620	621	630	631	638	639	641
645	649	652	653	658	659	660	661	667	668
669	677	678	684	685	686	687	695	698	700
701	704	709							

SEQ ID NO:21:

532	533	537	538	545	563	564	565	566	567
568	569	572	576	577	584	591	592	593	596
603	609	610	611	614	618	619	626	627	628
629	630	637	638	639	648	649	656	657	659
663	667	670	671	676	677	678	679	685	686
687	695	696	702	703	704	705	707	709	711
712	715	720							

SEQ ID NO:22:

287	288	291	294	301	316	317	318	319	320
321	324	328	329	336	343	344	345	348	355
361	363	364	367	372	373	380	381	382	383
384	391	392	393	394	403	404	411	412	414
418	422	425	426	431	432	433	434	440	441
450	451	457	458	459	460	462	464	466	467
470	474								

(Table V continued)

SEQ ID NO:23:

287	288	291	294	301	316	317	318	319	320
321	324	328	329	336	343	344	345	348	355
361	363	364	367	372	373	380	381	382	383
384	391	392	393	394	403	404	411	412	414
418	422	425	426	431	432	433	434	440	441
450	451	457	458	459	460	462	464	466	467
470	474								

SEQ ID NO:24:

292	293	296	297	304	322	323	324	325	326
327	330	334	335	342	349	350	351	353	360
366	368	369	372	376	377	384	385	386	387
388	395	396	397	406	407	414	415	417	420
424	427	428	433	434	435	436	442	443	444
445	453	454	460	461	462	463	465	467	469
470	473	478							

SEQ ID NO:25:

296	297	300	301	308	326	327	328	329	330
331	334	338	339	346	353	354	355	357	364
370	372	373	376	380	381	388	389	390	391
392	399	400	401	410	411	418	419	421	424
428	431	432	437	438	439	440	446	447	448
449	457	458	464	465	466	467	469	471	473
474	477	482							

(Table V continued)

SEQ ID NO:26:

	280	281	285	286	287	294	311	312	313	314
	315	316	319	323	324	331	338	339	340	343
5	350	356	358	359	362	367	368	375	376	377
	378	379	386	387	388	389	398	399	406	407
	409	413	417	420	421	426	427	428	429	435
	436	437	446	447	453	454	455	456	458	460
	462	463	466	470						

10 SEQ ID NO:27:

	273	274	278	279	280	287	304	305	306	307
	308	309	312	316	317	324	331	332	333	336
	343	349	351	352	355	360	361	368	369	370
	371	372	379	380	381	382	391	392	399	400
15	402	406	410	413	414	419	420	421	422	428
	429	438	439	445	446	447	448	450	452	454
	455	458	462							

SEQ ID NO:28:

	275	276	280	281	282	289	306	307	308	309
20	310	311	314	318	319	326	333	334	335	338
	345	351	353	354	357	362	363	370	371	372
	373	374	381	382	383	384	393	394	401	402
	404	408	412	415	416	421	422	423	424	430
	431	440	441	447	448	449	450	452	454	456
25	457	460	464							

(Table V continued)

SEQ ID NO:29:

276	277	281	282	283	290	307	308	309	310
311	312	315	319	320	327	334	335	336	339
346	352	354	355	358	363	364	371	372	373
374	375	382	383	384	385	394	395	402	403
405	409	413	416	417	422	423	424	425	431
432	441	442	448	449	450	451	453	455	457
458	461	465							

SEQ ID NO:30:

282	283	287	288	289	296	313	314	315	316
317	318	321	325	326	333	340	341	342	345
352	358	360	361	364	369	370	377	378	379
380	381	388	389	390	391	400	401	408	409
411	415	419	422	423	428	429	430	431	437
438	447	448	454	455	456	457	459	461	463
464	467	471							

SEQ ID NO:31:

283	284	288	289	290	297	314	315	316	317
318	319	322	326	327	334	341	342	343	346
353	359	361	362	365	370	371	378	379	380
381	382	389	390	391	392	401	402	409	410
412	416	420	423	424	429	430	431	432	438
439	448	449	455	456	457	458	460	462	464
465	468	472							

(Table V continued)

SEQ ID NO:32:

282	283	287	288	289	296	313	314	315	316
317	318	321	325	326	333	340	341	342	345
352	358	360	361	364	369	370	377	378	379
380	381	388	389	390	391	400	401	408	409
411	415	419	422	423	428	429	430	431	437
438	447	448	454	455	456	457	459	461	463
464	467	471							

SEQ ID NO:33:

282	283	287	288	289	296	313	314	315	316
317	318	321	325	326	333	340	341	342	345
352	358	360	361	364	369	370	377	378	379
380	381	388	389	390	391	400	401	408	409
411	415	419	422	423	428	429	430	431	437
438	447	448	454	455	456	457	459	461	463
464	467	471							

SEQ ID NO:34:

317	318	322	329	347	348	349	350	351	352
355	359	360	367	374	375	378	385	391	393
394	397	402	403	411	412	413	414	421	422
423	424	433	434	441	442	444	448	452	454
455	460	461	462	463	469	470	471	472	481
482	488	489	490	491	493	495	497	498	501
506									

(Table V continued)

SEQ ID NO:35:

317 318 322 329 347 348 349 350 351 352
355 359 360 367 374 375 378 385 391 393
394 397 402 403 411 412 413 414 421 422
423 424 433 434 441 442 444 448 452 454
455 460 461 462 463 469 470 471 472 481
482 488 489 490 491 493 495 497 498 501
506

SEQ ID NO:36:

315 316 320 327 345 346 347 348 349 350
353 357 358 365 372 373 376 383 389 391
392 395 400 401 409 410 411 412 419 420
421 422 431 432 439 440 442 446 450 452
453 458 459 460 461 467 468 469 470 479
480 486 487 488 489 491 493 495 496 499
504

SEQ ID NO:37:

317 318 322 329 347 348 349 350 351 352
355 359 360 367 374 375 378 385 391 393
394 397 402 403 411 412 413 414 421 422
423 424 433 434 441 442 444 448 452 454
455 460 461 462 463 469 470 471 472 481
482 488 489 490 491 493 495 497 498 501
506

(Table V continued)

SEQ ID NO:38:

317 318 322 329 347 348 349 350 351 352
355 359 360 367 374 375 378 385 391 393
394 397 402 403 411 412 413 414 421 422
423 424 433 434 441 442 444 448 452 454
455 460 461 462 463 469 470 471 472 481
482 488 489 490 491 493 495 497 498 501
506

SEQ ID NO:39:

368 369 373 380 398 399 400 401 402 403
406 410 411 418 425 426 429 436 442 444
445 448 453 454 462 463 464 465 472 473
474 475 484 485 492 493 495 499 503 505
506 511 512 513 514 520 521 522 523 532
533 539 540 541 542 544 546 548 549 552
557

SEQ ID NO:40:

364 365 369 376 394 395 396 397 398 399
402 406 407 415 422 423 426 433 439 441
442 445 450 451 459 460 461 462 469 470
471 472 481 482 489 490 492 496 500 502
503 508 509 510 511 517 518 519 520 529
530 536 537 538 539 541 543 545 546 549
554

(Table V continued)

SEQ ID NO:41:

341	342	346	353	371	372	373	374	375	376
379	383	384	391	398	399	402	409	415	417
418	421	426	427	435	436	437	438	445	446
447	448	457	458	465	466	468	472	476	478
479	484	485	486	487	493	494	495	496	505
506	512	513	514	515	517	519	521	522	525
530									

SEQ ID NO:42:

341	342	346	353	371	372	373	374	375	376
379	383	384	391	398	399	402	409	415	417
418	421	426	427	435	436	437	438	445	446
447	448	457	458	465	466	468	472	476	478
479	484	485	486	487	493	494	495	496	505
506	512	513	514	515	517	519	521	522	525
530									

SEQ ID NO:43:

341	342	346	353	371	372	373	374	375	376
379	383	384	391	398	399	402	409	415	417
418	421	426	427	435	436	437	438	445	446
447	448	457	458	465	466	468	472	476	478
479	484	485	486	487	493	494	495	496	505
506	512	513	514	515	517	519	521	522	525
530									

(Table V continued)

SEQ ID NO:44:

333	334	338	345	363	364	365	366	367	368
369	372	376	377	387	394	395	396	399	406
412	414	415	418	423	424	430	431	432	433
440	441	442	443	452	453	460	461	463	467
471	473	474	479	480	481	482	488	489	490
491	499	500	506	507	508	509	511	513	515
516	519	524							

SEQ ID NO:45:

334	335	339	346	364	365	366	367	368	369
370	373	377	378	388	395	396	397	400	407
413	415	416	419	424	425	431	432	433	434
441	442	443	444	453	454	461	462	464	468
472	474	475	480	481	482	483	489	490	491
492	500	501	507	508	509	510	512	514	516
517	520	525							

SEQ ID NO:46:

278	279	283	284	285	292	309	310	311	312
313	314	317	321	322	329	336	337	338	341
348	354	356	357	360	365	366	373	374	375
376	377	384	385	386	387	396	397	404	405
407	411	415	418	419	424	425	426	427	433
434	443	444	450	451	452	453	455	457	459
460	463	467							

(Table V continued)

SEQ ID NO:47:

287	288	292	293	294	300	318	319	320	321
322	324	328	329	336	343	344	345	348	355
361	363	364	367	372	373	375	376	377	378
379	386	387	388	389	398	399	406	407	409
413	417	420	421	426	427	428	429	435	436
437	437	446	447	453	454	455	456	458	460
462	463	466	471						

SEQ ID NO:48:

287	288	292	293	294	300	318	319	320	321
322	324	328	329	336	343	344	345	348	355
361	363	364	367	372	373	375	376	377	378
379	386	387	388	389	398	399	406	407	409
413	417	420	421	426	427	428	429	435	436
437	446	447	453	454	455	456	458	460	462
463	466	471							

SEQ ID NO:49:

292	293	297	298	299	306	323	324	325	326
327	328	329	332	336	337	344	351	352	353
356	363	369	371	372	374	379	380	387	388
389	390	391	398	399	400	401	410	411	418
419	421	425	429	432	433	438	439	440	441
447	448	457	458	464	465	466	467	469	471
473	474	477	481						

(Table V continued)

SEQ ID NO:50:

294	295	299	300	301	308	325	326	327	328
329	330	331	334	338	339	346	353	354	355
358	365	371	373	374	376	381	382	389	390
391	392	393	400	401	402	403	412	413	420
421	423	427	431	434	435	440	441	442	443
449	450	459	460	466	467	468	469	471	473
475	476	479	483						

SEQ ID NO:51:

293	294	298	299	300	307	324	325	326	327
328	329	330	333	337	338	345	352	353	354
357	364	370	372	373	375	380	381	388	389
390	391	392	399	400	401	402	411	412	419
420	422	426	430	433	434	439	440	441	442
448	449	458	459	465	466	467	468	470	472
474	475	478	482						

SEQ ID NO:52:

294	295	299	300	301	308	325	326	327	328
329	330	331	334	338	339	346	353	354	355
358	365	371	373	374	376	381	382	389	390
391	392	393	400	401	402	403	412	413	420
421	423	427	431	434	435	440	441	442	443
449	450	459	460	466	467	468	469	471	473
475	476	479	483						

(Table V continued)

SEQ ID NO:53:

378	379	383	390	408	409	410	411	412	413
416	420	421	428	435	436	439	446	452	454
455	458	463	464	472	473	474	475	482	483
484	485	494	495	502	503	505	509	513	515
516	521	522	523	524	530	531	532	533	542
543	549	550	551	552	554	556	558	559	562
567									

SEQ ID NO:54:

351	352	356	363	381	382	383	384	385	386
389	393	394	401	408	409	412	419	425	427
428	431	436	437	445	446	447	448	455	456
457	458	467	468	475	476	478	482	486	488
489	494	495	496	497	503	504	505	506	515
516	522	523	524	525	527	529	531	532	535
540									

SEQ ID NO:55:

351	352	356	363	381	382	383	384	385	386
389	393	394	401	408	409	412	419	425	427
428	431	436	437	445	446	447	448	455	456
457	458	467	468	475	476	478	482	486	488
489	494	495	496	497	503	504	505	506	515
516	522	523	524	525	527	529	531	532	535
540									

(Table V continued)

SEQ ID NO:56:

315	316	320	327	345	346	347	348	349	350
351	354	358	359	369	376	377	378	381	388
394	396	397	400	404	405	411	412	413	414
415	422	423	424	425	434	435	442	443	445
449	453	455	456	461	462	463	464	470	471
472	473	481	482	488	489	490	491	493	495
497	498	501	506						

SEQ ID NO:57:

327	334	353	354	355	356	357	360	364	365
372	379	380	381	384	391	397	399	400	403
408	409	413	414	415	416	417	424	425	426
427	436	437	444	445	447	451	455	457	458
463	464	465	466	472	473	474	483	484	490
491	492	493	495	497	499	500	503	508	

SEQ ID NO:58:

291	292	296	297	298	305	323	324	325	326
327	330	334	335	341	345	346	347	350	357
363	365	366	369	374	375	383	384	385	386
387	390	391	392	393	400	407	408	410	414
418	421	422	427	428	429	430	432	439	440
446	447	448	449	453	456	458	459	462	467

(Table V continued)

SEQ ID NO:59:

290	291	295	296	297	304	322	323	324	325
326	329	333	334	340	344	345	346	349	356
362	364	365	368	373	374	382	383	384	385
386	391	392	393	394	401	408	409	411	415
419	422	423	428	429	430	431	433		440
441	447	448	449	450	454	457	459	460	463
468									

SEQ ID NO:60:

268	269	273	274	275	282	300	301	302	303
304	307	311	312	318	322	323	324	327	334
340	342	343	346	351	352	360	361	362	363
364	371	372	373	374	381	388	389	391	395
399	402	403	408	409	410	411	413	420	421
427	428	429	430	434	437	439	440	443	448

SEQ ID NO:61:

291	292	296	297	298	305	323	324	325	326
327	330	334	335	341	345	346	347	350	357
362	364	365	368	373	374	380	381	382	383
384	387	388	389	390	397	404	405	407	411
415	418	419	424	425	426	427	429	436	437
443	444	445	446	450	453	455	456	459	464

(Table V end)

Positions with a high diversity number, i.e. equal or higher than 8, or even 10, have also been determined. The analysis revealed that these are mainly located in loop regions. These expose a high variability, i.e. flexibility, and as a result spatially bring together several surface exposed amino acids from the blade connecting loops. The results also suggest not using the interior surface of the tunnel for

randomization experiments. The inner three beta-sheets of each blade were also critical, because they resemble a high conservation and contributed to the core stability of the protein. Thus, solvent-exposed amino acids, which do not contribute to the hydrophobic core stability of the protein, which revealed a sufficient high diversity number and hence a low conservation, are in the focus of interest for a mutagenesis approach.

With this method it is possible to obtain a list of variable, i.e. alterable, amino acid positions in and for all proteins, which have been employed in the alignment, at the same time. For the hemopexin-like domain, as exemplified before, hemopexin-like domains of sixty proteins have been employed and thus for all sixty domains the positions of alterable, i.e. variable, amino acids have been identified. These positions are listed in table V (the numbering is according to the full length polypeptide/protein).

In table V the variable amino acid positions in the sixty hemopexin-like domains (SEQ ID NO:02 to SEQ ID NO:61) are listed. The amino acid positions are numbered according to the full length sequence of the protein containing the hemopexin-like domain. For example, for the hemopexin-like domain according to SEQ ID NO:02 these are the amino acid positions listed after the subheading SEQ ID NO:02 of table V and are accordingly 470, 471, 475, 476, 477, 484, 501, 502, 503, 504, 505, 506, 507, 510, 514, 515, 522, 529, 530, 531, 534, 541, 547, 549, 550, 553, 558, 559, 566, 567, 568, 569, 570, 577, 578, 579, 580, 589, 590, 597, 598, 600, 604, 608, 611, 612, 617, 618, 619, 620, 626, 627, 628, 629, 638, 639, 645, 646, 647, 648, 650, 652, 654, 655, 658, 663. The alterable amino acid positions for SEQ ID NO:03 to SEQ ID NO:61 are accordingly listed in table V after the respective subheading.

With the alterable amino acid positions available for SEQ ID NO:02~~1~~1 to SEQ ID NO:61 each of these sequences can be taken as starting point for further operations.

The cell-free production and analysis of rationally engineered protein variants can be automated, but the library size of rationally designed protein-constructs to be processed remains always limited by the technical throughput of each system. Therefore the analysis of the binding-properties of a vast multitude of gene-products demands for further efforts.

For display and screening of a polypeptide library multiple techniques are available, as e.g. phage-, ribosome- or bacterial-display (Smith, G.P., Science 228 (1985) 1315-1317; Hanes, J., and Pluckthun, A., PNAS 94 (1997) 4937-4942; Stahl, S., and Uhlen, M., TIBTECH 15 (1997) 185-192).

The current invention will be exemplified with the ribosome display technique (see e.g. Hanes, J., and Pluckthun, A., PNAS 94 (1997) 4937-4942; Mattheakis, L.C., et al., PNAS 91 (1994) 9022-9026; He, M., and Taussig, M.J., Nuc. Acids Res. 25 (1997) 5132-5134), but other techniques are also applicable.

Directed evolutionary techniques are well suited to complement the technical capability of a high throughput protein production platform. Based on the cell-free protein synthesis technology, ribosome display is an excellent method to be implemented into a high throughput protein production and analysis process. The aim of ribosome display is the generation of ternary complexes, in which the genotype, characterized by its messenger-RNA (mRNA), is physically linked by the ribosome to its encoded phenotype, characterized by the expressed polypeptides.

For this purpose, a linear DNA-template, which encodes a gene-library is transcribed and translated in vitro. Downstream of the gene-sequence a spacer sequence is fused, where the predominant feature is the lack of a translational stop codon. This spacer domain facilitates the display of the nascent translated and co-translationally folded polypeptide, which remains tethered to the ribosome. These complexes are subjected to a panning procedure, in which the ribosome-displayed polypeptide is allowed to bind to a predetermined ligand molecule. The mRNA from tightly bound complexes is isolated, reversibly transcribed and amplified by PCR. Sub cloning of the PCR products into a vector system and consecutive DNA sequencing reveals information about the genotype related to the phenotype of the bound polypeptide. In repeated cycles of mutagenesis and ribosome display specific protein-binders from libraries in the range of up to 1014 members can be identified (Mattheakis, L.C., et al., PNAS 91 (1994) 9022-9026; Hanes, J., and Pluckthun, A., PNAS 94 (1997) 4937-4942; Lamla, T., and Erdmann, V.A., J. Mol. Biol. 329 (2003) 381-388).

In general, ribosome display requires the stalling of the ribosome while reaching the 3´-end of the mRNA without the dissociation of the ribosomal subunits. After

the ribosome has encountered the 3´- end of the mRNA the ribosome's transfer-RNA (tRNA) entry site (A-site) is unoccupied. In prokaryotes, this state results in the activation of the ribosome rescue mechanism, induced by tmRNA (transfer messenger RNA; Abo, T., et al. EMBO J. 19 (2000) 3762-3769; Hayes, C.S., and Sauer, R.T., Mol. Cell. 12 (2003) 903-911; Keiler, K.C., et al., Science 271 (1996) 990-993). With regard to a ribosome display selection, this mechanism lowers the amount of functional ternary complexes and the PCR-product yield is significantly reduced (Hanes, J., and Pluckthun, A., PNAS 94 (1997) 4937-4942).

This tmRNA induced ribosome rescue mechanism can be bypassed, when the ribosome translation machinery has been forced to stall before the 3´-end of the mRNA was encountered by the ribosome. Due to the induced translation arrest the ribosome A-site is still occupied. The display spacer of the ribosome display construct has the sequence as denoted in SEQ ID NO:62. With this spacer the translation can be arrested after the full polypeptide is translated and before the ribosome rescue mechanism is set off.

This has been achieved by removing translation stop codons (Mattheakis, L.C., et al., PNAS 91 (1994) 9022-9026; Hanes, J., and Pluckthun, A., PNAS 94 (1997) 4937-4942) from the DNA spacer sequence of the ribosome display construct. As a consequence a high molecular weight complex consisting of mRNA, the ribosome and the translationally stalled polypeptide is generated.

For the generation of libraries numerous techniques are known to a person skilled in the art. An exemplified proceeding is outlined below.

Linear Expression Elements (LEE) as basis of a DNA-library were produced in a modular manner. To rapidly support the overlapping extension ligation PCR (OEL-PCR) with the randomized DNA-fragments, a library of DNA-modules was pre-produced. In order to obtain sufficient PCR-product yield it was a prerequisite to use HPLC purified primer oligonucleotides and a DNA polymerase with a 3´-5´ exonucleolytic activity, producing blunt-end DNA fragments (Garrity, P.A., and Wold, B.J., PNAS 89 (1992) 1021-1025).

Exemplarily, the genes encoding the proteins PEX2 (c-terminal hemopexin-like domain of human matrix metalloproteinase 2), TIMP2 (tissue inhibitor of human

matrix metalloproteinase 2), HDAC-I (human histone deacylase I), BirA (E.coli biotin holoenzyme ligase) and GFP (green fluorescent protein) were fused to different combinations of DNA-modules. The concentration of the PCR-products was determined by a comparative densitometric quantification using the LUMI Imager System (Roche Applied Sciences, Mannheim, Germany). The average PCR-product yield of the obtained Linear Expression Elements was about 60 ng/µl ± 20ng/µl (ng per µl of PCR-mixture). Using the P. woesii DNA polymerase (PWO) it was possible to generate LEEs up to 2000 bp in length.

In an example a small library in which 8 amino acid positions of the PEX2 polypeptide were randomized was generated. For this purpose these positions and accordingly the following amino acids were chosen from the list for SEQ ID NO:10 as listed in table V: 528 (Gln), 529 (Glu), 550 (Arg), 576 (Lys), 577 (Asn), 578 (Lys), 594 (Val) and 596 (Lys). The library was generated by template free PCR synthesis as described in example 2. A ribosome display template was assembled e.g. by the modules T7P-g10epsilon-ATG (SEQ ID NO:74), a polypeptide from the generated library and a ribosome display spacer (SEQ ID NO:62).

A prerequisite for a suitable protein scaffold is its capability to stably fold in its active conformation, even under conditions where it has to carry the burden of multiple substituted amino acids. This can be examined by targeting the library versus a known protein-binding partner. In an example the PEX2 library was displayed to recognize the tissue inhibitor of metalloproteinase 2 (TIMP2) protein ligand. The randomized polypeptides from the PEX2-library were still able to recognize their inherent TIMP2 binding partner in a ribosome display approach. This indicated that the structure-function of the scaffold was maintained despite that the scaffold was multiply mutated.

To prepare and optimize the binding properties of a specific binder based on a polypeptide scaffold to a predetermined target molecule, which is not inherently bound by the scaffold, a cycle comprising four main steps has to be passed through several times. These steps are (i) alteration of at least one amino acid position according to table V, (ii) preparation of the display construct, (iii) display and selection of a specific binding variant and (iv) isolation and sequencing of the

selected variant. Generally between two and five cycles are necessary to establish new specific binding characteristics in a scaffold.

The predetermined target molecule is not limited to a specific group of polypeptides. The predetermined polypeptide can belong e.g. to one of the groups of hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons, as well as to the groups of immunoglobulins, enzymes, inhibitors, ~~and~~ activators, and cell surface proteins.

In an example, the non-PEX2 binder IGF-I was chosen as predetermined target molecule, for the generation of a specific binder, based on the PEX2 scaffold. The target molecule was plate-presented as a biotinylated ligand. After the second cycle of ribosome display with the PEX2 library a visible PCR-product signal was retained. This shows that the library is well suited for the selection of proteins/polypeptides specifically binding a predetermined target molecule not inherently bound by the protein/polypeptide.

The following examples, references and sequence listings are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Examples

Example 1

Overlapping Extension Ligation PCR (OEL-PCR)

Linear Expression Elements were modularly assembled by a two step-PCR protocol, using the overlapping DNA ligation principle. In a standard PWO-PCR an intron-less open reading frame was amplified by sequence-specific terminal bridging primers, which generated overlapping homologous sequences to flanking DNA sequences. Two µl of the first PCR mixture containing approximately 50 ng of the elongated gene-fragment (gene-module) were transferred into a second PWO-PCR mixture. The mixture was supplied with 50 ng to 100 ng of pre-produced DNA-fragments (promotor- and terminator-module) and respective sequence specific, terminal primers at 1 µM each. Typically, this second PCR-step

was comprised 30 cycles. The physical parameters of the PCR profiles were adjusted according to the requirements of the DNA-fragments to be ligated.

Example 2

Synthesis of the PEX2 DNA library

The PEX2 triplet codons coding for the amino acid coordinates of the hemopexin-like domain 64, 65, 86, 112, 113, 114, 130 and 132 (equal to 528 (Gln), 529 (Glu), 550 (Arg), 576 (Lys), 577 (Asn), 578 (Lys), 594 (Val) and 596 (Lys) in the full length human matrix metalloproteinase 2) were randomized by NNK-motives. The human wild-type PEX2 DNA sequence was divided up into three sequence sections. A standard PWO-PCR, which was supplied with 10 ng vector-template pIVEX2.1MCS PEX2 and the primers PEX2forw (SEQ ID NO:63) and PEXR4 (SEQ ID NO:64) at 1 µM each amplified the 1 bp - 218 bp fragment. The 402 bp – 605 bp fragment was amplified in a standard PWO-PCR with 10 ng vector-template pIVEX2.1MCS PEX2 and the primers PEXF4 (SEQ ID NO:65) and PEX2rev (SEQ ID NO:66) at 1 µM each. The sequence 196 bp – 432 bp formed overlaps with the DNA fragments 1 bp – 218 bp and 402 bp – 605 bp and was synthesized by template-free PCR with the primers PEXF1 (SEQ ID NO:67) and PEXR1 (SEQ ID NO:68) at 1 µM each and PEXR3 (SEQ ID NO:69), PEXR2 (SEQ ID NO:70) and PEXF2 (SEQ ID NO:71) at 0.25 µM each. The PCR-profile was the same for all three PCRs: TIM (initial melting temperature): 1 min at 94 °C, TM (melting temperature): 20 sec at 94 °C, TA (annealing temperature): 30 sec at 60 °C, TE (elongation temperature): 15 sec at 72 °C, 25 cycles, TFE (final elongation temperature): 2 min at 72 °C. The full length randomized PEX2 sequence (588 bp) was obtained when 70 ng of each DNA sequence-fragment was applied to a standard PWO-PCR with the bridging primers T7P_PEX2 (SEQ ID NO:72) and PEX2_RD (SEQ ID NO:73) at 1 µM each. The PCR-profile was: TIM: 1 min at 94 °C, TM: 20 sec at 94 °C, TA: 30 sec at 60 °C, TE: 60 sec at 72 °C, 25 cycles, TFE: 5 min at 72 °C. The bridging primers introduced homologues DNA overlaps for an assembly of the PEX2 gene-library into a ribosome display template by OEL-PCR.

Example 3

Cell-free protein *in vitro* transcription and translation

According to the instructions of the manufacturer, Linear Expression Elements were transcribed and translated in the RTS 100 HY *E.coli* System. Linear DNA template (100 ng – 500 ng) were incubated at 30 °C. Optionally 6 µl GroE-supplement (Roche) was added.

Example 4

Site-specific biotinylation of fusion proteins

The RTS 100 *E.coli* HY System was modified for the sequence specific, enzymatic biotinylation. Sixty µl RTS mixture were assembled according to the manufacturer's instructions. The mixture was supplemented with 2 µl stock-solution Complete EDTA-Free Protease Inhibitor, 2 µM d-(+)-biotin, 50 ng T7P_BirA_T7T Linear Expression Element (1405 bp), coding for the *E.coli* Biotin Ligase (BirA, EC 6.3.4.15) and 100 ng to 500 ng linear template coding for the substrate fusion-protein. The substrate fusion-protein was N- or C-terminally fused to a Biotin Accepting Peptide sequence (BAP). In all experiments a 15-mer variant of sequence #85 as identified by Schatz (Schatz, P.J., Biotechnology (NY) 11 (1993) 1138-1143; Beckett, D. et al., Protein Sci. 8 (1999) 921-929) was used (Avitag, Avidity Inc., Denver, Colo. USA). Biotin Ligase was co-expressed from the linear template T7Pg10epsilon_birA_T7T.

Example 5

a) Ribosome Display Protocol

All buffers were kept on ice. All devices were sterile, Dnase- and Rnase-free. The workbench was cleaned with Rnase-ZAP.

10x Stock washing buffer (Stock WB) Ribosome Display: 0.5 M TRIS (tris(hydroxymethyl)-aminomethan), pH 7.5 (4°C) adjusted by AcOH (acetic acid); 1.5 M NaCl; 0.5 M magnesium acetate, store at -20°C

10x Elution buffer (Stock EB) Ribosome Display: 0.5 M TRIS, pH 7.5 (4°C) adjusted by AcOH; 1.5 M NaCl; 200 mM EDTA, store at -20°C

10 ml Ribosome Display Washing buffer (WB): 1200 µl 10x Stock WB pH 7.5, 0.05% TWEEN 20 (50µL 10 % TWEEN 20), 5 % BSA (5 ml Blocker BSA 10%), 5 µg/ml t-RNA, 670 mM KCl (0.5 g KCl) ad. 10ml with PCR-grade water

10ml Ribosome Display Stopbuffer (SB): 1200µL 10x Stock WB pH 7.5, 0.05% TWEEN 20 (50µL 10 % TWEEN 20), 5 % BSA (5 ml Blocker BSA 10%), 5 µg/ml t-RNA, 670 mM KCl (0.5 g KCl), 4 mM GSSG (oxidized glutathione), 25 µM cAMP (10µl Stock solution), ad. 10ml with PCR-grade water

2 ml Ribosome Display Elution buffer: 200µL 10x Stock EB, 0.25 % BSA (50 µl Blocker BSA 10 %), 5000 A260 units r-RNA 16S-23S ribosomal, 5 µg/ml t-RNA, ad. 2ml with PCR-grade water

Blocking Reagent: 5 % BSA Puffer (2.5 ml Blocker BSA 10 %), 50 % Conjugate Buffer Universal

10x PBS-buffer: 0.1 M NaH_2PO_4; 0.01 M KH_2PO_4 (10x pH 7.0; 1x pH 7.4); 1.37 M NaCl; 27 mM KCl.

b) Preparation of the ectodomains erbB2 and erbB3

The human receptor ectodomains erbB2 and erbB3 were obtained from R&D Systems as receptor chimeras. The receptor ectodomains were genetically fused to the human protein IgG1FC (human IgG1 antibody FC fragment). Both molecules revealed a molecular mass of 96 kDa and contained a hexahistidine-peptide at their C-terminus. As a result of glycosylation the molecular weight of the proteins was increased to 130 to 140 kDa. The chimeric proteins were obtained as lyophilized proteins and were resolubilized in PBS buffer containing 0.1 % BSA. The proteins were stored at -80 °C until use.

c) Coating of micro titer plates

One Reaction Volume (RV) of a micro titer (MT)-plate was washed three times with Conjugate Buffer Universal. Two and a half (2.5) µg ligand was resolved in

100 µl Blocking Reagent. Biotinylated ligands were alternately immobilized in the wells of Streptavidin- and Avidin-coated MT-plates. The erbB2/FC- and erbB3/FC-chimeras were immobilized alternately in the wells of protein A and protein G coated MT-plates. The ligand-solution was incubated for 1 h at room temperature in the MT-plate under 500 rpm shaking on a Biorobot 8000 robotic shaker platform. To determine the background-signal a well was coated with 100 µl Blocking Reagent without ligand. The wells were washed with 3 RV Blocking Reagent. Blocking Reagent (300 µl) was incubated in each well for 1 h at 4 °C and 200 rpm. Before the stopped translation-mixture was applied, the wells were washed with 3 RV ice-cold buffer WB.

d) Generation of ribosome display templates

For the standard ribosome display procedure a single gene or a gene-library was elongated with specific bridging primers. The elongated DNA-fragments were fused by OEL-PCR to the DNA-modules T7Pg10epsilon (SEQ ID NO:74) and to the ribosome display spacer (SEQ ID NO:62) using the terminal primers T7Pfor (SEQ ID NO:75) and R1A (SEQ ID NO:76) 5′-AAATCGAAAGGCCCAGTTTTTCG-3′. The PCR profile for the PCR assembly was: TIM: 1 min at 94°C, TM: 20 sec at 94 °C, TA: 30 sec at 60 °C, TE: 60 sec for 1000 bp at 72 °C, 30 cycles, TFE: 5 min at 72 °C.

Production of the linear expression element (LEE) T7PAviTagFXa-PEX2-T7T: The human PEX2-gene was amplified in a standard PWO-PCR from 10 ng plasmid template pDSPEX2 (Roche) using the bridging primer according to SEQ ID NO:77 and to SEQ ID NO:78. The overlapping gene was fused by an OEL-PCR to the DNA-modules T7PAviTagFXa (SEQ ID NO:79) and T7T (SEQ ID NO:80) using the primers T7Pfor (SEQ ID NO:82) and T7Trev (SEQ ID NO:81).

e) Preparation of the ribosome display translation mixture

The RTS *E.coli* 100 HY System was prepared according to the manufacture's instructions. One hundred µl of the mixture were supplemented with 40 units (1 µl) Rnasin, 2 µM (2 µl) anti ssrA-oligonucleotide 5′-TTAAGCTGCTAAAGCGTAGTTTTCGTCGTTTGCGACTA-3′ (SEQ ID NO:85), 1 µL stock solution of Complete Mini Protease Inhibitor EDTA-free and

500 ng linear ribosome display DNA-template in 20 µl PWO-PCR mixture. The ribosome display DNA-template was transcribed and translated in 1.5 ml reaction tubes at 30 °C for 40 min under shaking at 550 rpm. Complexes consisting of mRNA, ribosome and displayed polypeptide were stabilized when the reaction was immediately stopped with 500 µl ice-cold buffer SB. The mixture was centrifuged at 15.000 g at 2 °C for 10 min. The supernatant was transferred into a fresh, ice-cooled 1.5 ml reaction tube. Two hundred fifty µl of the mixture were transferred into a ligand-coated MT-plate well (signal) and another 250 µl into a non-ligand coated well (background). The mixture was incubated for 1 h at 4 °C and 300 rpm. To remove background protein and weak binding ternary complexes the wells were washed with ice-cold buffer WB. Messenger RNA from the bound ternary complexes was eluted by 100 µl ice-cold buffer EB for 10 min at 4 °C and 750 rpm.

f) Preparation of Protein G coated magnetic beads

Protein G coated magnetic beads were used to deplete the stopped ribosome display translation mixtures from protein derivatives, which unspecifically recognized IgG1-FC binders. One hundred µl of the magnetic bead suspension was equilibrated in stopping buffer SB by washing the beads five times in 500 µl buffer SB. The beads were incubated for 1 h at 4 °C in 500 µl buffer SB containing 50 µg IgG1-FC protein. The beads were washed three times with buffer SB and were stored on ice in 100 µl buffer SB. Prior to their use the beads were magnetically separated and stored on ice. The stopped ribosome display translation mixture was added to the beads. The mixture was incubated for 30 min at 4 °C at 750 rpm. Prior to use the beads were magnetically separated form the mixture.

g) Purification of mRNA and removal of remaining DNA

Messenger RNA was purified using the High Pure RNA Isolation Kit (Roche Applied Science, Mannheim, Germany). Remaining DNA-template in the eluate was removed with a modified protocol of the Ambion DNA-free kit (ambion Inc., USA). Fifty µl eluate were supplemented with 5.7 µl DNAse I buffer and 1.3 µl DNAse I containing solution. After incubation of the mixture at 37 °C for 30 min 6.5 µl DNAse I inactivating reagent was added. The slurry was incubated in the digestion-assay for 3 min at room temperature followed by 1 min centrifugation at 11,000 g. The supernatant was used in the reverse transcription

h) Reverse Transcription and cDNA amplification

For the reverse transcription of the mRNA the *C. therm.* RT Polymerase Kit (Roche Applied Sciences, Mannheim, Germany) was used. Twenty µl reactions were assembled: 4 µl 5x RT buffer, 1 µl DTT (dithiothreitol) solution, 1.6 µl dNTP´s, 1 µl DMSO solution, 0.1 µM (1 µl) RT 5´-CAGAGCCTGCACCAGCTCCAGAGCCAGC-3´ (SEQ ID NO:86), 40 units (1 µl) Rnasin, 1.5 µl *C. therm.* RNA-Polymerase, 9 µl mRNA containing eluate. Transcription was performed for 35 min at 70°C. Further amplification of the cDNA was performed in 100 µl PWO-PCRs containing 10 µl 10x PWO-PCR buffer with $MgSO_4$, 200 µM dNTPs, 12 µl transcription mixture, 2.5 units PWO DNA-Polymerase and the primers RT 5´-CAGAGCCTGCACCAGCTCCAGAGCCAGC-3´ (SEQ ID NO:86) and F1 5´-GTTTAACTTTAAGAAGGAGATATACATATG-3´ (SEQ ID NO:87) at 1 µM each. The PCR profile was TIM: 1 min at 94 °C, TM: 20 sec at 94 °C, TA: 30 sec at 60 °C, TE: 60 sec at 72 °C, 20 cycles, TFE: 5 min at 72 °C. A reamplification by a standard PWO-PCR was performed. Two µl of the PCR mixture were transferred into a second standard PWO-PCR. Gene-specific bridging primers were used wherever possible. The PCR-profiles were according to the physical parameters of the gene-templates and oligonucleotide-primers. Twenty five PCR cycles were performed. The gene-sequences were elongated with DNA overlaps to hybridize with the DNA-modules T7Pg10epsilon and the ribosome display spacer in a further OEL-PCR. The ribosome display DNA-templates were then reused in further ribosome display cycles.

i) Sub cloning of genes after ribosome display

The PCR-products were sub cloned into vector-systems with techniques know to a person skilled in the art. Library members of PEX2 were sub cloned via the NdeI/EcoRI sites into the vector pUC18 using the primers NdeI-PEX2for (SEQ ID NO:83) and EcoRI-PEX2rev (SEQ ID NO:84).

List of References

Abo, T., et al. EMBO J. 19 (2000) 3762-3769

Altruda, F. et al., Nucleic Acids Res. 13 (1985) 3841-3859

Andersson, M., et al., J. Immunol. Methods 283 (2003) 225-234

Ausubel, I., and Frederick, M., Curr. Prot. Mol. Biol. (1992) John Wiley and Sons, New York

Beckett, D. et al., Protein Sci. 8 (1999) 921-929

Binz, H.K., et al., J. Mol. Biol. 332 (2003) 489-503

Bode, W., Structure 3 (1995) 527-530

Brooks, P.C., et al., Cell 92 (1998) 391-400

Faber, H.R., et al., Structure 3 (1995) 551-559

Forrer, P., et al., ChemBioChem 5 (2004) 183-189

Fulop, V., and Jones, D.T., Curr. Opin. Struct. Biol. 9 (1999) 715-721

Garrity, P.A., and Wold, B.J., PNAS 89 (1992) 1021-1025

Gohlke, U., et al., FEBS Lett. 378 (1996) 126-130

Gomis-Ruth, F.X., et al., J. Mol. Biol. 264 (1996) 556-566

Hames, B.D., and Higgins, S.G., Nucleic acid hybridization – a practical approach (1985) IRL Press, Oxford, England

Hanes, J., and Pluckthun, A., PNAS 94 (1997) 4937-4942

Hayes, C.S., and Sauer, R.T., Mol. Cell. 12 (2003) 903-911

He, M., and Taussig, M.J., Nuc. Acids Res. 25 (1997) 5132-5134

Ho, S.N., et al., Gene 77 (1989) 51-59

Jenne, D., and Stanley, K.K., Biochemistry 26 (1987) 6735-6742

Jenne, D., Biochem. Biophys. Res. Commun. 176 (1991) 1000-1006

Kain, K.C., et al., Biotechniques 10 (1991) 366-374

Keiler, K.C., et al., Science 271 (1996) 990-993

Klevenz, B., et al., Cell. Mol. Life Sci. 59 (2002) 1993-1998

Lamla, T., and Erdmann, V.A., J. Mol. Biol. 329 (2003) 381-388

Lee, S.S., and Kang, C., Kor. Biochem. J. 24 (1991) 673-679

Letunic, I., et al., Nuc. Acids Res. 30 (2002) 242-244

Li, J., et al., Structure 3 (1995) 541-549

Libson, A.M., et al., Nat. Struct. Biol. 2 (1995) 938-942

Lu, Z., et al., Bio/Technology 13 (1995) 366-372

Mattheakis, L.C., et al., PNAS 91 (1994) 9022-9026

McConnell, S.J., and Hoess, R.H., J. Mol. Biol. 250 (1995) 460-470

Nygren, P.-A., and Skerra, A., J. Immun. Methods 290 (2004) 3-28

Predki, P.F., et al., Nat. Struct. Biol. 3 (1996) 54-58

Roberts, B.L., et al., Gene 121 (1992) 9-15

Roberts, B.L., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 2429-2433

Rottgen, P., and Collins, J., Gene 164 (1995) 243-250

Sambrook, J., et al., Molecular Cloning: A laboratory manual (1999) Cold Spring Harbor Laboratory Press, New York, USA

Sandstrom, K., et al., Protein Eng. 16 (2003) 691-697

Schatz, P.J., Biotechnology (NY) 11 (1993) 1138-1143

Schultz, J., et al., PNAS 95 (1998) 5857-5864

Segal, D.J., et al., Biochemistry 42 (2003) 2137-2148

Shuldiner, A.R., et al., Anal. Biochem. 194 (1991) 9-15

Skerra, A., J. Mol. Recognit. 13 (2000) 167-187

Smith, G.P., et al., J. Mol. Biol. 277 (1998) 317-332

Smith, G.P., Science 228 (1985) 1315-1317

Stahl, S., and Uhlen, M., TIBTECH 15 (1997) 185-192

Sykes, K.F., and Johnston, S.A., Nature Biotechnol. 17 (1999) 355-359

Visintin, M., et al., J. Immun. Methods 290 (2004) 135-153

Wallon, U.M., and Overall, C.M., J. Biol. Chem. 272 (1997) 7473-7481

Willenbrock, F., et al., Biochemistry 32 (1993) 4330-4337

WO 01/04144

Xu, L., et al., Chem. Biol. 9 (2002) 933-942

Patent Claims

1. Polypeptide, that specifically binds a predetermined target molecule, characterized in that the amino acid sequence of said polypeptide is selected from the group consisting of SEQ ID NO:10, wherein in said amino acid sequence at least one amino acid at position: 467, 468, 472, 473, 474, 481, 498, 499, 500, 501, 502, 503, 504, 507, 511, 512, 519, 526, 527, 528, 529, 531, 538, 544, 546, 547, 550, 555, 556, 563, 564, 565, 566, 567, 574, 575, 576, 577, 578, 586, 587, 594, 595, 596, 597, 601, 605, 608, 609, 614, 615, 616, 617, 623, 624, 625, 626, 635, 636, 642, 643, 644, 645, 647, 649, 651, 652, 655, 660 is replaced with a different amino acid and said specific binding properties to said predetermined target molecule are not naturally inherent to said polypeptide, and wherein predetermined target molecule denotes a molecule which is a member of the groups of proteins comprising hedgehog proteins, bone morphogenetic proteins, growth factors, erythropoietin, thrombopoietin, G-CSF, interleukins and interferons, immunoglobulins, enzymes, inhibitors, activators, and cell surface proteins.

2. Process for the production of a polypeptide as specified in claim 1 in a prokaryotic or eukaryotic microorganism, characterized in that said microorganism contains a nucleic acid sequence which encodes said polypeptide and said polypeptide is expressed.

3. Process as claimed in claim 2, characterized in that the polypeptide is isolated from the organism and purified.

4. Method for identifying a nucleic acid encoding a polypeptide which specifically binds a predetermined target molecule from a DNA-library, characterized in that said method comprises the steps of

   a) selecting a sequence from the group consisting of SEQ ID NO:10;

   b) preparing a DNA-library of the selected sequence in which at least one amino acid position according to table V is altered;

c) screening the prepared DNA-library for encoded polypeptides specifically binding a predetermined target molecule;

d) choosing the nucleic acid encoding one specific binder identified in step c);

e) repeating the steps b) to d) for two to five times; and

f) isolating said nucleic acid encoding a polypeptide specifically binding a predetermined target molecule.

5. Method as claimed in claim 4, characterized in that the DNA-library comprises linear expression elements.

6. Method as claimed in claim 4 or 5, characterized in that the members of the library of the polypeptide are expressed by display on ribosomes.

7. Method as claimed in claim 4 or 5, characterized in that the members of the library of the polypeptide are expressed by display on bacteriophages.

8. Vector which is suitable for the expression of a polypeptide in a prokaryotic or eukaryotic microorganism, characterized in that said vector encodes a polypeptide as specified in claim 1.

SEQUENCE LISTING

<110> F. Hoffmann-La Roche AG

<120> Hemopexin-like structure as new polypeptide-scaffold

<130> 22953

<150> EP 05000013.2
<151> 2005-01-03

<160> 88

<170> PatentIn version 3.2

<210> 1
<211> 195
<212> PRT
<213> Artificial

<220>
<223> consensus sequence

<400> 1

Pro Glu Ile Cys Lys Gln Asp Ile Val Phe Asp Gly Ile Ala Gln Ile
1 5 10 15

Arg Gly Glu Ile Phe Phe Phe Lys Asp Arg Phe Ile Trp Arg Thr Val
20 25 30

Thr Pro Arg Asp Lys Pro Met Gly Pro Leu Leu Val Ala Thr Phe Trp
35 40 45

Pro Glu Leu Pro Glu Lys Ile Asp Ala Val Tyr Glu Ala Pro Gln Glu
50 55 60

Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr Trp Ile Tyr Ser Ala
65 70 75 80

Ser Thr Leu Glu Arg Gly Tyr Pro Lys Pro Leu Thr Ser Leu Gly Leu
85 90 95

Pro Pro Asp Val Gln Arg Val Asp Ala Ala Phe Asn Trp Ser Lys Asn
100 105 110

Lys Lys Thr Tyr Ile Phe Ala Gly Asp Lys Phe Trp Arg Tyr Asn Glu
115 120 125

Val Lys Lys Lys Met Asp Pro Gly Phe Pro Lys Leu Ile Ala Asp Ala
130 135 140

Trp Asn Ala Ile Pro Asp Asn Leu Asp Ala Val Val Asp Leu Gln Gly
145 150 155 160

Gly Gly His Ser Tyr Phe Phe Lys Gly Ala Tyr Tyr Leu Lys Leu Glu
165 170 175

Asn Gln Ser Leu Lys Ser Val Lys Phe Gly Ser Ile Lys Ser Asp Trp
180 185 190

Leu Gly Cys
195

<210> 2
<211> 195
<212> PRT
<213> Gallus gallus

<400> 2

Pro Glu Leu Cys Lys His Asp Ile Val Phe Asp Gly Val Ala Gln Ile
1 5 10 15

Arg Gly Glu Ile Phe Phe Phe Lys Asp Arg Phe Met Trp Arg Thr Val
20 25 30

Asn Pro Arg Gly Lys Pro Thr Gly Pro Leu Leu Val Ala Thr Phe Trp
35 40 45

Pro Asp Leu Pro Glu Lys Ile Asp Ala Val Tyr Glu Ser Pro Gln Asp
50 55 60

Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr Trp Val Tyr Thr Ala
65 70 75 80

Ser Asn Leu Asp Arg Gly Tyr Pro Lys Lys Leu Thr Ser Leu Gly Leu
85 90 95

Pro Pro Asp Val Gln Arg Ile Asp Ala Ala Phe Asn Trp Gly Arg Asn
100 105 110

Lys Lys Thr Tyr Ile Phe Ser Gly Asp Arg Tyr Trp Lys Tyr Asn Glu

115 120 125

Glu Lys Lys Lys Met Glu Leu Ala Thr Pro Lys Phe Ile Ala Asp Ser
130 135 140

Trp Asn Gly Val Pro Asp Asn Leu Asp Ala Val Leu Gly Leu Thr Asp
145 150 155 160

Ser Gly Tyr Thr Tyr Phe Phe Lys Asp Gln Tyr Tyr Leu Gln Met Glu
165 170 175

Asp Lys Ser Leu Lys Ile Val Lys Ile Gly Lys Ile Ser Ser Asp Trp
180 185 190

Leu Gly Cys
195

<210> 3
<211> 305
<212> PRT
<213> Mus musculus

<400> 3

Met Ala Ala Arg Glu Glu Ser Thr Gln Ser Ala Asn Arg Val Leu Arg
1 5 10 15

Ile Ser Gln Leu Asp Ala Leu Glu Leu Asn Lys Ala Leu Glu Gln Leu
20 25 30

Val Trp Ser Gln Phe Thr Gln Cys Phe His Gly Phe Lys Pro Gly Leu
35 40 45

Leu Ala Arg Phe Glu Pro Glu Val Lys Ala Phe Leu Trp Leu Phe Leu
50 55 60

Trp Arg Phe Thr Ile Tyr Ser Lys Asn Ala Thr Val Gly Gln Ser Val
65 70 75 80

Leu Asn Ile Gln His Lys Asn Asp Ser Ser Pro Asn Pro Val Tyr Gln
85 90 95

Pro Pro Ser Lys Asn Gln Lys Leu Leu Tyr Ala Val Cys Thr Ile Gly
100 105 110

Gly Arg Trp Leu Glu Glu Arg Cys Tyr Asp Leu Phe Arg Asn Arg His
115 120 125

Leu Ala Ser Phe Gly Lys Ala Lys Gln Cys Met Asn Phe Val Val Gly
130 135 140

Leu Leu Lys Leu Gly Glu Leu Met Asn Phe Leu Ile Phe Leu Gln Lys
145 150 155 160

Gly Lys Phe Ala Thr Leu Thr Glu Arg Leu Leu Gly Ile His Ser Val
165 170 175

Phe Cys Lys Pro Gln Asn Met Arg Glu Val Gly Phe Glu Tyr Met Asn
180 185 190

Arg Glu Leu Leu Trp His Gly Phe Ala Glu Phe Leu Ile Phe Leu Leu
195 200 205

Pro Leu Ile Asn Ile Gln Lys Leu Lys Ala Lys Leu Ser Ser Trp Cys
210 215 220

Thr Leu Cys Thr Gly Ala Ala Gly His Asp Ser Thr Leu Gly Ser Ser
225 230 235 240

Gly Lys Glu Cys Ala Leu Cys Gly Glu Trp Pro Thr Met Pro His Thr
245 250 255

Ile Gly Cys Glu His Val Phe Cys Tyr Tyr Cys Val Lys Ser Ser Phe
260 265 270

Leu Phe Asp Ile Tyr Phe Thr Cys Pro Lys Cys Gly Thr Glu Val His
275 280 285

Ser Val Gln Pro Leu Lys Ala Gly Ile Gln Met Ser Glu Val Asn Ala
290 295 300

Leu
305

<210> 4
<211> 305
<212> PRT
<213> Rattus norvegicus

<400> 4

Met Ala Ala Arg Glu Glu Ser Thr Gln Ser Ala Asn Arg Val Leu Arg
1 5 10 15

Ile Ser Gln Leu Asp Ala Leu Glu Leu Asn Lys Ala Leu Glu Gln Leu
20 25 30

Val Trp Ser Gln Phe Thr Gln Cys Phe His Gly Phe Lys Pro Gly Leu
35 40 45

Leu Ala Arg Phe Glu Pro Glu Val Lys Ala Phe Leu Trp Leu Phe Leu
50 55 60

Trp Arg Phe Thr Ile Tyr Ser Lys Asn Ala Thr Val Gly Gln Ser Val
65 70 75 80

Leu Asn Ile Gln Tyr Lys Asn Asp Ser Ser Pro Asn Pro Val Tyr Gln
85 90 95

Pro Pro Ser Lys Asn Gln Lys Leu Leu Tyr Ala Val Cys Thr Ile Gly
100 105 110

Gly Arg Trp Leu Glu Glu Arg Cys Tyr Asp Leu Phe Arg Asn Arg His
115 120 125

Leu Ala Ser Phe Gly Lys Ala Lys Gln Cys Met Asn Phe Val Val Gly
130 135 140

Leu Leu Lys Leu Gly Glu Leu Met Asn Phe Leu Ile Phe Leu Gln Lys
145 150 155 160

Gly Lys Phe Ala Thr Leu Thr Glu Arg Leu Leu Gly Ile His Ser Val
165 170 175

Phe Cys Lys Pro Gln Ser Met Arg Glu Val Gly Phe Glu Tyr Met Asn
180 185 190

Arg Glu Leu Leu Trp His Gly Phe Ala Glu Phe Leu Val Phe Leu Leu
195 200 205

Pro Leu Ile Asn Ile Gln Lys Leu Lys Ala Lys Leu Ser Ser Trp Cys

210 215 220

Ile Pro Leu Thr Ser Thr Ala Gly Ser Asp Ser Thr Leu Gly Ser Ser
225 230 235 240

Gly Lys Glu Cys Ala Leu Cys Gly Glu Trp Pro Thr Met Pro His Thr
245 250 255

Ile Gly Cys Glu His Val Phe Cys Tyr Tyr Cys Val Lys Ser Ser Phe
260 265 270

Leu Phe Asp Met Tyr Phe Thr Cys Pro Lys Cys Gly Thr Glu Val His
275 280 285

Ser Val Gln Pro Leu Lys Ser Gly Ile Glu Met Ser Glu Val Asn Ala
290 295 300

Leu
305

<210> 5
<211> 195
<212> PRT
<213> Oryctolagus cuniculus

<400> 5

Pro Glu Ile Cys Thr Gln Asp Ile Val Phe Asp Gly Ile Ala Gln Ile
1 5 10 15

Arg Gly Glu Ile Phe Phe Phe Lys Asp Arg Phe Ile Trp Arg Thr Val
20 25 30

Thr Pro Gly Asp Lys Pro Met Gly Pro Leu Leu Val Ala Thr Phe Trp
35 40 45

Pro Glu Leu Pro Glu Lys Ile Asp Ala Val Tyr Glu Ala Pro Gln Glu
50 55 60

Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr Trp Val Tyr Ser Ala
65 70 75 80

Ser Thr Leu Glu Arg Gly Tyr Pro Lys Pro Leu Thr Ser Leu Gly Leu
85 90 95

Pro Pro Asp Val Gln Arg Val Asp Ala Ala Phe Asn Trp Ser Lys Asn
100 105 110

Lys Lys Thr Tyr Ile Phe Ala Gly Asp Lys Phe Trp Arg Tyr Asn Glu
115 120 125

Val Lys Lys Lys Met Asp Pro Gly Phe Pro Arg Leu Ile Ala Asp Ala
130 135 140

Trp Asn Ala Ile Pro Asp His Leu Asp Ala Val Val Asp Leu Gln Gly
145 150 155 160

Ser Gly His Ser Tyr Phe Phe Lys Gly Thr Tyr Tyr Leu Lys Leu Glu
165 170 175

Asn Gln Ser Leu Lys Ser Val Lys Val Gly Ser Ile Lys Thr Asp Trp
180 185 190

Leu Gly Cys
195

<210> 6
<211> 195
<212> PRT
<213> Bos taurus

<400> 6

Pro Glu Val Cys Asp Ser Lys Leu Thr Phe Asp Ala Ile Thr Thr Ile
1 5 10 15

Arg Gly Glu Val Met Phe Phe Lys Asp Arg Phe Tyr Met Arg Thr Asn
20 25 30

Pro Leu Tyr Pro Glu Val Glu Leu Asn Phe Ile Ser Val Phe Trp Pro
35 40 45

Gln Leu Pro Asn Gly Leu Gln Ala Ala Tyr Glu Val Ala Asp Arg Asp
50 55 60

Glu Val Arg Phe Phe Lys Gly Asn Lys Tyr Trp Ala Val Lys Gly Gln
65 70 75 80

Asp Val Leu Arg Gly Tyr Pro Arg Asp Ile Tyr Arg Ser Phe Gly Phe

85 90 95

Pro Arg Thr Val Lys Ser Ile Asp Ala Ala Val Ser Glu Glu Asp Thr
100 105 110

Gly Lys Thr Tyr Phe Phe Val Ala Asn Lys Cys Trp Arg Tyr Asp Glu
115 120 125

Tyr Lys Gln Ser Met Asp Ala Gly Tyr Pro Lys Met Ile Ala Glu Asp
130 135 140

Phe Pro Gly Ile Gly Asn Lys Val Asp Ala Val Phe Gln Lys Gly Gly
145 150 155 160

Phe Phe Tyr Phe Phe His Gly Arg Arg Gln Tyr Lys Phe Asp Pro Gln
165 170 175

Thr Lys Arg Ile Leu Thr Leu Leu Lys Ala Asn Ser Trp Phe Asn Cys
180 185 190

Arg Lys Asn
195

<210> 7
<211> 195
<212> PRT
<213> Equus caballus

<400> 7

Pro Glu Val Cys Asp Ser Lys Leu Thr Phe Asp Ala Ile Thr Thr Ile
1 5 10 15

Arg Gly Glu Val Met Phe Phe Lys Asp Arg Phe Tyr Met Arg Ile Asn
20 25 30

Pro Tyr Tyr Pro Glu Ala Glu Leu Asn Phe Ile Ser Ile Phe Trp Pro
35 40 45

Gln Leu Pro Asn Gly Leu Gln Ala Ala Tyr Glu Val Ser His Arg Asp
50 55 60

Glu Val Arg Phe Phe Lys Gly Asn Lys Tyr Trp Ala Val Lys Gly Gln
65 70 75 80

Asp Val Leu Tyr Gly Tyr Pro Lys Asp Ile His Arg Ser Phe Gly Phe
85 90 95

Pro Ser Thr Val Lys Asn Ile Asp Ala Ala Val Ser Glu Glu Asp Thr
100 105 110

Gly Lys Thr Tyr Phe Phe Val Ala Asp Lys Tyr Trp Arg Tyr Asp Glu
115 120 125

Tyr Lys Arg Ser Met Asp Ala Gly Tyr Pro Lys Met Ile Ala Asp Asp
130 135 140

Phe Pro Gly Ile Gly Asp Lys Val Asp Ala Val Phe Gln Lys Asp Gly
145 150 155 160

Phe Phe Tyr Phe Phe His Gly Thr Arg Gln Tyr Lys Phe Asp Pro Lys
165 170 175

Thr Lys Arg Ile Leu Thr Leu Gln Lys Ala Asn Ser Trp Phe Asn Cys
180 185 190

Arg Lys Asn
195

<210> 8
<211> 195
<212> PRT
<213> Homo sapiens

<400> 8

Pro Lys Ala Cys Asp Ser Lys Leu Thr Phe Asp Ala Ile Thr Thr Ile
1 5 10 15

Arg Gly Glu Val Met Phe Phe Lys Asp Arg Phe Tyr Met Arg Thr Asn
20 25 30

Pro Phe Tyr Pro Glu Val Glu Leu Asn Phe Ile Ser Val Phe Trp Pro
35 40 45

Gln Leu Pro Asn Gly Leu Glu Ala Ala Tyr Glu Phe Ala Asp Arg Asp
50 55 60

Glu Val Arg Phe Phe Lys Gly Asn Lys Tyr Trp Ala Val Gln Gly Gln

65 70 75 80

Asn Val Leu His Gly Tyr Pro Lys Asp Ile Tyr Ser Ser Phe Gly Phe
85 90 95

Pro Arg Thr Val Lys His Ile Asp Ala Ala Leu Ser Glu Glu Asn Thr
100 105 110

Gly Lys Thr Tyr Phe Phe Val Ala Asn Lys Tyr Trp Arg Tyr Asp Glu
115 120 125

Tyr Lys Arg Ser Met Asp Pro Gly Tyr Pro Lys Met Ile Ala His Asp
130 135 140

Phe Pro Gly Ile Gly His Lys Val Asp Ala Val Phe Met Lys Asp Gly
145 150 155 160

Phe Phe Tyr Phe Phe His Gly Thr Arg Gln Tyr Lys Phe Asp Pro Lys
165 170 175

Thr Lys Arg Ile Leu Thr Leu Gln Lys Ala Asn Ser Trp Phe Asn Cys
180 185 190

Arg Lys Asn
195

<210> 9
<211> 195
<212> PRT
<213> Sus scrofa

<400> 9

Pro Gln Val Cys Asp Ser Lys Leu Thr Phe Asp Ala Ile Thr Thr Leu
1 5 10 15

Arg Gly Glu Leu Met Phe Phe Lys Asp Arg Phe Tyr Met Arg Thr Asn
20 25 30

Ser Phe Tyr Pro Glu Val Glu Leu Asn Phe Ile Ser Val Phe Trp Pro
35 40 45

Gln Val Pro Asn Gly Leu Gln Ala Ala Tyr Glu Ile Ala Asp Arg Asp
50 55 60

Glu Val Arg Phe Phe Lys Gly Asn Lys Tyr Trp Ala Val Arg Gly Gln
65 70 75 80

Asp Val Leu Tyr Gly Tyr Pro Lys Asp Ile His Arg Ser Phe Gly Phe
85 90 95

Pro Ser Thr Val Lys Asn Ile Asp Ala Ala Val Phe Glu Glu Asp Thr
100 105 110

Gly Lys Thr Tyr Phe Phe Val Ala His Glu Cys Trp Arg Tyr Asp Glu
115 120 125

Tyr Lys Gln Ser Met Asp Thr Gly Tyr Pro Lys Met Ile Ala Glu Glu
130 135 140

Phe Pro Gly Ile Gly Asn Lys Val Asp Ala Val Phe Gln Lys Asp Gly
145 150 155 160

Phe Leu Tyr Phe Phe His Gly Thr Arg Gln Tyr Gln Phe Asp Phe Lys
165 170 175

Thr Lys Arg Ile Leu Thr Leu Gln Lys Ala Asn Ser Trp Phe Asn Cys
180 185 190

Arg Lys Asn
195

<210> 10
<211> 195
<212> PRT
<213> Homo sapiens

<400> 10

Pro Glu Ile Cys Lys Gln Asp Ile Val Phe Asp Gly Ile Ala Gln Ile
1 5 10 15

Arg Gly Glu Ile Phe Phe Phe Lys Asp Arg Phe Ile Trp Arg Thr Val
20 25 30

Thr Pro Arg Asp Lys Pro Met Gly Pro Leu Leu Val Ala Thr Phe Trp
35 40 45

Pro Glu Leu Pro Glu Lys Ile Asp Ala Val Tyr Glu Ala Pro Gln Glu

50 55 60

Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr Trp Ile Tyr Ser Ala
65 70 75 80

Ser Thr Leu Glu Arg Gly Tyr Pro Lys Pro Leu Thr Ser Leu Gly Leu
85 90 95

Pro Pro Asp Val Gln Arg Val Asp Ala Ala Phe Asn Trp Ser Lys Asn
100 105 110

Lys Lys Thr Tyr Ile Phe Ala Gly Asp Lys Phe Trp Arg Tyr Asn Glu
115 120 125

Val Lys Lys Lys Met Asp Pro Gly Phe Pro Lys Leu Ile Ala Asp Ala
130 135 140

Trp Asn Ala Ile Pro Asp Asn Leu Asp Ala Val Val Asp Leu Gln Gly
145 150 155 160

Gly Gly His Ser Tyr Phe Phe Lys Gly Ala Tyr Tyr Leu Lys Leu Glu
165 170 175

Asn Gln Ser Leu Lys Ser Val Lys Phe Gly Ser Ile Lys Ser Asp Trp
180 185 190

Leu Gly Cys
195

<210> 11
<211> 191
<212> PRT
<213> Homo sapiens

<400> 11

Pro Ala Asn Cys Asp Pro Ala Leu Ser Phe Asp Ala Val Ser Thr Leu
1 5 10 15

Arg Gly Glu Ile Leu Ile Phe Lys Asp Arg His Phe Trp Arg Lys Ser
20 25 30

Leu Arg Lys Leu Glu Pro Glu Leu His Leu Ile Ser Ser Phe Trp Pro
35 40 45

Ser Leu Pro Ser Gly Val Asp Ala Ala Tyr Glu Val Thr Ser Lys Asp
50 55 60

Leu Val Phe Ile Phe Lys Gly Asn Gln Phe Trp Ala Ile Arg Gly Asn
65 70 75 80

Glu Val Arg Ala Gly Tyr Pro Arg Gly Ile His Thr Leu Gly Phe Pro
85 90 95

Pro Thr Val Arg Lys Ile Asp Ala Ala Ile Ser Asp Lys Glu Lys Asn
100 105 110

Lys Thr Tyr Phe Phe Val Glu Asp Lys Tyr Trp Arg Phe Asp Glu Lys
115 120 125

Arg Asn Ser Met Glu Pro Gly Phe Pro Lys Gln Ile Ala Glu Asp Phe
130 135 140

Pro Gly Ile Asp Ser Lys Ile Asp Ala Val Phe Glu Glu Phe Gly Phe
145 150 155 160

Phe Tyr Phe Phe Thr Gly Ser Ser Gln Leu Glu Phe Asp Pro Asn Ala
165 170 175

Lys Lys Val Thr His Thr Leu Lys Ser Asn Ser Trp Leu Asn Cys
180 185 190

<210> 12
<211> 191
<212> PRT
<213> Mus musculus

<400> 12

Ser Pro Met Cys Ser Ser Thr Leu Phe Phe Asp Ala Val Ser Thr Leu
1 5 10 15

Arg Gly Glu Val Leu Phe Phe Lys Asp Arg His Phe Trp Arg Lys Ser
20 25 30

Leu Arg Thr Pro Glu Pro Glu Phe Tyr Leu Ile Ser Ser Phe Trp Pro
35 40 45

Ser Leu Pro Ser Asn Met Asp Ala Ala Tyr Glu Val Thr Asn Arg Asp

50 55 60

Thr Val Phe Ile Phe Lys Gly Asn Gln Phe Trp Ala Ile Arg Gly His
65 70 75 80

Glu Glu Leu Ala Gly Tyr Pro Lys Ser Ile His Thr Leu Gly Leu Pro
85 90 95

Ala Thr Val Lys Lys Ile Asp Ala Ala Ile Ser Asn Lys Glu Lys Arg
100 105 110

Lys Thr Tyr Phe Phe Val Glu Asp Lys Tyr Trp Arg Phe Asp Glu Lys
115 120 125

Lys Gln Ser Met Glu Pro Gly Phe Pro Arg Lys Ile Ala Glu Asp Phe
130 135 140

Pro Gly Val Asp Ser Arg Val Asp Ala Val Phe Glu Ala Phe Gly Phe
145 150 155 160

Leu Tyr Phe Phe Ser Gly Ser Ser Gln Leu Glu Phe Asp Pro Asn Ala
165 170 175

Lys Lys Val Thr His Ile Leu Lys Ser Asn Ser Trp Phe Asn Cys
180 185 190

<210> 13
<211> 191
<212> PRT
<213> Oryctolagus cuniculus

<400> 13

Pro Val Met Cys Asp Pro Asp Leu Ser Phe Asp Ala Ile Ser Thr Leu
1 5 10 15

Arg Gly Glu Ile Leu Phe Phe Lys Asp Arg Tyr Phe Trp Arg Lys Ser
20 25 30

Leu Arg Ile Leu Glu Pro Glu Phe His Leu Ile Ser Ser Phe Trp Pro
35 40 45

Ser Leu Pro Ser Ala Val Asp Ala Ala Tyr Glu Val Ile Ser Arg Asp
50 55 60

Thr Val Phe Ile Phe Lys Gly Thr Gln Phe Trp Ala Ile Arg Gly Asn
65 70 75 80

Glu Val Gln Ala Gly Tyr Pro Arg Ser Ile His Thr Leu Gly Phe Pro
85 90 95

Ser Thr Ile Arg Lys Ile Asp Ala Ala Ile Ser Asp Lys Glu Arg Lys
100 105 110

Lys Thr Tyr Phe Phe Val Glu Asp Lys Tyr Trp Arg Phe Asp Glu Lys
115 120 125

Arg Gln Ser Leu Glu Pro Gly Phe Pro Arg His Ile Ala Glu Asp Phe
130 135 140

Pro Gly Ile Asn Pro Lys Ile Asp Ala Val Phe Glu Ala Phe Gly Phe
145 150 155 160

Phe Tyr Phe Phe Ser Gly Ser Ser Gln Ser Glu Phe Asp Pro Asn Ala
165 170 175

Lys Lys Val Thr His Val Leu Lys Ser Asn Ser Trp Phe Gln Cys
180 185 190

<210> 14
<211> 191
<212> PRT
<213> Rattus norvegicus

<400> 14

Leu Pro Met Cys Ser Ser Ala Leu Ser Phe Asp Ala Val Ser Thr Leu
1 5 10 15

Arg Gly Glu Val Leu Phe Phe Lys Asp Arg His Phe Trp Arg Lys Ser
20 25 30

Leu Arg Thr Pro Glu Pro Gly Phe Tyr Leu Ile Ser Ser Phe Trp Pro
35 40 45

Ser Leu Pro Ser Asn Met Asp Ala Ala Tyr Glu Val Thr Asn Arg Asp
50 55 60

Thr Val Phe Ile Leu Lys Gly Asn Gln Ile Trp Ala Ile Arg Gly His

65 70 75 80

Glu Glu Leu Ala Gly Tyr Pro Lys Ser Ile His Thr Leu Gly Leu Pro
85 90 95

Glu Thr Val Gln Lys Ile Asp Ala Ala Ile Ser Leu Lys Asp Gln Lys
100 105 110

Lys Thr Tyr Phe Phe Val Glu Asp Lys Phe Trp Arg Phe Asp Glu Lys
115 120 125

Lys Gln Ser Met Asp Pro Glu Phe Pro Arg Lys Ile Ala Glu Asn Phe
130 135 140

Pro Gly Ile Gly Thr Lys Val Asp Ala Val Phe Glu Ala Phe Gly Phe
145 150 155 160

Leu Tyr Phe Phe Ser Gly Ser Ser Gln Leu Glu Phe Asp Pro Asn Ala
165 170 175

Gly Lys Val Thr His Ile Leu Lys Ser Asn Ser Trp Phe Asn Cys
180 185 190

<210> 15
<211> 192
<212> PRT
<213> Homo sapiens

<400> 15

Pro Lys Pro Cys Asp Pro Ser Leu Thr Phe Asp Ala Ile Thr Thr Leu
1 5 10 15

Arg Gly Glu Ile Leu Phe Phe Lys Asp Arg Tyr Phe Trp Arg Arg His
20 25 30

Pro Gln Leu Gln Arg Val Glu Met Asn Phe Ile Ser Leu Phe Trp Pro
35 40 45

Ser Leu Pro Thr Gly Ile Gln Ala Ala Tyr Glu Asp Phe Asp Arg Asp
50 55 60

Leu Ile Phe Leu Phe Lys Gly Asn Gln Tyr Trp Ala Leu Ser Gly Tyr
65 70 75 80

Asp Ile Leu Gln Gly Tyr Pro Lys Asp Ile Ser Asn Tyr Gly Phe Pro
85 90 95

Ser Ser Val Gln Ala Ile Asp Ala Ala Val Phe Tyr Arg Ser Lys Thr
100 105 110

Tyr Phe Phe Val Asn Asp Gln Phe Trp Arg Tyr Asp Asn Gln Arg Gln
115 120 125

Phe Met Glu Pro Gly Tyr Pro Lys Ser Ile Ser Gly Ala Phe Pro Gly
130 135 140

Ile Glu Ser Lys Val Asp Ala Val Phe Gln Gln Glu His Phe Phe His
145 150 155 160

Val Phe Ser Gly Pro Arg Tyr Tyr Ala Phe Asp Leu Ile Ala Gln Arg
165 170 175

Val Thr Arg Val Ala Arg Gly Asn Lys Trp Leu Asn Cys Arg Tyr Gly
180 185 190

<210> 16
<211> 190
<212> PRT
<213> Mus musculus

<400> 16

Pro Lys Ala Cys Asp Pro His Leu Arg Phe Asp Ala Thr Thr Thr Leu
1 5 10 15

Arg Gly Glu Ile Tyr Phe Phe Lys Glu Lys Tyr Phe Trp Arg Arg His
20 25 30

Pro Gln Leu Arg Thr Val Asp Leu Asn Phe Ile Ser Leu Phe Trp Pro
35 40 45

Gly Leu Pro Asn Gly Leu Gln Ala Ala Tyr Glu Asp Phe Asp Arg Asp
50 55 60

Leu Val Phe Leu Phe Lys Gly Arg Gln Tyr Trp Ala Leu Ser Gly Tyr
65 70 75 80

Asp Leu Gln Gln Gly Tyr Pro Arg Asp Ile Ser Asn Tyr Gly Phe Pro

85 90 95

Arg Ser Val Gln Ala Ile Asp Ala Ala Val Ser Tyr Asn Gly Lys Thr
100 105 110

Tyr Phe Phe Ile Asn Asn Gln Cys Trp Arg Tyr Asp Asn Glu Arg Arg
115 120 125

Ser Met Asp Pro Gly Tyr Pro Lys Ser Ile Pro Ser Met Phe Pro Gly
130 135 140

Val Asn Cys Arg Val Asp Ala Val Phe Leu Gln Asp Ser Phe Phe Leu
145 150 155 160

Phe Phe Ser Gly Pro Gln Tyr Phe Ala Phe Asn Phe Val Ser His Arg
165 170 175

Val Thr Arg Val Ala Arg Ser Asn Leu Trp Leu Asn Cys Ser
180 185 190

<210> 17
<211> 190
<212> PRT
<213> Rattus norvegicus

<400> 17

Pro Thr Ala Cys Asp Pro His Leu Arg Phe Asp Ala Ala Thr Thr Leu
1 5 10 15

Arg Gly Glu Ile Tyr Phe Phe Lys Asp Lys Tyr Phe Trp Arg Arg His
20 25 30

Pro Gln Leu Arg Thr Val Asp Leu Asn Phe Ile Ser Leu Phe Trp Pro
35 40 45

Phe Leu Pro Asn Gly Leu Gln Ala Ala Tyr Glu Asp Phe Asp Arg Asp
50 55 60

Leu Val Phe Leu Phe Lys Gly Arg Gln Tyr Trp Ala Leu Ser Ala Tyr
65 70 75 80

Asp Leu Gln Gln Gly Tyr Pro Arg Asp Ile Ser Asn Tyr Gly Phe Pro
85 90 95

Arg Ser Val Gln Ala Ile Asp Ala Ala Val Ser Tyr Asn Gly Lys Thr
100 105 110

Tyr Phe Phe Val Asn Asn Gln Cys Trp Arg Tyr Asp Asn Gln Arg Arg
115 120 125

Ser Met Asp Pro Gly Tyr Pro Thr Ser Ile Ala Ser Val Phe Pro Gly
130 135 140

Ile Asn Cys Arg Ile Asp Ala Val Phe Gln Gln Asp Ser Phe Phe Leu
145 150 155 160

Phe Phe Ser Gly Pro Gln Tyr Phe Ala Phe Asn Leu Val Ser Arg Arg
165 170 175

Val Thr Arg Val Ala Arg Ser Asn Leu Trp Leu Asn Cys Pro
180 185 190

<210> 18
<211> 195
<212> PRT
<213> Bos taurus

<400> 18

Glu Asp Val Cys Asn Val Asp Ile Phe Asp Ala Ile Ala Glu Ile Arg
1 5 10 15

Asn Arg Leu His Phe Phe Lys Ala Gly Lys Tyr Trp Arg Leu Ser Glu
20 25 30

Gly Gly Gly Arg Arg Val Gln Gly Pro Phe Leu Val Lys Ser Lys Trp
35 40 45

Pro Ala Leu Pro Arg Lys Leu Asp Ser Ala Phe Glu Asp Pro Leu Thr
50 55 60

Lys Lys Ile Phe Phe Phe Ser Gly Arg Gln Val Trp Val Tyr Thr Gly
65 70 75 80

Ala Ser Leu Leu Gly Pro Arg Arg Leu Asp Lys Leu Gly Leu Gly Pro
85 90 95

Glu Val Ala Gln Val Thr Gly Ala Leu Pro Arg Pro Glu Gly Lys Val

100 105 110

Leu Leu Phe Ser Gly Gln Ser Phe Trp Arg Phe Asp Val Lys Thr Gln
115 120 125

Lys Val Asp Pro Gln Ser Val Thr Pro Val Asp Gln Met Phe Pro Gly
130 135 140

Val Pro Ile Ser Thr His Asp Ile Phe Gln Tyr Gln Glu Lys Ala Tyr
145 150 155 160

Phe Cys Gln Asp His Phe Tyr Trp Arg Val Ser Ser Gln Asn Glu Val
165 170 175

Asn Gln Val Asp Tyr Val Gly Tyr Val Thr Phe Asp Leu Leu Lys Cys
180 185 190

Pro Glu Asp
195

<210> 19
<211> 195
<212> PRT
<213> Canis familiaris

<400> 19

Glu Asp Ile Cys Lys Val Asn Ile Phe Asp Ala Ile Ala Glu Ile Arg
1 5 10 15

Asn Tyr Leu His Phe Phe Lys Glu Gly Lys Tyr Trp Arg Phe Ser Lys
20 25 30

Gly Lys Gly Arg Arg Val Gln Gly Pro Phe Leu Ser Pro Ser Thr Trp
35 40 45

Pro Ala Leu Pro Arg Lys Leu Asp Ser Ala Phe Glu Asp Gly Leu Thr
50 55 60

Lys Lys Thr Phe Phe Phe Ser Gly Arg Gln Val Trp Val Tyr Thr Gly
65 70 75 80

Thr Ser Val Val Gly Pro Arg Arg Leu Asp Lys Leu Gly Leu Gly Pro
85 90 95

Glu Val Thr Gln Val Thr Gly Ala Leu Pro Gln Gly Gly Gly Lys Val
100 105 110

Leu Leu Phe Ser Arg Gln Arg Phe Trp Ser Phe Asp Val Lys Thr Gln
115 120 125

Thr Val Asp Pro Arg Ser Ala Gly Ser Val Glu Gln Met Tyr Pro Gly
130 135 140

Val Pro Leu Asn Thr His Asp Ile Phe Gln Tyr Gln Glu Lys Ala Tyr
145 150 155 160

Phe Cys Gln Asp Arg Phe Tyr Trp Arg Val Asn Ser Arg Asn Glu Val
165 170 175

Asn Gln Val Asp Glu Val Gly Tyr Val Thr Phe Asp Ile Leu Gln Cys
180 185 190

Pro Glu Asp
195

<210> 20
<211> 195
<212> PRT
<213> Homo sapiens

<400> 20

Asp Asp Ala Cys Asn Val Asn Ile Phe Asp Ala Ile Ala Glu Ile Gly
1 5 10 15

Asn Gln Leu Tyr Leu Phe Lys Asp Gly Lys Tyr Trp Arg Phe Ser Glu
20 25 30

Gly Arg Gly Ser Arg Pro Gln Gly Pro Phe Leu Ile Ala Asp Lys Trp
35 40 45

Pro Ala Leu Pro Arg Lys Leu Asp Ser Val Phe Glu Glu Pro Leu Ser
50 55 60

Lys Lys Leu Phe Phe Phe Ser Gly Arg Gln Val Trp Val Tyr Thr Gly
65 70 75 80

Ala Ser Val Leu Gly Pro Arg Arg Leu Asp Lys Leu Gly Leu Gly Ala
85 90 95

Asp Val Ala Gln Val Thr Gly Ala Leu Arg Ser Gly Arg Gly Lys Met
100 105 110

Leu Leu Phe Ser Gly Arg Arg Leu Trp Arg Phe Asp Val Lys Ala Gln
115 120 125

Met Val Asp Pro Arg Ser Ala Ser Glu Val Asp Arg Met Phe Pro Gly
130 135 140

Val Pro Leu Asp Thr His Asp Val Phe Gln Tyr Arg Glu Lys Ala Tyr
145 150 155 160

Phe Cys Gln Asp Arg Phe Tyr Trp Arg Val Ser Ser Arg Ser Glu Leu
165 170 175

Asn Gln Val Asp Gln Val Gly Tyr Val Thr Tyr Asp Ile Leu Gln Cys
180 185 190

Pro Glu Asp
195

<210> 21
<211> 200
<212> PRT
<213> Mus musculus

<400> 21

Asp Asn Pro Cys Asn Val Asp Val Phe Asp Ala Ile Ala Glu Ile Gln
1 5 10 15

Gly Ala Leu His Phe Phe Lys Asp Gly Trp Tyr Trp Lys Phe Leu Asn
20 25 30

His Arg Gly Ser Pro Leu Gln Gly Pro Phe Leu Thr Ala Arg Thr Trp
35 40 45

Pro Ala Leu Pro Ala Thr Leu Asp Ser Ala Phe Glu Asp Pro Gln Thr
50 55 60

Lys Arg Val Phe Phe Phe Ser Gly Arg Gln Met Trp Val Tyr Thr Gly
65 70 75 80

Lys Thr Val Leu Gly Pro Arg Ser Leu Asp Lys Leu Gly Leu Gly Pro
85 90 95

Glu Val Thr His Val Ser Gly Leu Leu Pro Arg Arg Pro Gly Lys Ala
100 105 110

Leu Leu Phe Ser Lys Gly Arg Val Trp Arg Phe Asp Leu Lys Ser Gln
115 120 125

Lys Val Asp Pro Gln Ser Val Ile Arg Val Asp Lys Glu Phe Ser Gly
130 135 140

Val Pro Trp Asn Ser His Asp Ile Phe Gln Tyr Gln Asp Lys Ala Tyr
145 150 155 160

Phe Cys His Gly Lys Phe Phe Trp Arg Val Ser Phe Gln Asn Glu Val
165 170 175

Asn Lys Val Asp Pro Glu Val Asn Gln Val Asp Asp Val Gly Tyr Val
180 185 190

Thr Tyr Asp Leu Leu Gln Cys Pro
195 200

<210> 22
<211> 191
<212> PRT
<213> Homo sapiens

<400> 22

Pro Ala Lys Cys Asp Pro Ala Leu Ser Phe Asp Ala Ile Ser Thr Leu
1 5 10 15

Arg Gly Glu Tyr Leu Phe Phe Lys Asp Arg Tyr Phe Trp Arg Arg Ser
20 25 30

His Trp Asn Pro Glu Pro Glu Phe His Leu Ile Ser Ala Phe Trp Pro
35 40 45

Ser Leu Pro Ser Tyr Leu Asp Ala Ala Tyr Glu Val Asn Ser Arg Asp
50 55 60

Thr Val Phe Ile Phe Lys Gly Asn Glu Phe Trp Ala Ile Arg Gly Asn
65 70 75 80

Glu Val Gln Ala Gly Tyr Pro Arg Gly Ile His Thr Leu Gly Phe Pro
85 90 95

Pro Thr Ile Arg Lys Ile Asp Ala Ala Val Ser Asp Lys Glu Lys Lys
100 105 110

Lys Thr Tyr Phe Phe Ala Ala Asp Lys Tyr Trp Arg Phe Asp Glu Asn
115 120 125

Ser Gln Ser Met Glu Gln Gly Phe Pro Arg Leu Ile Ala Asp Asp Phe
130 135 140

Pro Gly Val Glu Pro Lys Val Asp Ala Val Leu Gln Ala Phe Gly Phe
145 150 155 160

Phe Tyr Phe Phe Ser Gly Ser Ser Gln Phe Glu Phe Asp Pro Asn Ala
165 170 175

Arg Met Val Thr His Ile Leu Lys Ser Asn Ser Trp Leu His Cys
180 185 190

<210> 23
<211> 191
<212> PRT
<213> Mus musculus

<400> 23

Pro Asp Lys Cys Asp Pro Ala Leu Ser Phe Asp Ser Val Ser Thr Leu
1 5 10 15

Arg Gly Glu Val Leu Phe Phe Lys Asp Arg Tyr Phe Trp Arg Arg Ser
20 25 30

His Trp Asn Pro Glu Pro Glu Phe His Leu Ile Ser Ala Phe Trp Pro
35 40 45

Thr Leu Pro Ser Asp Leu Asp Ala Ala Tyr Glu Ala His Asn Thr Asp
50 55 60

Ser Val Leu Ile Phe Lys Gly Ser Gln Phe Trp Ala Val Arg Gly Asn
65 70 75 80

Glu Val Gln Ala Gly Tyr Pro Lys Gly Ile His Thr Leu Gly Phe Pro
85 90 95

Pro Thr Val Lys Lys Ile Asp Ala Ala Val Phe Glu Lys Glu Lys Lys
100 105 110

Lys Thr Tyr Phe Phe Val Gly Asp Lys Tyr Trp Arg Phe Asp Glu Thr
115 120 125

Arg His Val Met Asp Lys Gly Phe Pro Arg Gln Ile Thr Asp Asp Phe
130 135 140

Pro Gly Ile Glu Pro Gln Val Asp Ala Val Leu His Glu Phe Gly Phe
145 150 155 160

Phe Tyr Phe Phe Arg Gly Ser Ser Gln Phe Glu Phe Asp Pro Asn Ala
165 170 175

Arg Thr Val Thr His Ile Leu Lys Ser Asn Ser Trp Leu Leu Cys
180 185 190

<210> 24
<211> 198
<212> PRT
<213> Homo sapiens

<400> 24

Pro Asp Ala Cys Glu Ala Ser Phe Asp Ala Val Ser Thr Ile Arg Gly
1 5 10 15

Glu Leu Phe Phe Phe Lys Ala Gly Phe Val Trp Arg Leu Arg Gly Gly
20 25 30

Gln Leu Gln Pro Gly Tyr Pro Ala Leu Ala Ser Arg His Trp Gln Gly
35 40 45

Leu Pro Ser Pro Val Asp Ala Ala Phe Glu Asp Ala Gln Gly His Ile
50 55 60

Trp Phe Phe Gln Gly Ala Gln Tyr Trp Val Tyr Asp Gly Glu Lys Pro
65 70 75 80

Val Leu Gly Pro Ala Pro Leu Thr Glu Leu Gly Leu Val Arg Phe Pro
85 90 95

Val His Ala Ala Leu Val Trp Gly Pro Glu Lys Asn Lys Ile Tyr Phe
100 105 110

Phe Arg Gly Arg Asp Tyr Trp Arg Phe His Pro Ser Thr Arg Arg Val
115 120 125

Asp Ser Pro Val Pro Arg Arg Ala Thr Asp Trp Arg Gly Val Pro Ser
130 135 140

Glu Ile Asp Ala Ala Phe Gln Asp Ala Asp Gly Tyr Ala Tyr Phe Leu
145 150 155 160

Arg Gly Arg Leu Tyr Trp Lys Phe Asp Pro Val Lys Val Lys Ala Leu
165 170 175

Glu Gly Phe Pro Arg Leu Val Gly Pro Asp Phe Phe Gly Cys Ala Glu
180 185 190

Pro Ala Asn Thr Phe Leu
195

<210> 25
<211> 198
<212> PRT
<213> Mus musculus

<400> 25

Pro Asp Val Cys Glu Thr Ser Phe Asp Ala Val Ser Thr Ile Arg Gly
1 5 10 15

Glu Leu Phe Phe Phe Lys Ala Gly Phe Val Trp Arg Leu Arg Ser Gly
20 25 30

Arg Leu Gln Pro Gly Tyr Pro Ala Leu Ala Ser Arg His Trp Gln Gly
35 40 45

Leu Pro Ser Pro Val Asp Ala Ala Phe Glu Asp Ala Gln Gly Gln Ile
50 55 60

Trp Phe Phe Gln Gly Ala Gln Tyr Trp Val Tyr Asp Gly Glu Lys Pro
65 70 75 80

Val Leu Gly Pro Ala Pro Leu Ser Lys Leu Gly Leu Gln Gly Ser Pro
85 90 95

Val His Ala Ala Leu Val Trp Gly Pro Glu Lys Asn Lys Ile Tyr Phe
100 105 110

Phe Arg Gly Gly Asp Tyr Trp Arg Phe His Pro Arg Thr Gln Arg Val
115 120 125

Asp Asn Pro Val Pro Arg Arg Ser Thr Asp Trp Arg Gly Val Pro Ser
130 135 140

Glu Ile Asp Ala Ala Phe Gln Asp Ala Glu Gly Tyr Ala Tyr Phe Leu
145 150 155 160

Arg Gly His Leu Tyr Trp Lys Phe Asp Pro Val Lys Val Lys Val Leu
165 170 175

Glu Gly Phe Pro Arg Pro Val Gly Pro Asp Phe Phe Asp Cys Ala Glu
180 185 190

Pro Ala Asn Thr Phe Arg
195

<210> 26
<211> 192
<212> PRT
<213> Homo sapiens

<400> 26

Pro Ala Leu Cys Asp Pro Asn Leu Ser Phe Asp Ala Val Thr Thr Val
1 5 10 15

Gly Asn Lys Ile Phe Phe Phe Lys Asp Arg Phe Phe Trp Leu Lys Val
20 25 30

Ser Glu Arg Pro Lys Thr Ser Val Asn Leu Ile Ser Ser Leu Trp Pro
35 40 45

Thr Leu Pro Ser Gly Ile Glu Ala Ala Tyr Glu Ile Glu Ala Arg Asn
50 55 60

Gln Val Phe Leu Phe Lys Asp Asp Lys Tyr Trp Leu Ile Ser Asn Leu
65 70 75 80

Arg Pro Glu Pro Asn Tyr Pro Lys Ser Ile His Ser Phe Gly Phe Pro
85 90 95

Asn Phe Val Lys Lys Ile Asp Ala Ala Val Phe Asn Pro Arg Phe Tyr
100 105 110

Arg Thr Tyr Phe Phe Val Asp Asn Gln Tyr Trp Arg Tyr Asp Glu Arg
115 120 125

Arg Gln Met Met Asp Pro Gly Tyr Pro Lys Leu Ile Thr Lys Asn Phe
130 135 140

Gln Gly Ile Gly Pro Lys Ile Asp Ala Val Phe Tyr Ser Lys Asn Lys
145 150 155 160

Tyr Tyr Tyr Phe Phe Gln Gly Ser Asn Gln Phe Glu Tyr Asp Phe Leu
165 170 175

Leu Gln Arg Ile Thr Lys Thr Leu Lys Ser Asn Ser Trp Phe Gly Cys
180 185 190

<210> 27
<211> 191
<212> PRT
<213> Mus musculus

<400> 27

Ser Thr Phe Cys His Gln Ser Leu Ser Phe Asp Ala Val Thr Thr Val
1 5 10 15

Gly Glu Lys Ile Leu Phe Phe Lys Asp Trp Phe Phe Trp Trp Lys Leu
20 25 30

Pro Gly Ser Pro Ala Thr Asn Ile Thr Ser Ile Ser Ser Ile Trp Pro
35 40 45

Ser Ile Pro Ser Ala Ile Gln Ala Ala Tyr Glu Ile Glu Ser Arg Asn
50 55 60

Gln Leu Phe Leu Phe Lys Asp Glu Lys Tyr Trp Leu Ile Asn Asn Leu

65 70 75 80

Val Pro Glu Pro His Tyr Pro Arg Ser Ile Tyr Ser Leu Gly Phe Ser
85 90 95

Ala Ser Val Lys Lys Val Asp Ala Ala Val Phe Asp Pro Leu Arg Gln
100 105 110

Lys Val Tyr Phe Phe Val Asp Lys His Tyr Trp Arg Tyr Asp Val Arg
115 120 125

Gln Glu Leu Met Asp Pro Ala Tyr Pro Lys Leu Ile Ser Thr His Phe
130 135 140

Pro Gly Ile Lys Pro Lys Ile Asp Ala Val Leu Tyr Phe Lys Arg His
145 150 155 160

Tyr Tyr Ile Phe Gln Gly Ala Tyr Gln Leu Glu Tyr Asp Pro Leu Phe
165 170 175

Arg Arg Val Thr Lys Thr Leu Lys Ser Thr Ser Trp Phe Gly Cys
180 185 190

<210> 28
<211> 191
<212> PRT
<213> Oryctolagus cuniculus

<400> 28

Pro Thr Ala Cys Asp His Asn Leu Lys Phe Asp Ala Val Thr Thr Val
1 5 10 15

Gly Asn Lys Ile Phe Phe Phe Lys Asp Ser Phe Phe Trp Trp Lys Ile
20 25 30

Pro Lys Ser Ser Thr Thr Ser Val Arg Leu Ile Ser Ser Leu Trp Pro
35 40 45

Thr Leu Pro Ser Gly Ile Glu Ala Ala Tyr Glu Ile Gly Asp Arg His
50 55 60

Gln Val Phe Leu Phe Lys Gly Asp Lys Phe Trp Leu Ile Ser His Leu

65 70 75 80

Arg Leu Gln Pro Asn Tyr Pro Lys Ser Ile His Ser Leu Gly Phe Pro
85 90 95

Asp Phe Val Lys Lys Ile Asp Ala Ala Val Phe Asn Pro Ser Leu Arg
100 105 110

Lys Thr Tyr Phe Phe Val Asp Asn Leu Tyr Trp Arg Tyr Asp Glu Arg
115 120 125

Arg Glu Val Met Asp Ala Gly Tyr Pro Lys Leu Ile Thr Lys His Phe
130 135 140

Pro Gly Ile Gly Pro Lys Ile Asp Ala Val Phe Tyr Phe Gln Arg Tyr
145 150 155 160

Tyr Tyr Phe Phe Gln Gly Pro Asn Gln Leu Glu Tyr Asp Thr Phe Ser
165 170 175

Ser Arg Val Thr Lys Lys Leu Lys Ser Asn Ser Trp Phe Asp Cys
180 185 190

<210> 29
<211> 191
<212> PRT
<213> Rattus norvegicus

<400> 29

Ser Thr Val Cys His Gln Ser Leu Ser Phe Asp Ala Val Thr Thr Val
1 5 10 15

Gly Asp Lys Ile Phe Phe Phe Lys Asp Trp Phe Phe Trp Trp Arg Leu
20 25 30

Pro Gly Ser Pro Ala Thr Asn Ile Thr Ser Ile Ser Ser Met Trp Pro
35 40 45

Thr Ile Pro Ser Gly Ile Gln Ala Ala Tyr Glu Ile Gly Gly Arg Asn
50 55 60

Gln Leu Phe Leu Phe Lys Asp Glu Lys Tyr Trp Leu Ile Asn Asn Leu
65 70 75 80

Val Pro Glu Pro His Tyr Pro Arg Ser Ile His Ser Leu Gly Phe Pro
85 90 95

Ala Ser Val Lys Lys Ile Asp Ala Ala Val Phe Asp Pro Leu Arg Gln
100 105 110

Lys Val Tyr Phe Phe Val Asp Lys Gln Tyr Trp Arg Tyr Asp Val Arg
115 120 125

Gln Glu Leu Met Asp Ala Ala Tyr Pro Lys Leu Ile Ser Thr His Phe
130 135 140

Pro Gly Ile Arg Pro Lys Ile Asp Ala Val Leu Tyr Phe Lys Arg His
145 150 155 160

Tyr Tyr Ile Phe Gln Gly Ala Tyr Gln Leu Glu Tyr Asp Pro Leu Leu
165 170 175

Asp Arg Val Thr Lys Thr Leu Ser Ser Thr Ser Trp Phe Gly Cys
180 185 190

<210> 30
<211> 191
<212> PRT
<213> Bos taurus

<400> 30

Pro Asp Lys Cys Asp Pro Ser Leu Ser Leu Asp Ala Ile Thr Ser Leu
1 5 10 15

Arg Gly Glu Thr Leu Ile Phe Lys Asp Arg Phe Phe Trp Arg Leu His
20 25 30

Pro Gln Gln Val Glu Ala Glu Leu Phe Leu Thr Lys Ser Phe Gly Pro
35 40 45

Glu Leu Pro Asn Arg Ile Asp Ala Ala Tyr Glu His Pro Ser His Asp
50 55 60

Leu Ile Phe Ile Phe Arg Gly Arg Lys Phe Trp Ala Leu Ser Gly Tyr
65 70 75 80

Asp Ile Leu Glu Asp Tyr Pro Lys Lys Ile Ser Glu Leu Gly Phe Pro

85 90 95

Lys His Val Lys Lys Ile Ser Ala Ala Leu His Phe Glu Asp Ser Gly
100 105 110

Lys Thr Leu Phe Phe Ser Glu Asn Gln Val Trp Ser Tyr Asp Asp Thr
115 120 125

Asn His Val Met Asp Lys Asp Tyr Pro Arg Leu Ile Glu Glu Val Phe
130 135 140

Pro Gly Ile Gly Asp Lys Val Asp Ala Val Tyr Gln Lys Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Asn Gly Pro Ile Gln Phe Glu Tyr Ser Ile Trp Ser
165 170 175

Asn Arg Ile Val Arg Val Met Thr Thr Asn Ser Leu Leu Trp Cys
180 185 190

<210> 31
<211> 191
<212> PRT
<213> Equus caballus

<400> 31

Pro Asp Lys Cys Asp Pro Ser Leu Ser Leu Asp Ala Ile Thr Ser Leu
1 5 10 15

Arg Gly Glu Thr Met Val Phe Lys Asp Arg Phe Phe Trp Arg Leu His
20 25 30

Pro Gln Leu Val Asp Ala Glu Leu Phe Leu Thr Lys Ser Phe Trp Pro
35 40 45

Glu Leu Pro Asn Arg Ile Asp Ala Ala Tyr Glu His Pro Ser Lys Asp
50 55 60

Leu Ile Phe Ile Phe Arg Gly Arg Lys Phe Trp Ala Leu Asn Gly Tyr
65 70 75 80

Asp Ile Leu Glu Gly Tyr Pro Gln Lys Ile Ser Glu Leu Gly Phe Pro
85 90 95

Lys Asp Val Lys Lys Ile Ser Ala Ala Val His Phe Glu Asp Thr Gly
100 105 110

Lys Thr Leu Phe Phe Ser Gly Asn Gln Val Trp Arg Tyr Asp Asp Thr
115 120 125

Asn Arg Met Met Asp Lys Asp Tyr Pro Arg Leu Ile Glu Glu Asp Phe
130 135 140

Pro Gly Ile Gly Asp Lys Val Asp Ala Val Tyr Glu Lys Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Asn Gly Pro Ile Gln Phe Glu Tyr Ser Ile Trp Ser
165 170 175

Asn Arg Ile Val Arg Val Met Pro Thr Asn Ser Leu Leu Trp Cys
180 185 190

<210> 32
<211> 191
<212> PRT
<213> Homo sapiens

<400> 32

Pro Asp Lys Cys Asp Pro Ser Leu Ser Leu Asp Ala Ile Thr Ser Leu
1 5 10 15

Arg Gly Glu Thr Met Ile Phe Lys Asp Arg Phe Phe Trp Arg Leu His
20 25 30

Pro Gln Gln Val Asp Ala Glu Leu Phe Leu Thr Lys Ser Phe Trp Pro
35 40 45

Glu Leu Pro Asn Arg Ile Asp Ala Ala Tyr Glu His Pro Ser His Asp
50 55 60

Leu Ile Phe Ile Phe Arg Gly Arg Lys Phe Trp Ala Leu Asn Gly Tyr
65 70 75 80

Asp Ile Leu Glu Gly Tyr Pro Lys Lys Ile Ser Glu Leu Gly Leu Pro
85 90 95

Lys Glu Val Lys Lys Ile Ser Ala Ala Val His Phe Glu Asp Thr Gly
100 105 110

Lys Thr Leu Leu Phe Ser Gly Asn Gln Val Trp Arg Tyr Asp Asp Thr
115 120 125

Asn His Ile Met Asp Lys Asp Tyr Pro Arg Leu Ile Glu Glu Asp Phe
130 135 140

Pro Gly Ile Gly Asp Lys Val Asp Ala Val Tyr Glu Lys Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Asn Gly Pro Ile Gln Phe Glu Tyr Ser Ile Trp Ser
165 170 175

Asn Arg Ile Val Arg Val Met Pro Ala Asn Ser Ile Leu Trp Cys
180 185 190

<210> 33
<211> 191
<212> PRT
<213> Oryctolagus cuniculus

<400> 33

Pro Asp Lys Cys Asp Pro Ser Leu Ser Leu Asp Ala Ile Thr Ser Leu
1 5 10 15

Arg Gly Glu Thr Met Ile Phe Lys Asp Arg Phe Phe Trp Arg Leu His
20 25 30

Pro Gln Gln Val Asp Ala Glu Leu Phe Leu Thr Lys Ser Phe Trp Pro
35 40 45

Glu Leu Pro Asn Arg Ile Asp Ala Ala Tyr Glu His Pro Ala Arg Asp
50 55 60

Leu Ile Phe Ile Phe Arg Gly Lys Lys Phe Trp Ala Pro Asn Gly Tyr
65 70 75 80

Asp Ile Leu Glu Gly Tyr Pro Gln Lys Leu Ser Glu Leu Gly Phe Pro
85 90 95

Arg Glu Val Lys Lys Ile Ser Ala Ala Val His Phe Glu Asp Thr Gly
100 105 110

Lys Thr Leu Phe Phe Ser Gly Asn Gln Val Trp Ser Tyr Asp Asp Thr
115 120 125

Asn His Thr Met Asp Gln Asp Tyr Pro Arg Leu Ile Glu Glu Glu Phe
130 135 140

Pro Gly Ile Gly Gly Lys Val Asp Ala Val Tyr Glu Lys Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Asn Gly Pro Ile Gln Phe Glu Tyr Ser Ile Trp Ser
165 170 175

Lys Arg Ile Val Arg Val Met Pro Thr Asn Ser Leu Leu Trp Cys
180 185 190

<210> 34
<211> 196

<212> PRT
<213> Homo sapiens

<400> 34

Pro Asn Ile Cys Asp Gly Asn Phe Asp Thr Val Ala Met Leu Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Lys Arg Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Gln Val Met Asp Gly Tyr Pro Met Pro Ile Gly Gln Phe Trp Arg Gly
35 40 45

Leu Pro Ala Ser Ile Asn Thr Ala Tyr Glu Arg Lys Asp Gly Lys Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys His Trp Val Phe Asp Glu Ala Ser Leu
65 70 75 80

Glu Pro Gly Tyr Pro Lys His Ile Lys Glu Leu Gly Arg Gly Leu Pro
85 90 95

Thr Asp Lys Ile Asp Ala Ala Leu Phe Trp Met Pro Asn Gly Lys Thr
100 105 110

Tyr Phe Phe Arg Gly Asn Lys Tyr Tyr Arg Phe Asn Glu Glu Leu Arg
115 120 125

Ala Val Asp Ser Glu Tyr Pro Lys Asn Ile Lys Val Trp Glu Gly Ile
130 135 140

Pro Glu Ser Pro Arg Gly Ser Phe Met Gly Ser Asp Glu Val Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Asn Lys Tyr Trp Lys Phe Asn Asn Gln Lys Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Lys Ser Ala Leu Arg Asp Trp Met Gly
180 185 190

Cys Pro Ser Gly
195

<210> 35
<211> 196
<212> PRT
<213> Mus musculus

<400> 35

Pro Asn Ile Cys Asp Gly Asn Phe Asp Thr Val Ala Met Leu Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Glu Arg Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Gln Val Met Asp Gly Tyr Pro Met Pro Ile Gly Gln Phe Trp Arg Gly
35 40 45

Leu Pro Ala Ser Ile Asn Thr Ala Tyr Glu Arg Lys Asp Gly Lys Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys His Trp Val Phe Asp Glu Ala Ser Leu
65 70 75 80

Glu Pro Gly Tyr Pro Lys His Ile Lys Glu Leu Gly Arg Gly Leu Pro
85 90 95

Thr Asp Lys Ile Asp Ala Ala Leu Phe Trp Met Pro Asn Gly Lys Thr

100 105 110

Tyr Phe Phe Arg Gly Asn Lys Tyr Tyr Arg Phe Asn Glu Glu Phe Arg
115 120 125

Ala Val Asp Ser Glu Tyr Pro Lys Asn Ile Lys Val Trp Glu Gly Ile
130 135 140

Pro Glu Ser Pro Arg Gly Ser Phe Met Gly Ser Asp Glu Val Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Asn Lys Tyr Trp Lys Phe Asn Asn Gln Lys Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Lys Ser Ala Leu Arg Asp Trp Met Gly
180 185 190

Cys Pro Ser Gly
195

<210> 36
<211> 196
<212> PRT
<213> Sus scrofa

<400> 36

Pro Asn Ile Cys Asp Gly Asn Phe Asp Thr Val Ala Met Leu Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Glu Arg Trp Phe Trp Arg Val Arg Lys Asn
20 25 30

Gln Val Met Asp Gly Tyr Pro Met Pro Ile Gly Gln Phe Trp Arg Gly
35 40 45

Leu Pro Ala Ser Ile Asn Thr Ala Tyr Glu Arg Lys Asp Gly Lys Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys His Trp Val Phe Asp Glu Ala Ser Leu
65 70 75 80

Glu Pro Gly Tyr Pro Lys His Ile Lys Glu Leu Gly Arg Arg Leu Pro
85 90 95

Thr Asp Lys Ile Asp Ala Ala Leu Phe Trp Met Pro Asn Gly Lys Asp
100 105 110

Tyr Phe Phe Arg Gly Asn Lys Tyr Tyr Arg Phe Asn Glu Glu Leu Arg
115 120 125

Ala Val Asp Ser Glu Tyr Pro Lys Asn Ile Lys Val Trp Glu Gly Ile
130 135 140

Pro Glu Ser Pro Arg Gly Ser Phe Met Gly Ser Asp Glu Val Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Asn Lys Tyr Trp Lys Phe Asn Asn Gln Lys Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Lys Ser Ala Leu Arg Asp Trp Met Gly
180 185 190

Cys Pro Ser Gly
195

<210> 37
<211> 196
<212> PRT
<213> Oryctolagus cuniculus

<400> 37

Pro Lys Ile Cys Asp Gly Asn Phe Asp Thr Val Ala Val Phe Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Glu Arg Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Gln Val Met Asp Gly Tyr Pro Met Pro Ile Gly Gln Leu Trp Arg Gly
35 40 45

Leu Pro Ala Ser Ile Asn Thr Ala Tyr Glu Arg Lys Asp Gly Lys Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys His Trp Val Phe Asp Glu Ala Ser Leu
65 70 75 80

Glu Pro Gly Tyr Pro Lys His Ile Lys Glu Leu Gly Arg Gly Leu Pro

85 90 95

Thr Asp Lys Ile Asp Ala Ala Leu Phe Trp Met Pro Asn Gly Lys Thr
100 105 110

Tyr Phe Phe Arg Gly Asn Lys Tyr Tyr Arg Phe Asn Glu Glu Leu Arg
115 120 125

Ala Val Asp Ser Glu Tyr Pro Lys Asn Ile Lys Val Trp Glu Gly Ile
130 135 140

Pro Glu Ser Pro Arg Gly Ser Phe Met Gly Ser Asp Glu Val Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Asn Lys Tyr Trp Lys Phe Asn Asn Gln Lys Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Lys Ser Ala Leu Arg Asp Trp Met Gly
180 185 190

Cys Pro Ala Gly
195

<210> 38
<211> 196
<212> PRT
<213> Rattus norvegicus

<400> 38

Pro Asn Ile Cys Asp Gly Asn Phe Asp Thr Val Ala Met Leu Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Glu Arg Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Gln Val Met Asp Gly Tyr Pro Met Pro Ile Gly Gln Phe Trp Arg Gly
35 40 45

Leu Pro Ala Ser Ile Asn Thr Ala Tyr Glu Arg Lys Asp Gly Lys Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys His Trp Val Phe Asp Glu Ala Ser Leu

65 70 75 80

Glu Pro Gly Tyr Pro Lys His Ile Lys Glu Leu Gly Arg Gly Leu Pro
85 90 95

Thr Asp Lys Ile Asp Ala Ala Leu Phe Trp Met Pro Asn Gly Lys Thr
100 105 110

Tyr Phe Phe Arg Gly Asn Lys Tyr Tyr Arg Phe Asn Glu Glu Phe Arg
115 120 125

Ala Val Asp Ser Glu Tyr Pro Lys Asn Ile Lys Val Trp Glu Gly Ile
130 135 140

Pro Glu Ser Pro Arg Gly Ser Phe Met Gly Ser Asp Glu Val Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Asn Lys Tyr Trp Lys Phe Asn Asn Gln Lys Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Lys Ser Ala Leu Arg Asp Trp Met Gly
180 185 190

Cys Pro Ser Gly
195

<210> 39
<211> 196
<212> PRT
<213> Homo sapiens

<400> 39

Pro Asn Ile Cys Asp Gly Asp Phe Asp Thr Val Ala Met Leu Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Gly Arg Trp Phe Trp Arg Val Arg His Asn
20 25 30

Arg Val Leu Asp Asn Tyr Pro Met Pro Ile Gly His Phe Trp Arg Gly
35 40 45

Leu Pro Gly Asp Ile Ser Ala Ala Tyr Glu Arg Gln Asp Gly Arg Phe
50 55 60

Val Phe Phe Lys Gly Asp Arg Tyr Trp Leu Phe Arg Glu Ala Asn Leu
65 70 75 80

Glu Pro Gly Tyr Pro Gln Pro Leu Thr Ser Tyr Gly Leu Gly Ile Pro
85 90 95

Tyr Asp Arg Ile Asp Thr Ala Ile Trp Trp Glu Pro Thr Gly His Thr
100 105 110

Phe Phe Phe Gln Glu Asp Arg Tyr Trp Arg Phe Asn Glu Glu Thr Gln
115 120 125

Arg Gly Asp Pro Gly Tyr Pro Lys Pro Ile Ser Val Trp Gln Gly Ile
130 135 140

Pro Ala Ser Pro Lys Gly Ala Phe Leu Ser Asn Asp Ala Ala Tyr Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Thr Lys Tyr Trp Lys Phe Asp Asn Glu Arg Leu
165 170 175

Arg Met Glu Pro Gly Tyr Pro Lys Ser Ile Leu Arg Asp Phe Met Gly
180 185 190

Cys Gln Glu His
195

<210> 40
<211> 196
<212> PRT
<213> Mus musculus

<400> 40

Pro Asn Ile Cys Asp Gly Asn Phe Asp Thr Val Ala Val Leu Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Gly Arg Trp Phe Trp Arg Val Arg His Asn
20 25 30

Arg Val Leu Asp Asn Tyr Pro Met Pro Ile Gly His Phe Trp Arg Gly
35 40 45

Leu Pro Gly Asn Ile Ser Ala Ala Tyr Glu Arg Gln Asp Gly His Phe
50 55 60

Val Phe Phe Lys Gly Asn Arg Tyr Trp Leu Phe Arg Glu Ala Asn Leu
65 70 75 80

Glu Pro Gly Tyr Pro Gln Pro Leu Ser Ser Tyr Gly Thr Asp Ile Pro
85 90 95

Tyr Asp Arg Ile Asp Thr Ala Ile Trp Trp Glu Pro Thr Gly His Thr
100 105 110

Phe Phe Phe Gln Ala Asp Arg Tyr Trp Arg Phe Asn Glu Glu Thr Gln
115 120 125

His Gly Asp Pro Gly Tyr Pro Lys Pro Ile Ser Val Trp Gln Gly Ile
130 135 140

Pro Thr Ser Pro Lys Gly Ala Phe Leu Ser Asn Asp Ala Ala Tyr Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Thr Lys Tyr Trp Lys Phe Asn Asn Glu Arg Leu
165 170 175

Arg Met Glu Pro Gly His Pro Lys Ser Ile Leu Arg Asp Phe Met Gly
180 185 190

Cys Gln Glu His
195

<210> 41
<211> 196
<212> PRT
<213> Homo sapiens

<400> 41

Pro Asn Ile Cys Asp Gly Asn Phe Asn Thr Leu Ala Ile Leu Arg Arg
1 5 10 15

Glu Met Phe Val Phe Lys Asp Gln Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Arg Val Met Asp Gly Tyr Pro Met Gln Ile Thr Tyr Phe Trp Arg Gly

35 40 45

Leu Pro Pro Ser Ile Asp Ala Val Tyr Glu Asn Ser Asp Gly Asn Phe
50 55 60

Val Phe Phe Lys Gly Asn Lys Tyr Trp Val Phe Lys Asp Thr Thr Leu
65 70 75 80

Gln Pro Gly Tyr Pro His Asp Leu Ile Thr Leu Gly Ser Gly Ile Pro
85 90 95

Pro His Gly Ile Asp Ser Ala Ile Trp Trp Glu Asp Val Gly Lys Thr
100 105 110

Tyr Phe Phe Lys Gly Asp Arg Tyr Trp Arg Tyr Ser Glu Glu Met Lys
115 120 125

Thr Met Asp Pro Gly Tyr Pro Lys Pro Ile Thr Val Trp Lys Gly Ile
130 135 140

Pro Glu Ser Pro Gln Gly Ala Phe Val His Lys Glu Asn Gly Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Lys Glu Tyr Trp Lys Phe Asn Asn Gln Ile Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Arg Ser Ile Leu Lys Asp Phe Met Gly
180 185 190

Cys Asp Gly Pro
195

<210> 42
<211> 196
<212> PRT
<213> Mus musculus

<400> 42

Pro Asn Ile Cys Asp Gly Asn Phe Asn Thr Leu Ala Ile Leu Arg Arg
1 5 10 15

Glu Met Phe Val Phe Lys Asp Gln Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Arg Val Met Asp Gly Tyr Pro Met Gln Ile Thr Tyr Phe Trp Arg Gly
35 40 45

Leu Pro Pro Ser Ile Asp Ala Val Tyr Glu Asn Ser Asp Gly Asn Phe
50 55 60

Val Phe Phe Lys Gly Asn Lys Tyr Trp Val Phe Lys Asp Thr Thr Leu
65 70 75 80

Gln Pro Gly Tyr Pro His Asp Leu Ile Thr Leu Gly Asn Gly Ile Pro
85 90 95

Pro His Gly Ile Asp Ser Ala Ile Trp Trp Glu Asp Val Gly Lys Thr
100 105 110

Tyr Phe Phe Lys Gly Asp Arg Tyr Trp Arg Tyr Ser Glu Glu Met Lys
115 120 125

Thr Met Asp Pro Gly Tyr Pro Lys Pro Ile Thr Ile Trp Lys Gly Ile
130 135 140

Pro Glu Ser Pro Gln Gly Ala Phe Val His Lys Glu Asn Gly Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Lys Glu Tyr Trp Lys Phe Asn Asn Gln Ile Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Arg Ser Ile Leu Lys Asp Phe Met Gly
180 185 190

Cys Asp Gly Pro
195

<210> 43
<211> 196
<212> PRT
<213> Rattus norvegicus

<400> 43

Pro Asn Ile Cys Asp Gly Asn Phe Asn Thr Leu Ala Ile Leu Arg Arg
1 5 10 15

Glu Met Phe Val Phe Lys Asp Gln Trp Phe Trp Arg Val Arg Asn Asn
20 25 30

Arg Val Met Asp Gly Tyr Pro Met Gln Ile Thr Tyr Phe Trp Arg Gly
35 40 45

Leu Pro Pro Ser Ile Asp Ala Val Tyr Glu Asn Ser Asp Gly Asn Phe
50 55 60

Val Phe Phe Lys Gly Asn Lys Tyr Trp Val Phe Lys Asp Thr Thr Leu
65 70 75 80

Gln Pro Gly Tyr Pro His Asp Leu Ile Thr Leu Gly Asn Gly Ile Pro
85 90 95

Pro His Gly Ile Asp Ser Ala Ile Trp Trp Glu Asp Val Gly Lys Thr
100 105 110

Tyr Phe Phe Lys Gly Asp Arg Tyr Trp Arg Tyr Ser Glu Glu Met Lys
115 120 125

Thr Met Asp Pro Gly Tyr Pro Lys Pro Ile Thr Ile Trp Lys Gly Ile
130 135 140

Pro Glu Ser Pro Gln Gly Ala Phe Val His Lys Glu Asn Gly Phe Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Lys Glu Tyr Trp Lys Phe Asn Asn Gln Ile Leu
165 170 175

Lys Val Glu Pro Gly Tyr Pro Arg Ser Ile Leu Lys Asp Phe Met Gly
180 185 190

Cys Asp Gly Pro
195

<210> 44
<211> 198
<212> PRT
<213> Homo sapiens

<400> 44

Pro His Arg Cys Ser Thr His Phe Asp Ala Val Ala Gln Ile Arg Gly
1 5 10 15

Glu Ala Phe Phe Phe Lys Gly Lys Tyr Phe Trp Arg Leu Thr Arg Asp
20 25 30

Arg His Leu Val Ser Leu Gln Pro Ala Gln Met His Arg Phe Trp Arg
35 40 45

Gly Leu Pro Leu His Leu Asp Ser Val Asp Ala Val Tyr Glu Arg Thr
50 55 60

Ser Asp His Lys Ile Val Phe Phe Lys Gly Asp Arg Tyr Trp Val Phe
65 70 75 80

Lys Asp Asn Asn Val Glu Glu Gly Tyr Pro Arg Pro Val Ser Asp Phe
85 90 95

Ser Leu Pro Pro Gly Gly Ile Asp Ala Ala Phe Ser Trp Ala His Asn
100 105 110

Asp Arg Thr Tyr Phe Phe Lys Asp Gln Leu Tyr Trp Arg Tyr Asp Asp
115 120 125

His Thr Arg His Met Asp Pro Gly Tyr Pro Ala Gln Ser Pro Leu Trp
130 135 140

Arg Gly Val Pro Ser Thr Leu Asp Asp Ala Met Arg Trp Ser Asp Gly
145 150 155 160

Ala Ser Tyr Phe Phe Arg Gly Gln Glu Tyr Trp Lys Val Leu Asp Gly
165 170 175

Glu Leu Glu Val Ala Pro Gly Tyr Pro Gln Ser Thr Ala Arg Asp Trp
180 185 190

Leu Val Cys Gly Asp Ser
195

<210> 45
<211> 198
<212> PRT
<213> Mus musculus

<400> 45

Pro His Arg Cys Thr Ala His Phe Asp Ala Val Ala Gln Ile Arg Gly
1 5 10 15

Glu Ala Phe Phe Phe Lys Gly Lys Tyr Phe Trp Arg Leu Thr Arg Asp
20 25 30

Arg His Leu Val Ser Leu Gln Pro Ala Gln Met His Arg Phe Trp Arg
35 40 45

Gly Leu Pro Leu His Leu Asp Ser Val Asp Ala Val Tyr Glu Arg Thr
50 55 60

Ser Asp His Lys Ile Val Phe Phe Lys Gly Asp Arg Tyr Trp Val Phe
65 70 75 80

Lys Asp Asn Asn Val Glu Glu Gly Tyr Pro Arg Pro Val Ser Asp Phe
85 90 95

Ser Leu Pro Pro Gly Gly Ile Asp Ala Val Phe Ser Trp Ala His Asn
100 105 110

Asp Arg Thr Tyr Phe Phe Lys Asp Gln Leu Tyr Trp Arg Tyr Asp Asp
115 120 125

His Thr Arg Arg Met Asp Pro Gly Tyr Pro Ala Gln Gly Pro Leu Trp
130 135 140

Arg Gly Val Pro Ser Met Leu Asp Asp Ala Met Arg Trp Ser Asp Gly
145 150 155 160

Ala Ser Tyr Phe Phe Arg Gly Gln Glu Tyr Trp Lys Val Leu Asp Gly
165 170 175

Glu Leu Glu Ala Ala Pro Gly Tyr Pro Gln Ser Thr Ala Arg Asp Trp
180 185 190

Leu Val Cys Gly Glu Pro
195

<210> 46
<211> 191
<212> PRT
<213> Xenopus laevis

<400> 46

Pro Ser Arg Cys Asp Pro Asn Val Val Phe Asn Ala Val Thr Thr Met
1 5 10 15

Arg Gly Glu Leu Ile Phe Phe Val Lys Arg Phe Leu Trp Arg Lys His
20 25 30

Pro Gln Ala Ser Glu Ala Glu Leu Met Phe Val Gln Ala Phe Trp Pro
35 40 45

Ser Leu Pro Thr Asn Ile Asp Ala Ala Tyr Glu Asn Pro Ile Thr Glu
50 55 60

Gln Ile Leu Val Phe Lys Gly Ser Lys Tyr Thr Ala Leu Asp Gly Phe
65 70 75 80

Asp Val Val Gln Gly Tyr Pro Arg Asn Ile Tyr Ser Leu Gly Phe Pro
85 90 95

Lys Thr Val Lys Arg Ile Asp Ala Ala Val His Ile Glu Gln Leu Gly
100 105 110

Lys Thr Tyr Phe Phe Ala Ala Lys Lys Tyr Trp Ser Tyr Asp Glu Asp
115 120 125

Lys Lys Gln Met Asp Lys Gly Phe Pro Lys Gln Ile Ser Asn Asp Phe
130 135 140

Pro Gly Ile Pro Asp Lys Ile Asp Ala Ala Phe Tyr Tyr Arg Gly Arg
145 150 155 160

Leu Tyr Phe Phe Ile Gly Arg Ser Gln Phe Glu Tyr Asn Ile Asn Ser
165 170 175

Lys Arg Ile Val Gln Val Leu Arg Ser Asn Ser Trp Leu Gly Cys
180 185 190

<210> 47
<211> 190
<212> PRT
<213> Homo sapiens

<400> 47

Pro Asp Pro Cys Ser Ser Glu Leu Asp Ala Met Met Leu Gly Pro Arg
1 5 10 15

Gly Lys Thr Tyr Ala Phe Lys Gly Asp Tyr Val Trp Thr Val Ser Asp
20 25 30

Ser Gly Pro Gly Pro Leu Phe Arg Val Ser Ala Leu Trp Glu Gly Leu
35 40 45

Pro Gly Asn Leu Asp Ala Ala Val Tyr Ser Pro Arg Thr Gln Trp Ile
50 55 60

His Phe Phe Lys Gly Asp Lys Val Trp Arg Tyr Ile Asn Phe Lys Met
65 70 75 80

Ser Pro Gly Phe Pro Lys Lys Leu Asn Arg Val Glu Pro Asn Leu Asp
85 90 95

Ala Ala Leu Tyr Trp Pro Leu Asn Gln Lys Val Phe Leu Phe Lys Gly
100 105 110

Ser Gly Tyr Trp Gln Trp Asp Glu Leu Ala Arg Thr Asp Phe Ser Ser
115 120 125

Tyr Pro Lys Pro Ile Lys Gly Leu Phe Thr Gly Val Pro Asn Gln Pro
130 135 140

Ser Ala Ala Met Ser Trp Gln Asp Gly Arg Val Tyr Phe Phe Lys Gly
145 150 155 160

Lys Val Tyr Trp Arg Leu Asn Gln Gln Leu Arg Val Glu Lys Gly Tyr
165 170 175

Pro Arg Asn Ile Ser His Asn Trp Met His Cys Arg Pro Arg
180 185 190

<210> 48
<211> 189
<212> PRT
<213> Mus musculus

<400> 48

Pro Asn Pro Cys Ser Gly Glu Val Asp Ala Met Val Leu Gly Pro Arg

1 5 10 15

Gly Lys Thr Tyr Ala Phe Lys Gly Asp Tyr Val Trp Thr Val Thr Asp
20 25 30

Ser Gly Pro Gly Pro Leu Phe Gln Ile Ser Ala Leu Trp Glu Gly Leu
35 40 45

Pro Gly Asn Leu Asp Ala Ala Val Tyr Ser Pro Arg Thr Arg Arg Thr
50 55 60

His Phe Phe Lys Gly Asn Lys Val Trp Arg Tyr Val Asp Phe Lys Met
65 70 75 80

Ser Pro Gly Phe Pro Met Lys Phe Asn Arg Val Glu Pro Asn Leu Asp
85 90 95

Ala Ala Leu Tyr Trp Pro Val Asn Gln Lys Val Phe Leu Phe Lys Gly
100 105 110

Ser Gly Tyr Trp Gln Trp Asp Glu Leu Ala Arg Thr Asp Leu Ser Arg
115 120 125

Tyr Pro Lys Pro Ile Lys Glu Leu Phe Thr Gly Val Pro Asp Arg Pro
130 135 140

Ser Ala Ala Met Ser Trp Gln Asp Gly Gln Val Tyr Phe Phe Lys Gly
145 150 155 160

Lys Glu Tyr Trp Arg Leu Asn Gln Gln Leu Arg Val Ala Lys Gly Tyr
165 170 175

Pro Arg Asn Thr Thr His Trp Met His Cys Gly Ser Gln
180 185

<210> 49
<211> 191
<212> PRT
<213> Bos taurus

<400> 49

Pro Asp Leu Cys Asp Ser Asn Leu Ser Phe Asp Ala Val Thr Met Leu
1 5 10 15

Gly Lys Glu Leu Leu Leu Phe Arg Asp Arg Ile Phe Trp Arg Arg Gln
20 25 30

Val His Leu Met Ser Gly Ile Arg Pro Ser Thr Ile Thr Ser Ser Phe
35 40 45

Pro Gln Leu Met Ser Asn Val Asp Ala Ala Tyr Glu Val Ala Glu Arg
50 55 60

Gly Thr Ala Tyr Phe Phe Lys Gly Pro His Tyr Trp Ile Thr Arg Gly
65 70 75 80

Phe Gln Met Gln Gly Pro Pro Arg Thr Ile Tyr Asp Phe Gly Phe Pro
85 90 95

Arg Tyr Val Gln Arg Ile Asp Ala Ala Val Tyr Leu Lys Asp Ala Gln
100 105 110

Lys Thr Leu Phe Phe Val Gly Asp Glu Tyr Tyr Ser Tyr Asp Glu Arg
115 120 125

Lys Arg Lys Met Glu Lys Asp Tyr Pro Lys Ser Thr Glu Glu Glu Phe
130 135 140

Ser Gly Val Asn Gly Gln Ile Asp Ala Ala Val Glu Leu Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Ser Gly Pro Lys Ala Tyr Lys Ser Asp Thr Glu Lys
165 170 175

Glu Asp Val Val Ser Glu Leu Lys Ser Ser Ser Trp Ile Gly Cys
180 185 190

<210> 50
<211> 191
<212> PRT
<213> Homo sapiens

<400> 50

Pro Asp Leu Cys Asp Ser Ser Ser Ser Phe Asp Ala Val Thr Met Leu
1 5 10 15

Gly Lys Glu Leu Leu Leu Phe Lys Asp Arg Ile Phe Trp Arg Arg Gln

20 25 30

Val His Leu Arg Thr Gly Ile Arg Pro Ser Thr Ile Thr Ser Ser Phe
35 40 45

Pro Gln Leu Met Ser Asn Val Asp Ala Ala Tyr Glu Val Ala Glu Arg
50 55 60

Gly Thr Ala Tyr Phe Phe Lys Gly Pro His Tyr Trp Ile Thr Arg Gly
65 70 75 80

Phe Gln Met Gln Gly Pro Pro Arg Thr Ile Tyr Asp Phe Gly Phe Pro
85 90 95

Arg His Val Gln Gln Ile Asp Ala Ala Val Tyr Leu Arg Glu Pro Gln
100 105 110

Lys Thr Leu Phe Phe Val Gly Asp Glu Tyr Tyr Ser Tyr Asp Glu Arg
115 120 125

Lys Arg Lys Met Glu Lys Asp Tyr Pro Lys Asn Thr Glu Glu Glu Phe
130 135 140

Ser Gly Val Asn Gly Gln Ile Asp Ala Ala Val Glu Leu Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Ser Gly Pro Lys Thr Tyr Lys Tyr Asp Thr Glu Lys
165 170 175

Glu Asp Val Val Ser Val Val Lys Ser Ser Ser Trp Ile Gly Cys
180 185 190

<210> 51
<211> 191
<212> PRT
<213> Mus musculus

<400> 51

Pro Asp Leu Cys Asp Ser Ser Ser Ser Phe Asp Ala Val Thr Met Leu
1 5 10 15

Gly Lys Glu Leu Leu Phe Phe Lys Asp Arg Ile Phe Trp Arg Arg Gln
20 25 30

Val His Leu Pro Thr Gly Ile Arg Pro Ser Thr Ile Thr Ser Ser Phe
35 40 45

Pro Gln Leu Met Ser Asn Val Asp Ala Ala Tyr Glu Val Ala Glu Arg
50 55 60

Gly Ile Ala Phe Phe Phe Lys Gly Pro His Tyr Trp Val Thr Arg Gly
65 70 75 80

Phe His Met Gln Gly Pro Pro Arg Thr Ile Tyr Asp Phe Gly Phe Pro
85 90 95

Arg His Val Gln Arg Ile Asp Ala Ala Val Tyr Leu Lys Glu Pro Gln
100 105 110

Lys Thr Leu Phe Phe Val Gly Glu Glu Tyr Tyr Ser Tyr Asp Glu Arg
115 120 125

Lys Lys Lys Met Glu Lys Asp Tyr Pro Lys Asn Thr Glu Glu Glu Phe
130 135 140

Ser Gly Val Ser Gly His Ile Asp Ala Ala Val Glu Leu Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Ser Gly Arg Lys Thr Phe Lys Tyr Asp Thr Glu Lys
165 170 175

Glu Asp Val Val Ser Val Val Lys Ser Ser Ser Trp Ile Gly Cys
180 185 190

<210> 52
<211> 191
<212> PRT
<213> Sus scrofa

<400> 52

Pro Asp Ile Cys Asp Ser Ser Ser Ser Phe Asp Ala Val Thr Met Leu
1 5 10 15

Gly Lys Glu Leu Leu Phe Phe Arg Asp Arg Ile Phe Trp Arg Arg Gln
20 25 30

Val His Leu Met Ser Gly Ile Arg Pro Ser Thr Ile Thr Ser Ser Phe

35 40 45

Pro Gln Leu Met Ser Asn Val Asp Ala Ala Tyr Glu Val Ala Asp Arg
50 55 60

Gly Met Ala Tyr Phe Phe Lys Gly Pro His Tyr Trp Ile Thr Arg Gly
65 70 75 80

Phe Gln Met Gln Gly Pro Pro Arg Thr Ile Tyr Asp Phe Gly Phe Pro
85 90 95

Arg Tyr Val Gln Arg Ile Asp Ala Ala Val His Leu Lys Asp Thr Gln
100 105 110

Lys Thr Leu Phe Phe Val Gly Asp Glu Tyr Tyr Ser Tyr Asp Glu Arg
115 120 125

Lys Arg Lys Met Asp Lys Asp Tyr Pro Lys Asn Thr Glu Glu Glu Phe
130 135 140

Ser Gly Val Asn Gly Gln Ile Asp Ala Ala Val Glu Leu Asn Gly Tyr
145 150 155 160

Ile Tyr Phe Phe Ser Gly Pro Lys Ala Tyr Lys Tyr Asp Thr Glu Lys
165 170 175

Glu Asp Val Val Ser Val Leu Lys Ser Asn Ser Trp Ile Gly Cys
180 185 190

<210> 53
<211> 196
<212> PRT
<213> Homo sapiens

<400> 53

Pro Asn Ile Cys Asp Gly Asn Phe Asn Thr Val Ala Leu Phe Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Asp Arg Trp Phe Trp Arg Leu Arg Asn Asn
20 25 30

Arg Val Gln Glu Gly Tyr Pro Met Gln Ile Glu Gln Phe Trp Lys Gly
35 40 45

Leu Pro Ala Arg Ile Asp Ala Ala Tyr Glu Arg Ala Asp Gly Arg Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys Tyr Trp Val Phe Lys Glu Val Thr Val
65 70 75 80

Glu Pro Gly Tyr Pro His Ser Leu Gly Glu Leu Gly Ser Cys Leu Pro
85 90 95

Arg Glu Gly Ile Asp Thr Ala Leu Arg Trp Glu Pro Val Gly Lys Thr
100 105 110

Tyr Phe Phe Lys Gly Glu Arg Tyr Trp Arg Tyr Ser Glu Glu Arg Arg
115 120 125

Ala Thr Asp Pro Gly Tyr Pro Lys Pro Ile Thr Val Trp Lys Gly Ile
130 135 140

Pro Gln Ala Pro Gln Gly Ala Phe Ile Ser Lys Glu Gly Tyr Tyr Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Arg Asp Tyr Trp Lys Phe Asp Asn Gln Lys Leu
165 170 175

Ser Val Glu Pro Gly Tyr Pro Arg Asn Ile Leu Arg Asp Trp Met Gly
180 185 190

Cys Asn Gln Lys
195

<210> 54
<211> 196
<212> PRT
<213> Mus musculus

<400> 54

Pro Asn Ile Cys Asp Gly Asn Phe Asn Thr Val Ala Leu Phe Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Asp Arg Trp Phe Trp Arg Leu Arg Asn Asn
20 25 30

Arg Val Gln Glu Gly Tyr Pro Met Gln Ile Glu Gln Phe Trp Lys Gly

35 40 45

Leu Pro Ala Arg Ile Asp Ala Ala Tyr Glu Arg Ala Asp Gly Arg Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys Tyr Trp Val Phe Lys Glu Val Thr Val
65 70 75 80

Glu Pro Gly Tyr Pro His Ser Leu Gly Glu Leu Gly Ser Cys Leu Pro
85 90 95

Arg Glu Gly Ile Asp Thr Ala Leu Arg Trp Glu Pro Val Gly Lys Thr
100 105 110

Tyr Phe Phe Lys Gly Glu Arg Tyr Trp Arg Tyr Ser Glu Glu Arg Arg
115 120 125

Ala Thr Asp Pro Gly Tyr Pro Lys Pro Ile Thr Val Trp Lys Gly Ile
130 135 140

Pro Gln Ala Pro Gln Gly Ala Phe Ile Ser Lys Glu Gly Tyr Tyr Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Arg Asp Tyr Trp Lys Phe Asp Asn Gln Lys Leu
165 170 175

Ser Val Glu Pro Gly Tyr Pro Arg Asn Ile Leu Arg Asp Trp Met Gly
180 185 190

Cys Lys Gln Lys
195

<210> 55
<211> 196
<212> PRT
<213> Rattus norvegicus

<400> 55

Pro Asn Ile Cys Asp Gly Asn Phe Asn Thr Val Ala Leu Phe Arg Gly
1 5 10 15

Glu Met Phe Val Phe Lys Asp Arg Trp Phe Trp Arg Leu Arg Asn Asn
20 25 30

Arg Val Gln Glu Gly Tyr Pro Met Gln Ile Glu Gln Phe Trp Lys Gly
35 40 45

Leu Pro Ala Arg Ile Asp Ala Ala Tyr Glu Arg Ala Asp Gly Arg Phe
50 55 60

Val Phe Phe Lys Gly Asp Lys Tyr Trp Val Phe Lys Glu Val Thr Val
65 70 75 80

Glu Pro Gly Tyr Pro His Ser Leu Gly Glu Leu Gly Ser Cys Leu Pro
85 90 95

Arg Glu Gly Ile Asp Thr Ala Leu Arg Trp Glu Pro Val Gly Lys Thr
100 105 110

Tyr Phe Phe Lys Gly Glu Arg Tyr Trp Arg Tyr Ser Glu Glu Arg Arg
115 120 125

Ala Thr Asp Pro Gly Tyr Pro Lys Pro Ile Thr Val Trp Lys Gly Ile
130 135 140

Pro Gln Ala Pro Gln Gly Ala Phe Ile Ser Lys Glu Gly Tyr Tyr Thr
145 150 155 160

Tyr Phe Tyr Lys Gly Arg Asp Tyr Trp Lys Phe Asp Asn Gln Lys Leu
165 170 175

Ser Val Glu Pro Gly Tyr Pro Arg Asn Ile Leu Arg Asp Trp Met Gly
180 185 190

Cys Lys Gln Lys
195

<210> 56
<211> 198
<212> PRT
<213> Homo sapiens

<400> 56

Pro Asp Arg Cys Glu Gly Asn Phe Asp Ala Ile Ala Asn Ile Arg Gly
1 5 10 15

Glu Thr Phe Phe Phe Lys Gly Pro Trp Phe Trp Arg Leu Gln Pro Ser

20 25 30

Gly Gln Leu Val Ser Pro Arg Pro Ala Arg Leu His Arg Phe Trp Glu
35 40 45

Gly Leu Pro Ala Gln Val Arg Val Val Gln Ala Ala Tyr Ala Arg His
50 55 60

Arg Asp Gly Arg Ile Leu Leu Phe Ser Gly Pro Gln Phe Trp Val Phe
65 70 75 80

Gln Asp Arg Gln Leu Glu Gly Gly Ala Arg Pro Leu Thr Glu Leu Gly
85 90 95

Leu Pro Pro Gly Glu Glu Val Asp Ala Val Phe Ser Trp Pro Gln Asn
100 105 110

Gly Lys Thr Tyr Leu Val Arg Gly Arg Gln Tyr Trp Arg Tyr Asp Glu
115 120 125

Ala Ala Ala Arg Pro Asp Pro Gly Tyr Pro Arg Asp Leu Ser Leu Trp
130 135 140

Glu Gly Ala Pro Pro Ser Pro Asp Asp Val Thr Val Ser Asn Ala Gly
145 150 155 160

Asp Thr Tyr Phe Phe Lys Gly Ala His Tyr Trp Arg Phe Pro Lys Asn
165 170 175

Ser Ile Lys Thr Glu Pro Asp Ala Pro Gln Pro Met Gly Pro Asn Trp
180 185 190

Leu Asp Cys Pro Ala Pro
195

<210> 57
<211> 193
<212> PRT
<213> Homo sapiens

<400> 57

Phe Asp Ala Ile Thr Val Asp Arg Gln Gln Gln Leu Tyr Ile Phe Lys
1 5 10 15

Gly Ser His Phe Trp Glu Val Ala Ala Asp Gly Asn Val Ser Glu Pro
20 25 30

Arg Pro Leu Gln Glu Arg Trp Val Gly Leu Pro Pro Asn Ile Glu Ala
35 40 45

Ala Ala Val Ser Leu Asn Asp Gly Asp Phe Tyr Phe Phe Lys Gly Gly
50 55 60

Arg Cys Trp Arg Phe Arg Gly Pro Lys Pro Val Trp Gly Leu Pro Gln
65 70 75 80

Leu Cys Arg Ala Gly Gly Leu Pro Arg His Pro Asp Ala Ala Leu Phe
85 90 95

Phe Pro Pro Leu Arg Arg Leu Ile Leu Phe Lys Gly Ala Arg Tyr Tyr
100 105 110

Val Leu Ala Arg Gly Gly Leu Gln Val Glu Pro Tyr Tyr Pro Arg Ser
115 120 125

Leu Gln Asp Trp Gly Gly Ile Pro Glu Glu Val Ser Gly Ala Leu Pro
130 135 140

Arg Pro Asp Gly Ser Ile Ile Phe Phe Arg Asp Asp Arg Tyr Trp Arg
145 150 155 160

Leu Asp Gln Ala Lys Leu Gln Ala Thr Thr Ser Gly Arg Trp Ala Thr
165 170 175

Glu Leu Pro Trp Met Gly Cys Trp His Ala Asn Ser Gly Ser Ala Leu
180 185 190

Phe

<210> 58
<211> 191
<212> PRT
<213> Homo sapiens

<400> 58

Pro Ser Gln Glu Glu Cys Glu Gly Ser Ser Leu Ser Ala Val Phe Glu

1 5 10 15

His Phe Ala Met Met Gln Arg Asp Ser Trp Glu Asp Ile Phe Glu Leu
20 25 30

Leu Phe Trp Gly Arg Thr Ser Ala Gly Thr Arg Gln Pro Gln Phe Ile
35 40 45

Ser Arg Asp Trp His Gly Val Pro Gly Gln Val Asp Ala Ala Met Ala
50 55 60

Gly Arg Ile Tyr Ile Ser Gly Met Ala Pro Arg Pro Ser Leu Ala Lys
65 70 75 80

Lys Gln Arg Phe Arg His Arg Asn Arg Lys Gly Tyr Arg Ser Gln Arg
85 90 95

Gly His Ser Arg Gly Arg Asn Gln Asn Ser Arg Arg Pro Ser Arg Ala
100 105 110

Thr Trp Leu Ser Leu Phe Ser Ser Glu Glu Ser Asn Leu Gly Ala Asn
115 120 125

Asn Tyr Asp Asp Tyr Arg Met Asp Trp Leu Val Pro Ala Thr Cys Glu
130 135 140

Pro Ile Gln Ser Val Phe Phe Phe Ser Gly Asp Lys Tyr Tyr Arg Val
145 150 155 160

Asn Leu Arg Thr Arg Arg Val Asp Thr Val Asp Pro Pro Tyr Pro Arg
165 170 175

Ser Ile Ala Gln Tyr Trp Leu Gly Cys Pro Ala Pro Gly His Leu
180 185 190

<210> 59
<211> 192
<212> PRT
<213> Mus musculus

<400> 59

Pro Ser Gln Glu Glu Cys Glu Gly Ser Ser Leu Ser Ala Val Phe Glu
1 5 10 15

His Phe Ala Leu Leu Gln Arg Asp Ser Trp Glu Asn Ile Phe Glu Leu
20 25 30

Leu Phe Trp Gly Arg Ser Ser Asp Gly Ala Arg Glu Pro Gln Phe Ile
35 40 45

Ser Arg Asn Trp His Gly Val Pro Gly Lys Val Asp Ala Ala Met Ala
50 55 60

Gly Arg Ile Tyr Val Thr Gly Ser Leu Ser His Ser Ala Gln Ala Lys
65 70 75 80

Lys Gln Lys Ser Lys Arg Arg Ser Arg Lys Arg Tyr Arg Ser Arg Arg
85 90 95

Gly Arg Gly His Arg Arg Ser Gln Ser Ser Asn Ser Arg Arg Ser Ser
100 105 110

Arg Ser Ile Trp Phe Ser Leu Phe Ser Ser Glu Glu Ser Gly Leu Gly
115 120 125

Thr Tyr Asn Asn Tyr Asp Tyr Asp Met Asp Trp Leu Val Pro Ala Thr
130 135 140

Cys Glu Pro Ile Gln Ser Val Tyr Phe Phe Ser Gly Asp Lys Tyr Tyr
145 150 155 160

Arg Val Asn Leu Arg Thr Arg Arg Val Asp Ser Val Asn Pro Pro Tyr
165 170 175

Pro Arg Ser Ile Ala Gln Tyr Trp Leu Gly Cys Pro Thr Ser Glu Lys
180 185 190

<210> 60
<211> 195
<212> PRT
<213> Sus scrofa

<400> 60

Pro Ser Arg Glu Glu Cys Glu Gly Ser Ser Pro Ser Asp Val Phe Ala
1 5 10 15

His Phe Ala Leu Met Gln Arg Asp Ser Trp Glu Asp Ile Phe Arg Leu
20 25 30

Leu Phe Trp Ser His Ser Phe Gly Gly Ala Ile Glu Pro Arg Val Ile
35 40 45

Ser Gln Asp Trp Leu Gly Leu Pro Glu Gln Val Asp Ala Ala Met Ala
50 55 60

Gly Gln Ile Tyr Ile Ser Gly Ser Ala Leu Lys Pro Ser Gln Pro Lys
65 70 75 80

Met Thr Lys Ser Ala Arg Arg Ser Gly Lys Arg Tyr Arg Ser Arg Arg
85 90 95

Gly Arg Gly Arg Gly Arg Gly His Ser Arg Ser Gln Lys Ser His Arg
100 105 110

Gln Ser Arg Ser Thr Trp Leu Pro Trp Phe Ser Ser Glu Glu Thr Gly
115 120 125

Pro Gly Gly Tyr Asn Tyr Asp Asp Tyr Lys Met Asp Trp Leu Val Pro
130 135 140

Ala Thr Cys Glu Pro Ile Gln Ser Val Tyr Phe Phe Ser Gly Glu Glu
145 150 155 160

Tyr Tyr Arg Val Asn Leu Arg Thr Gln Arg Val Asp Thr Val Thr Pro
165 170 175

Pro Tyr Pro Arg Ser Ile Ala Gln Tyr Trp Leu Gly Cys Pro Val Pro
180 185 190

Asp Gln Lys
195

<210> 61
<211> 188
<212> PRT
<213> Oryctolagus cuniculus

<400> 61

Pro Ser Gln Glu Glu Cys Glu Gly Ser Ser Leu Ser Ala Val Phe Glu

1 5 10 15

His Phe Ala Met Leu His Arg Asp Ser Trp Glu Asp Ile Phe Lys Leu
20 25 30

Leu Phe Trp Gly Arg Pro Ser Gly Gly Ala Arg Gln Pro Gln Phe Ile
35 40 45

Ser Arg Asp Trp His Gly Val Pro Gly Lys Val Asp Ala Ala Met Ala
50 55 60

Gly Arg Ile Tyr Ile Ser Gly Leu Thr Pro Ser Pro Ser Ala Lys Lys
65 70 75 80

Gln Lys Ser Arg Arg Arg Ser Arg Lys Arg Tyr Arg Ser Arg Tyr Gly
85 90 95

Arg Gly Arg Ser Gln Asn Ser Arg Arg Leu Ser Arg Ser Ile Ser Arg
100 105 110

Leu Trp Phe Ser Ser Glu Glu Val Ser Leu Gly Pro Tyr Asn Tyr Glu
115 120 125

Asp Tyr Glu Thr Ser Trp Leu Lys Pro Ala Thr Ser Glu Pro Ile Gln
130 135 140

Ser Val Tyr Phe Phe Ser Gly Asp Lys Tyr Tyr Arg Val Asn Leu Arg
145 150 155 160

Thr Gln Arg Val Asp Thr Val Asn Pro Pro Tyr Pro Arg Ser Ile Ala
165 170 175

Gln Tyr Trp Leu Gly Cys Pro Ala Pro Gly Gly Gln
180 185

<210> 62
<211> 345
<212> DNA
<213> Artificial

<220>
<223> Ribosome Display Spacer

<400> 62
gctggctctg gagctggtgc aggctctggt gctggcgcag gttctggcgc tggtgctggt 60

tctggcactg gtgcttctcc ggcagctgtt ccggcagcgg ttccagcagc ggtgccggca 120

gcagttcctg ctgcggtggg cgaaggagaa ggagaaggcg agggagaggg cgaaggatac 180

ccgtacgacg taccggacta cgccgaaggt ggtggtggct ccgagcagaa gctcatctcc 240

gaagaagacc tggagggtgg tggtggctcc acagactaca aggacgacga cgacaaatcc 300

caaatcaaac gaaaggccca gtcgaaaaac tgggcctttc gattt 345

<210> 63
<211> 22
<212> DNA
<213> Artificial

<220>
<223> PEX2forw

<400> 63
atgcctgaaa tctgcaaaca gg 22

<210> 64
<211> 54
<212> DNA
<213> Artificial

<220>
<223> PEXR4

<220>
<221> misc_feature
<222> (25)..(26)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (28)..(29)
<223> n is a, c, g, or t

<400> 64
cctgcaaaga acacagcttt ctcmnnmnnt ggggcctcgt ataccgcatc aatc 54

<210> 65
<211> 42
<212> DNA
<213> Artificial

<220>
<223> PEXF4

<400> 65

ggaccctggc ttccccaagc tcatcgcaga tgcctggaat gc 42

<210> 66
<211> 19
<212> DNA
<213> Artificial

<220>
<223> PEX2rev

<400> 66
ggagctcgct cgagtcagc 19

<210> 67
<211> 60
<212> DNA
<213> Artificial

<220>
<223> PEXF1

<400> 67
gagaaagctg tgttctttgc agggaatgaa tactggatct actcagcgag caccttggag 60

<210> 68
<211> 60
<212> DNA
<213> Artificial

<220>
<223> PEXR1

<220>
<221> misc_feature
<222> (29)..(30)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (35)..(36)
<223> n is a, c, g, or t

<400> 68
gagcttgggg aagccagggt ccattttmnn cttmnnctcg ttgtacctcc agaacttgtc 60

<210> 69
<211> 57
<212> DNA
<213> Artificial

<220>
<223> PEXR3

<220>
<221> misc_feature
<222> (37)..(38)
<223> n is a, c, g, or t

<400> 69
ggcagtccga ggctagtcag tggtttggga taaccmnnct ccaaggtgct cgctgag 57

<210> 70
<211> 52
<212> DNA
<213> Artificial

<220>
<223> PEXR2

<220>
<221> misc_feature
<222> (23)..(24)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (26)..(27)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (29)..(30)
<223> n is a, c, g, or t

<400> 70
gccagcgaag atgtatgtct tmnnmnnmnn gctccagtta aaggctgcat cc 52

<210> 71
<211> 60
<212> DNA
<213> Artificial

<220>
<223> PEXF2

<400> 71
ctgactagcc tcggactgcc ccctgatgtt caacgtgtgg atgcagcctt taactggagc 60

<210> 72
<211> 55
<212> DNA
<213> Artificial

<220>

<223> T7P_PEX2

<400> 72
gtttaacttt aagaaggaga tatacatatg cctgaaatct gcaaacagga tatcg 55

<210> 73
<211> 49
<212> DNA
<213> Artificial

<220>
<223> PEX2_RD

<400> 73
cctgcaccag ctccagagcc agcgcagcct agccagtcgg atttgatgc 49

<210> 74
<211> 186
<212> DNA
<213> Artificial

<220>
<223> T7Pg10epsilon

<400> 74
ggtgatgtcg gcgatatagg cgccagcaac cgcacctgtg gcgccggtga tgccggccac 60

gatgcgtccg gcgtagagga tcgagatctc gatcccgcga aattaatacg actcactata 120

gggagaccac aacggtttcc ctctagaaat aattttgttt aactttaaga aggagatata 180

catatg 186

<210> 75
<211> 27
<212> DNA
<213> Artificial

<220>
<223> T7Pfor

<400> 75
ggtgatgtcg gcgatatagg cgccagc 27

<210> 76
<211> 23
<212> DNA
<213> Artificial

<220>
<223> R1A

<400> 76

aaatcgaaag gcccagtttt tcg 23

<210> 77
<211> 55
<212> DNA
<213> Artificial

<220>
<223> bridging primer

<400> 77
gtttaacttt aagaaggaga tatacatatg cctgaaatct gcaaacagga tatcg 55

<210> 78
<211> 50
<212> DNA
<213> Artificial

<220>
<223> bridging primer

<400> 78
gtcgttcaga ccacgaccct cgatgcagcc tagccagtcg gatttgatgc 50

<210> 79
<211> 243
<212> DNA
<213> Artificial

<220>
<223> T7PAviTagFXa

<400> 79
ggtgatgtcg gcgatatagg cgccagcaac cgcacctgtg gcgccggtga tgccggccac 60

gatgcgtccg gcgtagagga tcgagatctc gatcccgcga aattaatacg actcactata 120

gggagaccac aacggtttcc ctctagaaat aattttgttt aactttaaga aggagatata 180

catatgggtc ttaatgatat ttttgaagct cagaaaatcg aatggcacga aatcgagggt 240

cgt 243

<210> 80
<211> 332
<212> DNA
<213> Artificial

<220>
<223> T7T

<400> 80

taggaagctc agaaaatcga atggcacgaa taatgagctc ccgggagcgc ttggagccac 60

ccgcagttcg aaaaataata agggcctccc actgactgct cttctgtcag tgggctactc 120

ctggactcgg caccagattg cctcattttt ctcctctggc attttgtata aatccacctt 180

gactggggaa attctcctgg ggtcaggtgg caccagcctg gatccggctg ctaacaaagc 240

ccgaaaggaa gctgagttgg ctgctgccac cgctgagcaa taactagcat aacccccttgg 300

ggcctctaaa cgggtcttga ggggtttttt gc 332

<210> 81
<211> 30
<212> DNA
<213> Artificial

<220>
<223> T7Trev

<400> 81
gcaaaaaacc cctcaagacc cgtttagagg 30

<210> 82
<211> 22
<212> DNA
<213> Artificial

<220>
<223> T7Pfor

<400> 82
ggtgatgtcg gcgatatagg cg 22

<210> 83
<211> 37
<212> DNA
<213> Artificial

<220>
<223> NdeI-PEX2for

<400> 83
ctgagagtgc accatatgcc tgaaatctgc aaacagg 37

<210> 84
<211> 33
<212> DNA
<213> Artificial

<220>
<223> EcoRI-PEX2rev

<400> 84
ccatgattac gaattcgcag cctagccagt cgg 33

<210> 85
<211> 38
<212> DNA
<213> Artificial

<220>
<223> anti ssrA-oligonucleotide

<400> 85
ttaagctgct aaagcgtagt tttcgtcgtt tgcgacta 38

<210> 86
<211> 28
<212> DNA
<213> Artificial

<220>
<223> primer RT

<400> 86
cagagcctgc accagctcca gagccagc 28

<210> 87
<211> 30
<212> DNA
<213> Artificial

<220>
<223> primer F1

<400> 87
gtttaacttt aagaaggaga tatacatatg 30

<210> 88
<211> 210
<212> PRT
<213> Artificial

<220>
<223> consensus sequence - Xaa denotes a hyphen (-)

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa can be any naturally occurring amino acid

<220>

<221> misc_feature
<222> (34)..(34)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (55)..(57)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (97)..(97)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (119)..(120)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (189)..(195)
<223> Xaa can be any naturally occurring amino acid

<400> 88

Pro Glu Ile Cys Lys Gln Asp Ile Val Phe Asp Gly Ile Ala Gln Ile
1 5 10 15

Arg Gly Glu Xaa Ile Phe Phe Phe Lys Asp Arg Phe Ile Trp Arg Thr
20 25 30

Val Xaa Thr Pro Arg Asp Lys Pro Met Gly Pro Leu Leu Val Ala Thr
35 40 45

Phe Trp Pro Glu Leu Pro Xaa Xaa Xaa Glu Lys Ile Asp Ala Val Tyr
50 55 60

Glu Ala Pro Gln Glu Glu Lys Ala Val Phe Phe Ala Gly Asn Glu Tyr
65 70 75 80

Trp Ile Tyr Ser Ala Ser Thr Leu Glu Arg Gly Tyr Pro Lys Pro Leu
85 90 95

Xaa Thr Ser Leu Gly Leu Pro Pro Asp Val Gln Arg Val Asp Ala Ala
100 105 110

Phe Asn Trp Ser Lys Asn Xaa Xaa Lys Lys Thr Tyr Ile Phe Ala Gly
115 120 125

Asp Lys Phe Trp Arg Tyr Asn Glu Val Lys Lys Lys Met Asp Pro Gly
130 135 140

Phe Pro Lys Leu Ile Ala Asp Ala Trp Asn Ala Ile Pro Asp Asn Leu
145 150 155 160

Asp Ala Val Val Asp Leu Gln Gly Gly Gly His Ser Tyr Phe Phe Lys
165 170 175

Gly Ala Tyr Tyr Leu Lys Leu Glu Asn Gln Ser Leu Xaa Xaa Xaa Xaa
180 185 190

Xaa Xaa Xaa Lys Ser Val Lys Phe Gly Ser Ile Lys Ser Asp Trp Leu
195 200 205

Gly Cys
210